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Abstract
Vision research has contributed to an increased understanding of the 
neurophysiological substrates and disease processes of a number of neurological 
conditions, recently including the investigation of psychiatric disorders. Initial studies 
among individuals with depressive disorders have documented subtle vision 
abnormalities. However, this research has not yet assessed the impact of antidepressant 
pharmacology. In addition to contributing to knowledge regarding depression, 
investigation of the visual consequences of antidepressant treatment is important given 
the increased prevalence of prescription medication for both depressive and 
nondepressive disorders. Thus, the present study examined fundamental processes of 
photopic visual functioning associated with the use of selective-serotonin reuptake 
inhibitors (SSRIs), the most commonly prescribed type of antidepressant medication. The 
impact of depression was also assessed, both in terms of mood symptoms and clinical 
criteria, and measures of anxiety were included due to high comorbidity with depression 
and the use of antidepressant medications to treat anxiety disorders. Expanding on recent 
psychophysical studies that have measured only luminance-based spatiotemporal contrast 
sensitivity associated with depression (Szabo et al., 2004; Wesner & Tan, 2006), the 
present study additionally measured isoluminant “red-green” and “blue-yellow” 
chromatic contrast sensitivity, as well as S-cone sensitivity assessed by short-wavelength 
perimetry. Participants included 44 adult volunteers from the university student 
population and larger community. Results indicated that SSRI medications were 
associated with reductions in “red-green” chromatic contrast sensitivity and a trend of
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decreased luminance contrast sensitivity limited to high spatial frequencies. Depression 
was associated with overall reductions in luminance contrast sensitivity, most apparent in 
the low-to-mid range of spatial frequency, as well as overall reductions in “blue-yellow” 
chromatic contrast sensitivity and selective decreases in “red-green” chromatic contrast 
sensitivity. By contrast, S-cone sensitivity enhancements were observed among 
depressed participants in their peripheral (30-50°) temporal hemiretinas. Anxiety 
appeared to have the opposite effects of depression, showing a trend of enhanced 
luminance contrast sensitivity for low-to-mid spatial frequencies, significant overall 
enhancement of “red-green” contrast sensitivity, and a trend of increased “blue-yellow” 
contrast sensitivity at certain spatiotemporal frequencies, as well as significant reductions 
of S-cone sensitivity in the peripheral (30-50°) temporal and paracentral (10-22°) 
superior nasal sections of their retina. Results are discussed with reference to 
involvement of the magno-, parvo-, and koniocellular streams of visual perception.
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Introduction
Anomalies o f vision have been documented in both seasonal and non-seasonal 
depression. These abnormalities are subtle and generally not detected by standard clinical 
tests o f vision, but instead require noninvasive psychophysical assessment for the 
identification of dysregulated pathway operations. Although usually unnoticed by 
affected individuals, these types o f vision abnormalities have nevertheless been 
important for investigation o f pathophysiology, as well as diagnostic and treatment 
considerations, in a number of neurological diseases. In the area of psychiatric disorders, 
psychophysical measures of vision have been used extensively in schizophrenia research 
and are beginning to be applied to the study of mood disorders. The present study seeks 
to add to the psychophysical research that has been initiated with respect to visual 
functioning in depressive disorders. Specifically, this study will attempt to clarify the 
nature of the luminance contrast anomalies that have been observed in depressive 
disorders and will additionally introduce an exploration of chromatic visual functioning 
and an examination of the effects o f antidepressant pharmacology on early-stage visual 
processes.
Psychophysical Assessment and Neurological Disorders
Psychophysical assessment of visual functioning is increasingly being used as a 
tool to investigate neurological disorders not typically characterized by visual 
impairment. For example, abnormal visual functioning has been identified in several 
neurodegenerative disorders, including Parkinson’s disease, multiple sclerosis, 
Huntington’s chorea, Alzheimer’s disease and other dementias (e.g., Bassi, Solomon, &
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Young, 1993; Bodis-Wollner et al., 1987; Caruana et al., 2000; Cronin-Golomb et al., 
1991; Gilmore & Levy, 1991; Hutton, Morris, Elias, & Poston, 1993;
Lakshiminarayanan, Lagrave, Keane, Dick, & Shankle, 1996; Logi et al., 2001; 
O ’Donnell et al., 2003; Silva et al., 2005; Skrandies & Gottlieb, 1986) as well as 
neurodevelopmental disorders, such as autism and fragile X syndrome (e.g., Bertone, 
Mottron, Jelenic, & Fauber, 2005; Davis, Bockbrader, Murphy, Hetrick, & O ’Donnell, 
2006; Kogan et al., 2004). In some cases, vision deficits are manifest as overt 
ophthalmologic impairment, adding significantly to the disability associated with the 
disease. In other cases, anomalies of vision are subtle, highly specific, and not detected 
by standard clinical vision tests. These may be reported as vague visual complaints of 
blurring or dullness, but are more often not noticed by affected individuals. However, 
even when asymptomatic, visual abnormalities can serve as important markers of 
neurological disease processes.
The utility of psychophysical assessment of visual functioning in neurological 
disorders is manifold. First, psychophysical tests provide a sensitive and noninvasive 
method o f identifying discrete visual anomalies overlooked by standard clinical 
procedures. Second, the information provided by psychophysical assessment contributes 
to an increased understanding of the potential substrates of the disorder. Psychophysical 
paradigms can be designed to isolate distinct and localized functions of the visual system, 
shedding light on physiological and anatomical components o f neurological pathology 
(Caruana et al., 2000; Silva et al., 2005). Additionally, investigators have explored visual 
dysfunction as contributing to an explanation o f core symptoms of certain neurological
DEPRESSION, ANTIDEPRESSANTS, AND VISION 11
diseases. For example, deficits in visual processing have been suggested as contributing 
to the observed motoric and cognitive impairments associated with Parkinson’s and 
Alzheimer’s, respectively (Bodis-Wollner, 2002; Cormack, Tovee, & Ballard, 2000; 
Cronin-Golomb, Gorkin, & Growdon, 1995; Pieri, Diederich, Raman, & Goetz, 2000). 
Third, psychophysical findings provide valuable information for diagnostic 
considerations. Research has demonstrated that closely related disorders, such as 
Parkinson’s disease and multiple system atrophy (Delalande et al., 1996; Tebartz van 
Elst, Greenlee, Foley, & Lucking, 1997) or Alzheimer’s disease and other dementias 
(Bassi et al., 1993), can be distinguished on the basis of sub-clinical differences in visual 
functioning. Psychophysical assessment has also identified vision deficits in the earliest 
stages o f some illnesses, such as multiple sclerosis, before many of the core symptoms 
have emerged, thus highlighting possible prodromal indicators (Blumhardt, 1984; Bodis- 
Wollner & Camisa, 1980; Flalliday, McDonald, & Mushin, 1973). Fourth, 
psychophysical testing has the potential to inform treatment considerations. For some 
neurological diseases, such as Parkinson’s disease, visual dysfunction has been linked to 
the severity of illness, and can thus provide an indication of disease progression (Bodis- 
Wollner, 2002; Bodis-Wollner, Yahr, & Thornton, 1981; Diedrich, Raman, Leurgens, & 
Goetz, 2002). Knowledge of sub-clinical visual dysfunction is also being used in 
treatment strategies aimed at reducing functional disability and enhancing activities of 
daily living among individuals with Alzheimer’s disease (Cormack et al., 2000; Cronin- 
Golomb, 1995). Thus, psychophysical procedures have contributed to a better 
understanding of the sites and mechanisms associated with a given neuropathology, have
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provided information useful for early and differential diagnosis, and have assisted with 
symptom management.
Phototherapy and Vision Research in Mood Disorders
The visual system became a point of interest in mood disorder research with the 
demonstrated efficacy o f light therapy for seasonal affective disorder (SAD; Eastman, 
Young, Fogg, Liu, & Meaden, 1998; T.M. Lee & Chan, 1999; Rosenthal, 1995;
Rosenthal et al., 1985; Terman et al., 1989) and the observation that its antidepressant 
effect is mediated through the eyes (Wehr, Skwerer, Jacobsen, Sack, & Rosenthal, 1987). 
Two opposing theories of pathophysiology have been proposed. The hyposensitivity 
hypothesis suggests that individuals with SAD do not absorb enough light in the winter 
months to maintain a euthymie state (Reme, Terman, & Wirz-Justice, 1990).
Specifically, based on animal studies (Parker & Williams, 1995; Penn & Williams,
1986), it is proposed that most individuals are able to accommodate for decreased light 
levels in the winter months with an ocular compensatory mechanism that increases their 
sensitivity to ambient light. Individuals with SAD are thought to have deficient 
compensatory mechanisms and thus require the additional light exposure of 
phototherapy. By contrast, the hypersensitivity hypothesis suggests that the visual 
systems o f SAD individuals have a heightened sensitivity to ambient light which causes 
them to process and respond to artificial indoor illumination as if it were natural 
environmental light (Beersma, 1990). In the winter months, because indoor illumination 
generally extends much later than the natural outdoor light, individuals with SAD 
experience a lengthening of their natural photoperiod, instigating a depressogenic phase
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delay o f their natural circadian rhythms. Early morning phototherapy is thought to anchor 
their rhythms. While these two theories propose opposite dysfunction, both emphasize 
light-gathering processes of the visual system and have guided investigation of retinal 
mechanisms in individuals with SAD.
Support for either the hyposensitivity or hypersensitivity hypotheses appears to 
depend upon the method by which retinal sensitivity is studied. Dark adaptation studies 
use psychophysical procedures to determine thresholds of light sensitivity and have 
generally found increased sensitivity among SAD individuals in the winter months 
compared to healthy control participants (Oren, Joseph-Vanderpool, & Rosenthal, 1991; 
Terman & Terman, 1999), although no differences in dark adaptation thresholds were 
noted in one study (Oren et al., 1993). Studies o f electrooculogram (EGG) ratios instead 
support the theory of hyposensitivity during the winter (Lam, Beattie, Buchanan,
Remick, & Zis, 1991; Ozaki, Rosenthal, Moul, Schwartz, & Oren, 1993; Ozaki, 
Rosenthal, Myers, Schwartz, & Oren, 1995) and have also demonstrated a significant 
increase in EOG ratios among healthy control participants from the summer to the winter 
months, but no seasonal change among individuals with SAD (Ozaki et al., 1995). 
Similarly, electroretinography (ERG) research tends to support the hyposensitivity 
hypothesis, although results are mixed. Most ERG studies have found retinal sensitivity 
to be reduced among individuals with SAD or subsyndromal SAD compared to healthy 
control participants in the winter (Hebert, Beattie, Tam, Yatham, & Lam, 2004; Hebert, 
Dumont, & Lachapelle, 2002), although this was only evident among women in one 
study (Lam, Beattie, Buchanan, & Mador, 1992), while another study found no
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differences (Oren et al., 1993). With respect to phototherapy, some research has found 
that anomalies in retinal sensitivity among individuals with SAD were normalized with 
clinically effective light therapy (Tam, Lam, Yatham, & Zis, 1998; Terman & Terman,
1999), while another study found that differences in retinal sensitivity persisted despite 
effective phototherapy (Oren et al., 1993).
Since its success with SAD, phototherapy has been explored as a treatment option 
for a number of other mood disorders. Recent meta-analyses provide support for the use 
of phototherapy with non-seasonal major depression (Golden et al., 2005; Tuunainen, 
Kripke, & Endo, 2004) and treatment trials for premenstrual depression (Lam et al.,
1999), postpartum depression (Epperson et al., 2004), and bipolar disorder (Benedetti et 
al., 2004) have also found phototherapy to be effective. Investigations of visual 
mechanisms in non-seasonal mood disorders have found increased light sensitivity 
among depressed individuals when using dark adaptation thresholds and ERG procedures 
(Seggie, Canny, Mai, McCrank, & Waring, 1989; Seggie & Steiner, 1990). An early 
study of EOG ratios suggested that depressed individuals with psychomotor retardation 
had low sensitivity to light, while manic individuals had heightened sensitivity to light 
(Economou & Stefanis, 1979), although subsequent EOG research has found little 
difference between depressed individuals and healthy control participants (Seggie et al., 
1991). Thus, results vary according to the procedure used, with the most consistent 
findings suggesting that non-seasonal depression may be associated with a heightened 
retinal sensitivity to light.
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Retinal light sensitivity in depression may be instigated by an inability of the 
retina to process appropriate amounts o f ambient light. The effect o f ambient light 
exposure on mood has been explored in naturalistic studies with non-clinical populations, 
which have demonstrated a correlation between reduced daily illumination and depressed 
mood (Espiritu et al., 1994; Kripke et al., 1994, 2004; Youngstedt, Kripke, Elliot, Baehr, 
& Sepulveda, 1998). One such study of older adults included an investigation of various 
ophthalmic factors and determined that the relationship between daily light exposure and 
depressed mood was mediated by visual impairment (Jean-Louis, Kripke, Cohen, Zizi, & 
Wolintz, 2005). Both visual deficits and reduced daily illumination were associated with 
depressed mood, but the relationship between illumination levels and mood was 
minimized when specific vision factors were accounted for. More specifically, although 
several ophthalmic features were measured, including intraocular pressure, nerve fiber 
layer thickness, vertical and horizontal cup-to-disk ratios, and visual field defects, only 
visual acuity was significantly correlated with measures of mood.
Other studies among geriatric populations have found a similar correlation 
between depressive symptoms and various visual deficits, such as low visual acuity and 
macular degeneration (Rovner, Casten, & Tasman, 2002; Rovner & Ganglui, 1998; 
Shmuely-Dulitzki & Rovner, 1997; Tsai et al., 2003). Interpretations o f these findings 
have generally attributed decreased mood to the functional disability, and consequent 
reduction in quality of life, associated with having a vision impairment. However, in the 
study by Jean-Louis et al. (2005), depressed mood was only linked to visual acuity 
deficits and not to the other ophthalmic factors investigated. This suggests that it is not
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visual impairment in general, or the resulting disability, that contributes to depressed 
mood, but rather a process specific to visual acuity. The researchers also determined that 
there was no direct relationship between vision deficits and daily illumination, meaning 
that illumination levels were similar among those with and without visual impairment. 
Thus, ophthalmic factors had a direct impact upon mood, whereas reduced daily 
illumination was only associated with substantial reductions in mood among individuals 
with vision impairments, and specifically among those with visual acuity deficits. 
Relatedly, bright light treatment has been found effective in improving circadian rhythm 
functions in Alzheimer’s patients, but does not work among those who have visual 
impairment resulting from cataracts (Van Someren, Kessler, Mirmiran, & Swaab, 1997).
Despite a focus on retinal mechanisms in phototherapy research, visual 
perception has not yet been extensively explored in clinical populations with mood 
disorders. Instead, the vast majority o f research on the visual system in phototherapy has 
examined the eye as a gateway to circadian rhythm mechanisms. Studies o f sensitivity 
and adaptation to environmental light have been interpreted in terms o f circadian 
phototransduction, which involves the retinohypothalamic pathway connecting the eye to 
the suprachiasmatic nucleus o f the hypothalamus, considered the major circadian 
pacemaker. However, this pathway does not involve perceptual components o f the visual 
system, which are instead processed along the retinogeniculostriate pathway connecting 
the eye to the cortex through the lateral geniculate nucleus. Perceptual processes 
comprise the largest portion of the visual system and may provide a non-invasive avenue 
for studying neurophysiological correlates of depression. Additionally, the circadian
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effects of light on mood disorders may be mediated by processes associated with visual 
perception.
Early Stages of the Visual System
Of the various perceptual systems, vision has been the most extensively studied, 
due in part to the accessibility o f the eye as the first stage of a highly sophisticated 
network o f neural communication. Light information from the environment is collected 
through photoreceptors in the retina and transmitted from the eye through the optic nerve 
to multiple levels of pre-cortical regions, including the lateral geniculate nucleus, and on 
to the primary visual cortex and subsequent cortical areas. Early stages of this system 
process basic components o f the visual environment, including chromatic and luminance 
differences, edge orientations, and temporal or dynamic pattern contrasts. This 
information is combined in later stages to create richly detailed and complex 
representations o f the visual scene.
Throughout these hierarchical levels, the existence of at least two anatomically 
and functionally distinct parallel visual processing streams have been established: the 
magnocellular stream with its predominately dorsal occipito-parietal poststriatal 
projections, and the parvocellular stream with its predominately ventral occipito­
temporal poststriatal projections (Bassi & Lehmkulle, 1990; Kessels, Postma, & Haan, 
1999; Livingstone & Hubei, 1988; Merrigan & Maunsell, 1993; Shapley, 1992; 
Ungerleider & Mishkin, 1982). The magnocellular stream carries information involving 
rapid temporal changes and low spatial frequencies in the visual environment from the 
retina to layers IV-B and IV-Ca of the primary visual cortex (VI). This information is
DEPRESSION, ANTIDEPRESSANTS, AND VISION 18
projected dorsally to areas in the parietal lobe, where it is synthesized into perception o f 
motion and spatial location. The parvocellular stream is sensitive to lower temporal 
frequencies and medium to high spatial frequencies, and transmits information 
concerning fine detail o f static or slow-moving stimuli. Additionally, the parvocellular 
stream is responsible for colour information. From the retina, the parvocellular stream 
carries information to layers IV-A and IV-Cp of the primary visual cortex, and projects 
ventrally to the inferior temporal lobe, where information is synthesized into recognition 
o f colour and object properties. There is some cross-communication in higher cortical 
areas, but the magnocellular and parvocellular streams remain fairly distinct in earlier 
stages o f visual processing (Merrigan & Maunsell, 1993; Sawatari & Callaway, 1996; 
Vidyasagar, Kulikowski, Lipnicki, & Dreher, 2002).
A third parallel stream has more recently been confirmed as being part of 
perceptual processing. Originally believed to be more involved with the vegetative visual 
functions associated with the superior colliculus (i.e., analogous to the W-cell pathway in 
cats), the koniocellular stream now appears to also relay information from the retina to 
both the colour processing blobs and layer I o f the primary visual cortex (see Hendry & 
Reid, 2000, for review). Evidence has accumulated that closely links the koniocellular 
stream with S-cone information and “blue-yellow” colour opponent channels (Calkins, 
Tsukamoto, & Sterling, 1998; Dacey, 1999; Dacey & Lee, 1994; Martin, White, 
Goodchild, Wilder, & Sefton, 1997; Mullen & Kingdom, 2002). Although the 
parvocellular stream was previously considered to be responsible for all chromatic 
processing, it now appears to be primarily limited to M- and L-cone information and
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“red-green” colour opponency (Sun, Smithson, Zaidi, & Lee, 2006a; Martin et ah, 1997; 
Mullen & Kingdom, 2002). The koniocellular stream has additionally been associated 
with low acuity visual information and responds maximally to spatial frequencies 
intermediate to those o f the magnocellular and parvocellular streams (Forte, Hashemi- 
Nezhad, Dobbie, Dreher, & Martin, 2005; Flendry & Reid, 2000; Roy et al., 2009; White, 
Solomon, & Martin, 2001).
Due to the highly structured organization of the human visual system, knowledge 
of anomalies in visual perception can point to particular mechanisms or sites of 
disruption. Psychophysical tests can be constructed to isolate specific visual processes 
and pathways. One of the simplest and most thorough psychophysical techniques for 
analyzing basic visual functioning involves the use of sinusoidal gratings, perceived as 
alternating bands of dark and light, in order to measure thresholds of sensitivity to 
luminance contrast (Campbell, 1983; Campbell & Robson, 1968; Kelly, 1977; Robson, 
1966).
Contrast is the primary feature by which the visual system distinguishes an object 
from its background. Luminance contrast denotes intensity edges, which contribute to 
perception of form and texture, and it is therefore integral in object identification. The 
perception of luminance contrast, without nuances o f colour, motion, or directionality, is 
a response which begins in the retina and underlies the functioning of much subsequent 
central visual processing (DeValois & DeValois, 1990). Higher-level visual abilities are 
contingent upon the performance of these basic functions in early stages of the visual 
system.
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Sensitivity to luminance contrast varies with spatial and temporal frequency.
Thus, contrast sensitivity is different when viewing coarse patterns (i.e., low spatial 
frequency) than patterns with fine detail (i.e., high spatial frequency). Similarly, contrast 
sensitivity is different for static visual scenes than when the visual stimuli involve 
motion. Thresholds o f the minimum amount of contrast needed to detect a stimulus can 
be determined for gratings representing the full spectrum of observable spatial and 
temporal frequencies. Contrast sensitivity values, which are the inverse o f contrast 
thresholds, can be plotted across these ranges to create a contrast sensitivity function. 
Under average luminance conditions, the contrast sensitivity function o f normal adult 
observers resembles an inverted U-shape (Kelly, 1977, 1979; B.B. Lee et al., 1990;
Legge, 1978; Tolhurst, D.J., Sharpe, C.R., & Hart, C., 1973; Wandell, 1995; Woodhouse 
& Barlow, 1982). When temporal modulation is low (i.e., 0-1 cycles per second or Hz), 
the contrast sensitivity function has a bandpass characteristic across a full range of spatial 
frequencies, with peak sensitivity to spatial frequencies between 2-4 cycles per degree 
(cpd) o f visual angle. When temporal modulation is increased, the contrast sensitivity 
function becomes low-pass, with better sensitivity to lower spatial frequencies. At these 
low spatial frequencies, contrast sensitivity is maximized for temporal frequencies of 
approximately 10 Hz.
The observation of shifts in the contrast sensitivity function due to varying spatial 
and temporal parameters led to the theory of at least two separate perceptual channels in 
visual processing, referred to as the transient and the sustained channels (Legge, 1978). 
Although a complete contrast sensitivity function represents an envelope o f the
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sensitivities from the different visual streams, the use o f minimum thresholds helps to 
isolate only the most sensitive channel when there is functional overlap at given spatial 
and temporal frequencies (Smith, 1991). The transient channel has been shown to have 
higher sensitivity for stimuli with low spatial frequencies (i.e., less than 3 cpd) and high 
temporal frequencies (i.e., 4-15 Hz), whereas the sustained channel is better stimulated 
by higher spatial and lower temporal frequencies (Bassi & Lehmkuhle, 1990;
Breitmeyer, 1992; Green, 1981; Legge, 1978; Livingstone & Hubei, 1978; Wilson,
1980). These characteristics resemble the distinct neuronal responses of the different 
anatomical visual streams, with the magnocellular stream responsive to motion, but only 
coarse patterns, and the parvocellular stream responsive to fine detail, but not motion. 
Although there is a notable association between the perceptual channels and the 
anatomical pathways, it should be noted that the mapping is not exact (Merrigan & 
Maunsell, 1993). Further, the koniocellular stream has not yet been considered in 
reference to transient and sustained channels. Nevertheless, by assessing contrast 
sensitivity across a range of spatial and temporal frequencies, the functioning of parallel 
visual streams can be compared.
Schizophrenia, Luminance Contrast Sensitivity, and Medication
Within the area of psychiatric disorders, contrast sensitivity tests have been used 
extensively in research on schizophrenia. The first series of studies were conducted by 
Schwartz and colleagues (Schwartz, McGuinn, & Winstead, 1987; Schwartz, Nelson, 
Wall, & Winstead, 1985; Schwartz & Winstead, 1985). Deficits were most reliably 
observed for temporally modulated gratings, indicating transient channel dysfunction.
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The sustained channel appeared to be largely intact, although some anomalies were 
observed. Keri, Antal, Szekeres, Benedek, and Janka (2002) similarly found reduced 
contrast sensitivity among individuals with schizophrenia compared to healthy control 
participants when viewing drifting gratings, but additionally noted lower contrast 
sensitivity to static gratings of medium to high spatial frequencies, suggesting both a 
transient and sustained channel dysfunction. Broad-hand spatial and temporal deficits 
were also noted in Slaghuis (1998, 2004), but only among individuals with mainly 
negative symptomology (i.e., anhedonia, affective flattening, paucity of speech content, 
reduced motivation, deficits in social functioning). Individuals with predominantly 
positive symptomology (i.e., hallucinations, delusions, thought disorder, odd behaviours) 
either had moderate difficulty with medium to high spatial frequencies or no impairment 
at any spatial frequency. Cimmer et al. (2006) more recently found no contrast sensitivity 
differences between different symptom groups; all schizophrenic individuals performed 
worse than control participants in response to a low spatial and high temporal frequency 
grating, indicative of a transient channel deficit. By contrast, Chen, Palafox, et al. (1999) 
found that a nonsignificant trend of reduced contrast sensitivity for static low spatial 
frequencies was eliminated with the addition of temporal modulation, indicating a greater 
motion gain among individuals with schizophrenia compared to healthy controls. This 
was interpreted as a hyperactive or compensatory mechanism within the transient 
channel of individuals with schizophrenia. Additionally, two other studies of contrast 
sensitivity demonstrated no differences between individuals with schizophrenia and 
healthy control participants (Antal, Keri, Szekeres, Benedek, & Janka, 1999; Chen,
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Nakayami, Levy, Matthysse, & Holzman, 1999). Overall, while there is some variability, 
results o f contrast sensitivity tests in schizophrenia most often implicate the transient 
channel or magnocellular stream, which is consistent with other psychophysical studies 
o f vision for this disorder.
Some variation in results may be due to differences in the medication regimes of 
individuals with schizophrenia. A study by Chen et al. (2003) found that individuals with 
schizophrenia who were taking typical antipsychotic medications demonstrated reduced 
contrast sensitivity to transient channel stimuli, while those receiving atypical 
antipsychotic medications performed similar to healthy control participants. A review o f 
the medication status of participants in previous studies indicates that this finding may 
account for many o f the discrepant results of earlier research. Further, the Chen et al. 
(2003) study found that individuals not taking any antipsychotic medications 
demonstrated elevated contrast sensitivity. This was also observed in a preliminary report 
by Keri, Antal, Szekeres, Benedek, and Janka (1998) which showed the contrast 
sensitivity of never-medicated, first-episode schizophrenic patients to be enhanced 
compared to healthy matched control participants for static and drifting gratings at low 
spatial frequencies. No differences were noted for medium to high spatial frequencies. 
These findings suggest that contrast sensitivity deficiencies o f individuals with 
schizophrenia may only be evident among those receiving typical antipsychotic 
medications, whereas unmedicated schizophrenic individuals may actually possess 
enhanced contrast sensitivity when mediated by the transient channel or magnocellular 
stream o f the visual system. This has been interpreted as a reflection of enhanced retinal
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sensitivity to luminance contrast caused by the elevated levels of endogenous dopamine 
among individuals with schizophrenia (Chen et ah, 2003). The dopamine-antagonist 
effects of antipsychotic medications are hypothesized to correct, and may even over­
compensate for, the contrast sensitivity enhancements associated with schizophrenia.
Not all studies with luminance contrast gratings reveal the same patterns, 
however. Harris, Calvert, Leendertz and Phillipson (1990) showed that the depot 
injection of a typical antipsychotic medication resulted in an increase in contrast 
sensitivity to low spatial frequency gratings and a decrease with medium to high spatial 
frequency gratings. Because there were no control participants included in this study, it is 
unclear whether the contrast sensitivity values were above or below normal levels, but 
the pre- to post- injection changes do not easily fit the hypothesis by Chen et al. (2003) 
regarding typical antipsychotics. Recent studies with atypical antipsychotics also present 
some contradiction. O ’Donnell et al. (2006) found that individuals with schizophrenia 
who were taking atypical antipsychotic medications and those who had recently 
withdrawn from medication performed similarly on tests of contrast sensitivity for 
transient and sustained channel stimuli, and both groups performed worse than healthy 
control participants. Similarly, most of the schizophrenic participants in a study by Butler 
et al. (2005) were taking atypical antipsychotic medications, but nevertheless 
demonstrated reduced contrast sensitivity with low and medium spatial frequency grating 
presentations. These researchers noted possible methodological differences that may 
account for the discrepancy with previous investigations, and called for further research 
to clarify the effects of medication on contrast sensitivity in schizophrenia.
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Anomalies in early-stage visual processing among individuals with 
schizophrenia are often interpreted as a reflection of the underlying neurotransmitter 
dysfunction of this disorder. Specifically, schizophrenia is characterized by abnormal 
transmission of dopamine, which is also a primary neuromodulator o f the retina. 
Disturbance of basic visual functions in schizophrenia may thus be related to the same 
dopaminergic dysregulation that causes schizophrenic symptomology. In fact, it has been 
suggested that some of the core symptoms of schizophrenia, such as cognitive 
fragmentation, thought disorder, and visual hallucinations, may be the result of disturbed 
visual input causing dysregulation of higher cortical functions (Braff, 1989; Braff & 
Sacuzzo, 1981; Butler et al., 2006). Variation in early-stage visual processes among 
individuals with schizophrenia appears to be partly related to the distinct 
pharmacodynamic actions of different medications. Although all antipsychotic drugs act 
on dopamine receptors, atypical antipsychotics are characterized by shorter occupancy 
periods than typical antipsychotics (Seeman & Tallarico, 1999) and also demonstrate 
more involvement with additional neurotransmitter systems, including serotonergic, 
histaminergic, and adrenergic processes (Chen et ah, 2003). Understanding the effects of 
medication on visual functioning is important to clarify results o f vision studies in 
schizophrenia. Additionally, neurotransmitter pathology can be explored through the 
visual corollaries of both medication and the disorder itself.
Depressive Disorders and Luminance Contrast Sensitivity
A handful o f studies have begun to explore visual contrast sensitivity within the 
area of depressive disorders. Early investigations focused exclusively on SAD and relied
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on contrast cards and charts to measure contrast sensitivity. Murphy et al. (1993) found 
no differences in contrast sensitivity between control participants and individuals with 
SAD measured in the winter season. Gallin et al. (1995) also found no pathological 
deficits in contrast sensitivity among SAD patients while depressed. However, for 20 o f 
the 40 tested eyes (in 12 o f the 20 SAD patients), contrast sensitivity values were 
borderline low according to normative performance values. Two weeks of phototherapy 
corrected the baseline abnormality in 9 cases, while contrast sensitivity remained 
borderline low in the other 11 cases.
Since these earlier studies, computerized measures have been developed to allow 
for more sensitive assessments of contrast sensitivity which use stimuli that have specific 
spatial frequency and temporal modulation parameters. Employing these technologies, 
Szabo et al. (2004) found a nonsignificant trend of lower contrast sensitivity for static 
gratings among individuals with SAD during a depressive phase, compared to healthy 
control participants. Four weeks of phototherapy led to increases in contrast sensitivity 
for both SAD and healthy individuals, although the change was only significant among 
SAD patients and only for static gratings at low and medium spatial frequencies. 
Following phototherapy, static contrast sensitivities of SAD individuals and control 
participants were comparable. Szabo et al. also investigated moving gratings but found 
no trends or significant results, either in terms of differences between SAD and controls 
or between pre- and post-treatment performances.
Contrary to the findings of Szabo et al. (2004), which suggested marginal deficits 
in baseline eontrast sensitivity, Wesner and Tan’s (2006) investigation of SAD
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participants demonstrated enhanced contrast sensitivity to high spatial frequencies in the 
winter months compared to healthy control participants. These enhancements were noted 
for static gratings and for gratings modulated at low temporal frequencies, but were not 
observed for gratings with high temporal modulation. Phototherapy was conducted with a 
subset of participants and indicated a return-to-normal decrease in contrast sensitivity for 
high spatial frequency gratings among individuals with SAD (Ly, Wesner, & Tan, 2001).
Although the direction of abnormality is different, the findings o f both Szabo et 
al. (2004) and Wesner and Tan (2006) indicate anomalies in the contrast sensitivity o f 
SAD patients which may be normalized following phototherapy. Also apparent in both 
studies is the observation that temporal modulation was generally not associated with 
abnormal contrast sensitivity, pointing away from the transient channel and 
magnocellular stream of visual processing. This interpretation is consistent with the 
spatial frequency results o f Wesner and Tan, in which affected contrast sensitivities were 
limited to high spatial frequencies, processed by the parvocellular stream or sustained 
channel. In Szabo et al. contrast sensitivity enhancements in response to phototherapy 
were evident for low and medium, but not high, spatial frequencies, suggesting a possible 
magnocellular involvement that is less coherent with the lack of temporal modulation 
effects they observed.
Several methodological differences can be noted for these investigations. For 
example, Wesner and Tan’s (2006) study included 46 SAD individuals, while only 10 
SAD participants were involved in the study by Szabo et al. (2004). Also, while both 
studies relied on a forced choice detection paradigm, Wesner and Tan presented
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alternatives simultaneously, while Szabo et al. displayed alternatives consecutively, 
which may affect adaptational processes related to retinal gain mechanisms.
Additionally, none of the participants in the Szabo et al. study were taking medication at 
the time of testing, while a minority of the SAD patients in Wesner and Tan’s study were 
receiving antidepressant medication.
Non-seasonal depression was also explored in Wesner and Tan’s (2006) study, 
with results paralleling those found with SAD. Although less pronounced than among the 
SAD participants, individuals with non-seasonal depression similarly exhibited elevated 
contrast sensitivities for high spatial frequencies compared to control participants in the 
winter months. These enhancements were noted in response to static and low temporal 
frequency gratings, but not high temporal frequency gratings, comparable to SAD results. 
Phototherapy also resulted in return-to-normal decreases in the high spatial frequency 
enhancements o f individuals with non-seasonal depression (Ly et al., 2001). Thus, 
evidence for elevated performance in the sustained channel or parvocellular stream of the 
visual system was common to both SAD and non-seasonal depression.
Wesner and colleagues (Gallant & Wesner, 2004; Pavlou & Wesner, 2006) 
conducted preliminary investigations of the effect o f season and antidepressant 
medication on contrast sensitivity in depressive disorders. When measured in the summer 
months, elevations in contrast sensitivity for high spatial and low temporal frequencies 
persisted among individuals with SAD compared to control participants, with neither 
group demonstrating notable seasonal variation in contrast sensitivity functions. 
Surprisingly, non-seasonally depressed individuals displayed the most seasonal
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variability in contrast sensitivity, with their wintertime enhancements diminishing in the 
summer months to levels comparable to control participants. Standard SSRJ treatments 
did not appear to impact the contrast sensitivity functions of SAD individuals in either 
the winter or summer testing sessions, with consistent high spatial frequency 
enhancements displayed regardless of medication status (Gallant & Wesner, 2004). 
Antidepressant medication similarly did not affect the wintertime contrast sensitivity 
enhancements o f participants with non-seasonal depression, but did exacerbate their 
summertime reductions. Consequently, among individuals with non-seasonal depression, 
contrast sensitivity values for high spatial frequency gratings decreased to control 
participants’ levels among those not taking medication, while those receiving standard 
SSRI treatment demonstrated high spatial frequency contrast sensitivity that was lower 
than that o f control participants in the summer months. Thus, although characterized by 
seasonal fluctuation in mood symptoms, SAD does not seem to exhibit variability in 
visual functioning. Instead, non-seasonal depression may be more affected by season and 
pharmacology with respect to early-stage visual processes.
Both SAD and non-seasonal depression have demonstrated subtle anomalies in 
basic visual functioning, as indicated by recent psychophysical assessments of luminance 
contrast sensitivity. However, the nature of abnormality remains to be clarified. Both 
marginal deficits and significant enhancements in luminance contrast sensitivity have 
been observed. Further, indications of transient or magnocellular stream involvement are 
inconsistent, and the degree to which the sustained or parvocellular stream is affected is 
not clear. Thus, more research is required to verify recent findings and extricate the
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contributions o f parallel visual streams. The present study will examine luminance 
contrast sensitivity associated with the magnocellular and parvocellular streams to help 
clarify these initial findings with respect to depression.
Chromatic Visual Functioning
In addition to spatial and temporal distinctions, magnocellular and parvocellular 
streams are also distinguished by responsiveness to colour, with chromatic signaling only 
occurring in the latter. The possible involvement o f the parvocellular stream in 
depressive disorders suggests that an exploration of chromatic visual functioning may be 
useful. Additionally, the chromatic visual system is itself comprised o f distinct channels, 
which may facilitate further localization o f visual anomaly.
The human retina contains three types o f cone photoreceptors, which are 
selectively responsive to different wavelengths of light. Short-wavelength (S-) cones are 
most sensitive to wavelengths o f light around 440 nm; middle-wavelength (M-) cones 
have peak sensitivity around 530 nm; and long-wavelength (L-) cones are maximally 
responsive around 560 nm. Signals from the three cone classes are recoded into post- 
receptoral channels of opponency. One chromatic channel contrasts the signals from L- 
cones and M-cones, giving rise to a perceptual opponency of “red” and “green”. The 
second chromatic channel contrasts the signals from S-cones with some combination of 
L- and M-cone signals, resulting in a perceptual opponency of “blue” and “yellow”. A 
third channel focuses on luminance comparisons and corresponds to a perceptual 
dimension of black and white, with no chromatic distinctions. This luminance channel 
combines L- and M-cone signals additively, and avoids S-cone input.
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Colour and luminance contrast vision in neurodegenerative disorders. Both 
luminance and chromatic contrast sensitivity have been investigated in 
neurodegenerative disorders. Studies of multiple sclerosis have found vision deficits in 
both areas, with chromatic contrast sensitivity more notably affected than luminance 
contrast sensitivity (e.g., Caruana et ah, 2000; Fallowfield & Krauskopf, 1984; Flanagan 
& Markuleve, 2005; Flanagan & Zele, 2004; Travis & Thompson, 1989). Impairment for 
“red-green” contrasts has been found to be more severe than impairment for “blue- 
yellow” contrasts, although both are associated with worse performance in multiple 
sclerosis patients than among healthy control participants (Flanagan & Markuleve, 2005; 
Flanagan & Zele, 2004; Travis & Thompson, 1989). Alzheimer’s disease has similarly 
demonstrated both broad-band luminance and selective chromatic contrast deficits, in the 
latter case related to short-wavelength or “blue” light (e.g., Cronin-Golomb et ah, 1995; 
Gilmore, Koss, Wenk & Whitehouse, 1993; Kurylo et ah, 1994). Studies of Parkinson’s 
disease have documented pronounced losses of luminance contrast sensitivity, most 
commonly associated with the middle range of spatial frequencies, to which normal 
observers are most sensitive (e.g., Bodis-Wollner, 1990, 2002; Bodis-Wollner et ah,
1987; Diederich et ah, 2002; Marx et ah, 1986), as well as some impairment in colour 
vision which also appears to be selective for short-wavelength or “blue” light (e.g., 
Buttner et ah 1995; Haug, Kolle, Trenkwalder, Oertel, & Paulus, 1995; Pieri, Diederich, 
Raman, & Goetz, 2000; Price, Feldman, Adelberg, & Kaynes, 1992).
Colour vision and depressive disorders. Colour vision has received little 
attention in the area of psychiatric disorders. Isolated studies o f vision in schizophrenia
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have tested chromatic functioning, relying on a battery of standard clinical tests 
(Shuwairi, Cronin-Golomb, McCarley, & O ’Donnell, 2002) or psychophysical tests 
using patterns o f squares or vernier stimuli (Butler et ah, 2001; Keri, Kelemen, Benedek, 
& Janka, 2004; Keri, Kelemen, Janka, & Benedek, 2005), but not contrast gratings.
These have not evidenced any colour vision impairments, which fits with the most 
consistent finding of magnocellular deficits in schizophrenia.
In mood disorder research, psychophysical measurements of chromatic visual 
functioning have not been reported. Instead, clinical tests of colour vision have been 
described in two ophthalmic investigations o f SAD. Specifically, Oren et al. (1993) 
found no colour vision deficiencies in his study o f SAD patients in the winter months and 
Gallin et al. (1995) similarly found that two weeks of phototherapy was not associated 
with changes in colour perception. Interestingly, three patients had a previous diagnosis 
of “red-green” colour deficiency, but nevertheless demonstrated an antidepressant 
response to bright light therapy.
Some wavelength specificity has been found in research exploring parameters o f 
effective phototherapy in SAD. A meta-analysis conducted by T.M. Lee, Chan, Paterson, 
Janzen and Blashko (1997) concluded that long-wavelength light was neither necessary 
nor sufficient to produce antidepressant effects in SAD patients. By comparison, short- 
and medium-wavelengths of light were related to symptom improvement. The studies 
used for analysis by Lee and colleagues were limited, however, in their ability to isolate 
specific wavelengths. Light sources used at the time were associated with relatively large 
bandwidths, even when designed to focus on specific wavelengths. A recent study.
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relying on an LED light source to produce more narrow-bandwidth light, exposed SAD 
patients to three weeks o f either bright light limited to short-wavelengths (468 nm) or 
dim long-wavelength light (654 nm) included as a placebo control (Glickman, Byrne, 
Pineda, Hauck, & Brainard, 2005). Symptom improvement was evident in both groups of 
SAD patients, but the change was significantly higher among those treated with bright 
short-wavelength light. Because a condition o f broad-band “white” light was not used, it 
is unclear how the narrow-band short-wavelength light compares to the current standard 
protocol for phototherapy treatment. Nevertheless, this study does indicate that short- 
wavelength or “blue” light is sufficient to induce an antidepressant effect significantly 
better than placebo. Short-wavelength light has also been found to be more potent than 
longer wavelengths at shifting circadian rhythms of melatonin (Lockley, Brainard, & 
Czeisler, 2003), which has been discussed as a possible mechanism for phototherapeutic 
efficacy.
Ly et al. (2001) investigated the effects of bright light treatment on luminance 
contrast sensitivity among individuals with SAD and non-seasonal depression, as well as 
healthy control individuals. Participants underwent seven days o f one-hour light sessions 
involving either broad-band “white” light, narrow-band short-wavelength or “blue” light 
(440 nm), or narrow-band “yellow” light (580 nm). Prior to treatment, individuals with 
SAD and non-seasonal depression demonstrated higher contrast sensitivity at medium 
and high spatial frequencies than control participants. These enhancements were reduced 
to normal levels following treatment with broad-band “white” light and narrow-band 
“blue” light. No changes in contrast sensitivity resulted from the narrow-band “yellow”
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light. Thus, it was concluded that the contrast sensitivity enhancements among 
individuals with SAD and non-seasonal depression were corrected by bright light 
treatment, but only if it included short-wavelength light. O f note, the narrow-band “blue” 
light condition was also associated with some reduction of CS in healthy control 
participants.
Seggie et al. (1989) has similarly demonstrated enhanced dark adapted sensitivity 
to “blue” light points that was normalized following treatment with antidepressant 
medication. His study was not designed to test chromaticity, however, so no other 
wavelengths o f light were used for comparison. A report by Lagerloff (1982) assessed 
colour vision directly among a group of individuals being treated with tricyclic 
psychotropics. Fourteen participants were taking tricyclic antidepressants, ten were 
taking neuroleptics with a tricyclic molecular structure, and twelve were taking 
benzodiazepines with a tricyclic molecular structure. O f the 72 eyes tested, 60 
demonstrated “blue-yellow” colour deficiency as measured by clinical tests, while none 
showed evidence of “red-green” impairment. Among participants taking standard 
tricyclic antidepressants, 24 of the 28 eyes tested displayed “blue-yellow” deficits. These 
rates are substantially higher than those in the general population and Lagerloff 
accordingly concluded that acquired Type III colour deficiency is common with tricyclic 
pharmacology. However, it is not clear whether Lagerloff controlled for the age of his 
participants, most o f whom were over 50 years old. Since increasing age is associated 
with reduced sensitivity to short-wavelength light (Gaillard, Zheng, Merriam, & Dillon,
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2000; Packer & Williams, 2003; Werner, Peterzell, & Scheetz, 1990), this could offer an 
alternative explanation to his findings other than the effects of tricyclic medication.
In sum, psychophysical assessment o f chromatic visual functioning has not yet 
been conducted within the area o f depressive disorders. Although studies o f SAD have 
reported no impairment on standard clinical tests of colour vision, these measurements 
often lack the sensitivity to detect anything less than clinical dysfunction (see Silva et ah,
2005) and are also not capable of identifying possible enhancements in performance. 
Treatment studies have provided some suggestion that chromatic processes are involved 
in depressive disorders. For instance, effective phototherapy has been associated with 
wavelength selectivity; visual mechanisms which process short-wavelength light, and 
possibly medium-wavelength light, are important for an antidepressant response in SAD 
patients, whereas the processing o f long-wavelength light appears ineffective. One 
interpretation is that short-wave length or “blue” light corrects circadian mechanisms 
related to mood impairment. At the same time, repeated exposure to short-wavelength 
light has been shown to normalize contrast sensitivity elevations in SAD and non- 
seasonal depressed individuals, which may mean that the adaptation or desensitization of 
short-wavelength light mechanisms also corrects vision abnormalities. Additionally, 
tricyclic antidepressant medication may diminish “blue-yellow” colour vision, although 
this needs to be confirmed. Overall, information on chromatic visual functioning in 
depressive disorders is sparse, but does indicate that further research, particularly in 
relation to short-wavelength visual processing, is warranted. The present study will 
examine chromatic contrast sensitivity and S-cone sensitivity in order to gain a better
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understanding of the involvement o f distinct channels o f colour vision in depression and 
its treatment.
Summary of Vision Research in Depressive Disorders
The investigation o f early visual processing in mood disorders is still in its 
infancy and more research is needed to extend knowledge regarding the full range of 
mood disorders, clarify the involvement of parallel visual streams, elucidate seasonal 
patterns, and confirm the effects o f treatment, including phototherapy and antidepressant 
medications. Nevertheless, initial research does suggest that depressive disorders are 
associated with abnormal functioning in early stages o f the visual system. Both SAD and 
non-seasonal depression have been associated with abnormal luminance contrast 
sensitivity, as well as chromatically selective effects involving the processing of short- 
wavelength light. Chromatic mechanisms related to S-cones comprise a distinct channel 
o f colour vision, with demarcation beginning in the first layer of the retina. Fundamental 
aspects of luminance and chromatic contrast detection, such as those measured by 
sinusoidal gratings, are processed in early stages of the visual system (DeValois & 
DeValois, 1990; Sclar, Maunsell, & Lennie, 1990; Shapley & Enroth-Cugell, 1984). 
Although contrast sensitivity degradation may, in fact, arise anywhere along the visual 
hierarchy, the finding of possible enhancement argues strongly for mechanisms involved 
in the initiation of the signal. In particular, with the lowest signal to noise ratios o f the 
visual system, the retina acts as the limiting neural agent, setting ceiling levels for higher 
order visual performance (Attwell, 1986; Atwell & Wilson, 1983). In concert with 
observations of abnormal retinal light sensitivity in dark adaptation, ERG, and EGG
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studies of SAD and non-seasonal depression, the observed irregularities in chromatic 
processing and luminance contrast sensitivity suggest that visual anomalies in depressive 
disorders are at least partly associated with early stages o f the visual system, are retinal ly 
based, and involve not only vegetative functioning, but visual perception pathways as 
well.
The retina is a particularly accessible part of the brain for investigation, both in 
terms of structure and function. Consequently, understanding of the retina has proceeded 
faster than that o f other areas o f the nervous system, and retinal research has greatly 
contributed to knowledge regarding phenomena of general importance to the field of 
neuroscience (Ames & Nesbett, 1981; Dowling, 1987; Kolb, Nelson, Ahnelt, & Curcia, 
2001). Representing approximately 0.5% of the human brain, the retina involves the 
same mechanisms o f communication found throughout the nervous system, including the 
same neurotransmitter and neuromodulator systems (Sterling & Demb, 2004). 
Dysfunction in retinal communication processes may reflect dysfunction in similar 
processes elsewhere in the brain. Thus, in both schizophrenia and Parkinson’s disease, 
early-stage vision dysfunctions are considered to be a consequence of the 
neurotransmitter dysregulation inherent to the illness.
Neurotransmitters in Depressive Disorders
Neurotransmitters have played a central role in biological theories o f mood 
disorders, beginning with the original monoamine theories of the 1960s which first 
implicated norepinephrine (Schildkraut, 1965), then serotonin (Coppen, 1967), in the 
pathogenesis of depression. The following decade saw an additional interest in dopamine
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as a forerunner in monoaminergic models of mood disorders (Randrup et al., 1975).
These early theories proposed that symptoms of depression were the result of reduced 
levels of the specified monoamine and were based upon the observed therapeutic 
effectiveness o f pharmaceutical compounds acting on respective monoaminergic 
transmitter systems (Slattery, Hudson, & Nutt, 2004). Subsequent research, however, 
suggests that a simple deficiency model is insufficient to explain the involvement of 
monoamines in mood disorders.
While some research has found support for reduced levels of monoamine 
transmitters in depression, results are inconsistent overall (e.g., Cheetham, Katona, & 
Horton, 1991; Duman, Heninger, & Nestler, 1997; Kalia, 2005; Manji, Drevets, & 
Charney, 2001; Nestler et ah, 2002). Moreover, antidepressant medications cause an 
immediate increase in synaptic levels o f monoamines, but the associated mood 
improvements are generally not evident until after at least ten to fourteen days of 
continued administration. Thus, contemporary biological theories o f depression do not 
address monoamines as direct etiological agents, but rather emphasize their extensive 
modulatory actions on a range of other neural processes, including mechanisms of 
neurogenesis and interactions with stress hormones (e.g., Arborelius, Owens, Plotsky, & 
Nemeroff, 1999; Duman, 2002, 2004; Malberg & Schecter, 2005; McEwen, 2005;
Nestler et ah, 2002; Norman, 2006; Pariante & Miller, 2001 ; Slattery et ah, 2004; Young, 
Bakish, & Beaulieu, 2002). Indeed, the number of monoaminergic neurons in the brain 
is relatively small compared to other transmitter systems, but their axonal projections are
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distributed widely throughout the central nervous system and interact with a diversity o f 
other neurochemicals and receptors (Kalia, 2005).
Recent investigations have begun to explore the relationship between mood 
disorders and the more prevalent amino acid transmitters. A growing body of evidence 
implicates both GABA, which is the primary inhibitory neurotransmitter in the brain, and 
glutamate, the main excitatory neurotransmitter. Abnormal levels o f these transmitters 
have been associated with mood disorders (Brambilla, Perez, Barale, Schettini, & Soares, 
2003; Choudry et ah, 2005; Kelmendi, Saricicek, & Sanacora, 2006; Paul & Skolnick, 
2003; Sanacora et ah, 2004). Pharmacological compounds which affect the GABAergic 
and glutamateric systems have shown antidepressant efficacy (Brambilla et ah, 2003; 
Kendell, Krystal, & Sanacora, 2005; Sanacora, Rothman, Mason, & Krystal, 2003; 
Slattery & Cry an, 2006; Zarate et ah, 2004, 2006). Current medication treatments for 
mood disorders exert modulatory effects on both of these systems (Kelmendi et ah, 2006; 
Sanacora, Mason, Rothman, & Krystal, 2002; Slattery & Cry an, 2006), which is likely 
related to the known interactions of both GABA and glutatmate with serotonin and 
dopamine in the CNS (Gong, Neil, & Justice, 1998; Kelmendi et ah, 2006; Kendell et ah, 
2005; Varga, Sik, Freund, & Kocisis, 2002).
Antidepressant medications. Although recent inquiries are exploring neural 
processes beyond a simple monoamine deficiency model, it should be noted that the 
currently approved antidepressant medications in clinical use exert their primary effects 
through increases in synaptic levels o f serotonin, norepinephrine, and dopamine, alone or 
in combination, and this increase does lead to therapeutic improvements in mood
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(Slattery et al., 2004). There are several classes o f antidepressants that vary in terms o f 
their method of increasing monoamine functioning as well as their degree of involvement 
with the different monoamines (Marangell & Martinez, 2006; Schatzberg, Cole, & 
DeBattista, 2005). First generation antidepressant medications, including monoamine 
oxidase inhibitors (MAO-Is) and tricyclic antidepressants (TCAs), increase the 
availability of monoamines in a non-selective manner, leading to notable side-effects 
along with symptom improvement. Second generation antidepressants have been 
designed to limit their actions to specific monoamines. Serotonin has been a primary 
focus o f the majority o f these newer drugs, which include several selective serotonin 
reuptake inhibitors (SSRIs), as well as 5-HT receptor antagonists. The norepinephrine 
system is targeted by selective norepinephrine reuptake inhibitors and mirtazapine, a 
norepinephrine modulator. Dual-action antidepressants include those which affect both 
serotonin and norepinephrine levels, as well as bupropion, which increases 
norepinephrine and dopamine. It is worth noting that the various pharmacological 
profiles of antidepressant medications may also have differential effects on retinal 
neurotransmission.
The use o f antidepressant medications has increased steadily since their 
introduction, with a particularly dramatic rise in prevalence in recent years. Analysis o f a 
province-wide person-specific pharmacy database found that 7.2% of British Columbia 
residents had filled an antidepressant prescription in 2004, compared to only 3.4% in 
1996 (Raymond, Morgan, & Gaetano, 2007). These prevalence rates were consistent with 
other Canadian reports (Beck et al., 2005; Fransoo et al., 2005) and reflect a trend of
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increasing antidepressant use that has been observed in several North American and 
European studies (Mant et ah, 2004; Olfson et ah, 2002; Poluzzi et ah, 2004; Rosholm, 
Andersen, & Gram, 2001; Stagnitti, 2005, as cited in Patten, Esposito, & Carter, 2007). 
One explanation for this trend is the notable expansion of therapeutic indications for 
antidepressant medications. Various SSRIs and serotonin norepinephrine re uptake 
inhibitors (SNRIs) have been approved for the treatment of anxiety disorders, including 
obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), 
generalized anxiety disorder (GAD), and social phobia (Marangell & Martinez, 2006; 
Physicians’ Desk Reference, 2007; Schatzberg et ah, 2005). Additionally, antidepressant 
medications are prescribed for the treatment o f bulimia, borderline personality disorder, 
attention-deficit disorder, autism, neuropathic pain conditions, sexual dysfunction, 
migraine headaches, and smoking cessation (Larson, Miller, & Fleming, 2007; Marangell 
& Martinez, 2006; Patten et ah, 2007; Schatzberg et ah, 2005; Stone, Viera, & Parman, 
2003). In 2005, just under two-thirds o f the antidepressant medication treatments 
recommended by a representative sample of Canadian physicians were for reasons 
related to depression (Patten et ah, 2007). Thus, there is widespread applicability for 
antidepressant pharmacology, especially the second generation drugs which are generally 
better tolerated than original antidepressant medications, although nevertheless 
associated with their own sets of side-effects (Marangell & Martinez, 2006; Schatzberg 
et ah 2005). Diverse uses o f antidepressant medication make it possible to examine their 
effects outside o f depression, which may help disentangle the influence o f drug versus 
disorder in studies o f visual functioning.
DEPRESSION, ANTIDEPRESSANTS, AND VISION 42
Visual consequences of antidepressant medication. Ophthalmic side-effects are 
common with the use o f antidepressant medications. Tricyclic antidepressants, in 
particular, are frequently accompanied by visual disturbances due to their high affinity 
for muscarinic acetylcholine receptors leading to notable anticholinergic side-effects 
(Schatzberg et ah, 2005). Blurred vision occurs in 30% of patients beginning TCA 
treatment (Oshika, 1995) and is usually caused by interference with accommodation due 
to cycloplegia, a paresis of the ciliary muscles of the lens (Pollack & Rosenbaum, 1987; 
Pollack & Smoller, 1996; Riedel & van Praag, 1995). Disturbances of near vision or 
presbyopia are also common with TCAs as a result o f mydriasis, which involves 
pupillary dilation and sluggish pupillary reaction to light (Pollack & Rosenbaum, 1987; 
Pollack & Smoller, 1996; Riedel & van Praag, 1995). These conditions tend to remit 
after a few weeks o f treatment and are generally reported as mild to moderate 
disturbance. However, more serious ophthalmic conditions are also possible with TCA 
use, such as increased intraocular pressure and increased risk of acute glaucoma (Oshika, 
1995; Pollack & Rosenbaum, 1987; Pollack & Smoller, 1996; Riedel & van Praag,
1995). Other types of antidepressant drugs, including newer medications, are similarly 
associated with visual disturbances, despite minimal anticholinergic effects. Duloxetine 
is linked to an increased risk of glaucoma due to mydriasis (Marangell & Martinez,
2006). Imipramine and nefazodone are commonly discontinued by patients due to 
complaints o f amblyopia (Preskorn, 1995). Nefazodone and trazodone are both 
associated with blurred and abnormal vision, including scotoma, palinopsia, and visual 
trails (Marangell & Martinez, 2006; Mosberian, Leung, Hollander, & Remick, 1999;
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Schatzberg et ah, 2005; Schwartz, 1997). MAO-Is have mild effects on accommodation, 
leading to blurred vision (Oshika, 1995). In fact, blurred or abnormal vision is listed as a 
side-effect for nearly all antidepressant medications (P hysician’s Desk Reference, 
2009). Side-effects studies generally do not investigate causal mechanisms or report on 
the severity or duration of these side-effects, so the nature of these visual disturbances is 
often unclear. Nevertheless, taken as a whole, the literature indicates that antidepressant 
pharmacologies are commonly associated with ophthalmic dysfunction.
Only one study has directly examined the effect of antidepressant medication on 
early-stage visual processing. Seggie et ah (1989) found that two to six weeks of 
treatment with doxepin, a TCA, decreased the light sensitivity o f depressed participants 
in a dark adaptation study. Specifically, cone-mediated sensitivity, which had been 
elevated prior to treatment, was normalized to levels similar to those of healthy control 
participants. Rod-mediated sensitivity, which had previously been comparable to control 
levels, was significantly lower in depressed individuals following treatment. This finding 
of reduced retinal light sensitivity is similar to results regarding the visual effects of 
lithium (Wirz-Justice et ah, 1997), a mood stabilizer used to treat bipolar depressive 
disorder.
Contrast sensitivity has been explored in a study using nomifensine, a dopamine 
reuptake inhibitor which was originally used as an antidepressant in the 1970s, but is 
now restricted to research purposes due to concerns about its long-term use. An 
investigation of healthy volunteers found that a single dose of nomifensine increased 
contrast sensitivity for medium and high spatial frequencies and lowered contrast
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sensitivity to spatial frequencies below 2 cpd (Domenici, Trimarchi, Piccolino,
Fiorentini, & Maffei, 1985). The same study also examined the effects o f levodopa, a 
precursor to dopamine commonly used to treat Parkinson’s disease. Results were similar 
among healthy volunteers, with a single dose of levodopa increasing contrast sensitivity 
for medium spatial frequencies most notably, as well as high spatial frequencies. This is 
consistent with other studies o f levodopa that found contrast sensitivity improvements for 
patients with Parkinson’s disease (e.g., Hutton, Morris, & Elias, 1993; Mestre, Blin, van 
den Brand, Azulay, & Serratrice, 1996; Pierelli et ah, 1988). Other medications used in 
the treatment o f Parkinson’s disease have also been associated with contrast sensitivity 
effects. For example, healthy volunteers were tested with apomorphine, a dopamine 
agonist, and demonstrated reduced contrast sensitivity for low spatial and high temporal 
frequencies, as well as elevated contrast sensitivity for high spatial frequencies (Blin, 
Mestre, Masson, & Serratrice, 1991). Piribedil, another dopamine agonist used for 
Parkinson’s disease, improved age-related contrast sensitivity deficits for low spatial 
frequencies among healthy elderly individuals (Corbe, Arnaud, Brault, & Janiak- 
Bolzinger, 1992). Finally, contrast sensitivity has also been explored in relation to 
lorazepam, which acts on GABA receptors, and is most commonly used as an anxiolytic. 
A single dose of lorazepam in healthy volunteers resulted in reduced contrast sensitivity 
to moving gratings which was most pronounced at lower spatial frequencies and not 
apparent above 8 cpd (Harris & Phillipson, 1995). Among long-term lorazepam users, 
impaired contrast sensitivity was observed in the low to middle range of spatial
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frequencies, particularly between 1 and 4 cpd (Giersch, Speeg-Schatz, Tondre, & 
Gottenkiene, 2006).
The use o f antidepressant medication has commonly been linked with certain 
visual side-effects, but these are generally related to disturbances in the optics of the eye, 
including the lens and pupil. Investigation of visual functions related to the retina and 
other early neural processes has been minimal, but does indicate that antidepressant 
medication can impact early-stage neural functions of the visual system. As evident in 
schizophrenia research, an understanding of pharmacological effects is important at the 
outset of vision research in depressive disorders. Thus, one of the primary purposes of 
the present study is to examine the consequences of anti depressant medication on basic 
visual functions, including luminance and chromatic contrast sensitivity.
Retina] Connections and Communication
A number of disorders that involve substantial dysregulation o f brain 
neurotransmitters have demonstrated abnormal visual functioning. Similarly, the 
neurotransmitter actions of neuropharmacological medications are also known to induce 
visual disturbances related to both the optics and neural processes o f the early visual 
system. In the area of mood disorders, vision research is relatively new but does indicate 
anomalies o f light sensitivity, luminance contrast sensitivity, and chromatic functioning, 
all of which are dependent upon the connections and neurotransmission of information in 
the retina before being processed by central visual systems.
Several layers of neurons compose the retina (see Sterling & Demb, 2004, for 
review). Photoreceptors are the first of these, collecting light which has traveled through
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the pupil and lens and arrived at the back of the eye. Their primary job is to transduce 
light energy into neural energy. Photoreceptors connect to bipolar cells in the outer 
plexiform layer, which connect to ganglion cells in the inner plexiform layer, whose 
axons gather to form the optic nerve. These connections represent the forward 
transmission of neural information through the eye to visual areas in the rest o f the brain. 
There are also neurons for lateral communication at each of these layers; horizontal cells 
extend across the outer plexiform layer and amacrine cells run laterally throughout the 
inner plexiform layer. Lateral processes coordinate information across the expanse of the 
eye and are integral in shaping the receptive fields o f bipolar and ganglion cells involved 
in forward transmission.
There is substantial diversity in the methods o f neural communication observed in 
the retina, including conventional chemical synapses, chemical synapses that involve 
synaptic ribbons, and electrical synapses, such as gap junctions between neighbouring 
neurons. Most retinal neurons use graded potentials, signaling an increase or decrease of 
activity through an incremental disruption of sustained transmitter release. Action 
potentials are only observed in ganglion cells, whose axons extend a notable distance 
through the optic nerve, as well as certain amacrine cells. Chemical communication 
occurs both traditionally, with neurotransmitters released into synaptic clefts, as well as 
in a paracrine or hormone-like manner, where certain transmitters diffuse throughout 
retinal space to affect neurons distant from the site of release (Witovsky, Nicholson,
Rice, Bowmaker, & Meller, 1993; Yazulla & Studholme, 1995).
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Neurotransmitters in the retina. Essentially all of the neurotransmitters found 
throughout the CNS are evident in the retina (Sterling & Demb, 2004). Glutamate and 
GABA are the most prominent retinal transmitters, involved in excitatory and inhibitory 
responses, respectively. Glutamate is the primary transmitter of forward transmission, 
released by photoreceptors onto bipolar and horizontal cells and by bipolar cells onto 
ganglion and amacrine cells. GABA is the primary transmitter o f lateral transmission, 
released by horizontal cells onto cone terminals and bipolar cells and by amacrine cells 
onto bipolar and ganglion cells. Many retinal neurons contain more than one transmitter. 
For example, certain bipolar cells release both glutamate and GABA (Kao et ah, 2003). 
Half o f amacrine cells contain glycine, while the other half contain GABA. The latter 
also often contain a second transmitter, such as acetylcholine, various neuropeptides, or 
monoamines, including dopamine and serotonin (Casini & Brecha, 1992; Sagar, 1987; 
Vaney, 1990, 2003).
Dopamine has been established as a major retinal neuro transmitter and 
neuromodulator, involved in multiple processes throughout the retina, including 
mechanisms of contrast detection and light adaptation. It is present in certain amacrine 
and interplexiform cells of mammalian retina (Djamgoz, Hankins, & Archer, 1997; 
Frederick, Rayborn, Laties, Lam, & Hollyfield, 1982; Massey & Redburn, 1987), 
synthesized in conditions of light and released in a graded light-dependent manner 
(Djamgoz & Wagner, 1992; Haggendal & Malmfors, 1965; luvone, Galli, Garrison- 
Gund, & Neff, 1978). Several classes o f dopamine receptors have been identified in the 
retina, associated with different processes or in some cases, associated with the same
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process, but with antagonistic regulatory effects (Djamgoz et ah, 1997). As well as 
working at conventional synapses, dopamine also acts in a paracrine fashion. For 
example, dopamine released by amacrine cells in the inner plexiform layer diffuses 
through the retina to inhibit the gap junction connections of horizontal cells and 
photoreceptors in the outer plexiform layer (DeVries & Schwartz, 1989; Dowling, 1991; 
Piccolino, Neyton, Gerschenfeld, 1984; Lasater & Dowling, 1985; Sterling & Demb, 
2004; Teranishi, Negishi, & Kato, 1983, 1984).
Contrast sensitivity is affected by dopamine modulation of receptive field 
organization (Djamgoz et ah, 1997). This is largely achieved through inhibition of gap 
junction coupling in horizontal cells, which feed the surround portion o f receptive fields 
in forward transmission (Kaneko, 1973). By regulating the spatial summation o f lateral 
neurons, dopamine modulates the center-surround signal o f forward neural pathways, 
which is critical for contrast detection. Dopamine deficiency, induced experimentally in 
animal studies and in pathological hypodopaminergic conditions, such as Parkinson’s 
disease, results in decreased contrast sensitivity, with some studies finding reductions 
limited to low spatial frequencies and other studies reporting decreases most apparent for 
medium and high spatial frequencies (e.g., Bodis-Wollner, 1988, 1990; Ghilardi, Bodis- 
Wollner, Onofrj, Marx, & Glover, 1988; Masson, Mestre, & Blin, 1993; Tagliati, Bodis- 
Wollner, & Yahr, 1996). Conversely, an excess of dopamine may lead to increased 
contrast sensitivity. In pharmacological studies with healthy volunteers, the 
administration o f a dopamine agonist results in enhanced contrast sensitivity for medium 
to high spatial frequencies and a tendency toward reduced sensitivity to low spatial
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frequencies (Domenici et al., 1985; Masson et al., 1993). Investigation of drug treatments 
for Parkinson’s disease and animal studies have similarly observed that the effects of 
dopamine on contrast sensitivity vary according to spatial frequency, causing low 
frequency attenuation and medium to high frequency amplification (Bodis-Wollner,
1987, 1990; Hutton, Morris, Elias, 1993). This may be due to different dopamine 
receptors; some evidence suggests that D 1 receptors are associated with low spatial 
frequencies, attributed to their presumed involvement with large-centre ganglion cells, 
while D2 receptors are associated with medium and high spatial frequencies, related to 
possible center-response amplification o f ganglion cells with smaller centres (Bodis- 
Wollner & Tzelepi, 1998; Stormann, Gdula, Weiner & Brown, 1990). Dopamine has also 
been implicated in the contrast gain associated with temporal modulation and 
illumination levels (Jensen & Daw, 1986; Masson et al., 1993).
The bipolar and ganglion cells o f forward retinal pathways are thought to be 
affected by dopamine directly, as well as the indirect effects caused by dopaminergic 
modulation of the lateral neurons they connect with. Specifically, both the spontaneous 
and light-evoked responses of bipolar and ganglion cells have been shown to be 
influenced by dopamine (Djamgoz et al., 1997; Djamgoz & Wagner, 1992; Holopigan, 
Clewner, Seiple, & Kupersmith, 1994; Jensen & Daw, 1988; Maguire & Hamasaki,
1994; Maguire & Werblin, 1994; Shiells & Falk, 1985; Wellis & Werblin, 1995). 
Additionally, some ganglion cells use dopamine as a neurotransmitter in their 
communication with central areas of the visual system (Simon & Nguyen-Legros, 1995).
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Dopamine is also known to regulate the efficiency o f other retinal transmitter systems, 
including GAB A and glutamate (Yazulla & Kleinshmidt, 1982).
Dopamine is mainly active in light or day phases, and is thus linked primarily to 
cone-mediated vision and the transition to photopic vision (Djamgoz et al., 1997; 
Djamgoz & Wagner, 1992; Dong & McReynolds, 1991; Godley & Wurtman, 1988). 
Photoreceptor disc shedding is inhibited by dopamine (Besharse, luvone, & Pierce,
1988). Additionally, dopamine potentiates the glutamatergic input o f photoreceptors to 
horizontal cells (Hankins & Ikeda, 1991; Hedden & Dowling, 1978; Knapp & Dowling, 
1987). Because there is cone selectivity in connections between photoreceptors and 
horizontal cells (Ahnelt & Kolb, 1994), dopamine regulation at this level may be 
associated with chromatic signal specificity (Djamgoz et ah, 1997).
There is a mutually antagonistic relationship between dopamine and melatonin in 
the retina which optimizes the visual system’s adaptation to natural cycles of dark and 
light (Morgan & Boelen, 1996). Specifically, dopamine production is stimulated by light 
and inhibited by melatonin, while melatonin synthesis occurs in dark conditions 
(Dubocovich, 1983; Dubocovich, Lucas, & Takahashi, 1985) and is inhibited by 
dopamine (Cohen, Todd, Harmon, & O ’Malley, 1992; Tosini & Dirden, 2000). 
Importantly, serotonin is a precursor to retinal melatonin. Processes which affect the 
conversion of serotonin to melatonin thus alter the availability o f retinal serotonin.
Serotonin has been implicated in retinal functioning for several decades (Ames & 
Pollen, 1969). Indoleamine accumulating cells (IAGs) are specific amacrine cells in the 
retina that actively take up serotonin through both high and low affinity transporter
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mechanisms (Brunken, Jin, & Pis-Lopez, 1993; Ehinger & Holmgren, 1979; Holmgren- 
Taylor, 1982; Matsumoto, Ueda, & Kawata, 1992; Osborne & Barnett, 1990; Osborne, 
Nesselhut, Nicholas, Patel, & Cuello, 1982; Sandell & Masland, 1986; Sandell, Masland, 
Raviola, & Dacheux, 1989; Wassle, Voigt, & Patel, 1987). lACs do not appear to 
synthesize notable amounts of endogenous serotonin, however. In fact, only low levels of 
endogenous serotonin have been found in mammalian retina, most o f which appears to be 
synthesized by photoreceptors as a precursor for melatonin (Chanut, Nguyen-Legros, 
Labarthe, Trouvin, & Versaux-Botteri, 2002; Ehinger & Floren, 1978; Gastinger, Tian, 
Horvath, & Marshak, 2006; Osborne, 1980, 1984; Osborne & Barnett, 1990; Redburn & 
Churchill, 1987). However, all major serotonin receptors have been identified in the 
retina (Mitchell & Redburn, 1985; Osborne et al., 1993; Perez-Leon, Sarabia, Miledi, & 
Garcia-Alcocer, 2004; Pootanakit & Brunken, 2000, 2001; Pootanakits, Prior, Hunter, & 
Brunken, 1999), indicating that, in addition to serving as a melatonin precursor, serotonin 
also plays a role in retinal neuromodulation and/or neurotransmission.
Serotonin is the primary transmitter for one o f two sets of retinopetal axons that 
extend into the retina from other parts of the brain (Chanut et ah, 2002; Gastinger et ah, 
2006; Gastinger & Marshak, 2005; Lima & Urban, 1998). These are not specialized to 
supply the retina, but rather are a subset of ascending arousal systems that project 
throughout the CNS. The centrifugal fibers of the serotonergic retinopetal system 
originate in the dorsal raphe and branch mainly in the layer of retinal ganglion cells 
(Gastinger et al., 2006). Serotonin released by these fibers is used as a transmitter by 
retinal neurons and collected by lACs (Gastinger et al., 2006). The majority of lACs
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arborize extensively in the inner plexiform layer, forming a dense network that spans the 
retina, while a smaller number o f lACs distribute sparsely through both the inner and 
outer plexiform layers (Sandell & Masland, 1986).
Indoleamine accumulating cells form reciprocal synaptic connections specifically 
with rod bipolar cells, suggesting a role for serotonin in scotopic or mesopic conditions 
of illumination (Daw, Brunken, & Parkinson, 1989; Daw, Jensen, & Brunken, 1990; 
Fletcher & Wassle, 1999; Sandell et al., 1989). Serotonin is also important in scotopic or 
mesopic vision as a precursor for melatonin, which is synthesized in dark conditions. 
Alternatively, investigators have observed a light-evoked release o f retinal serotonin 
(Ames & Pollen, 1969; Brunken & Daw, 1988a; Mangel & Brunken, 1992; Valenciano, 
Alonso-Gomez, & luvone, 1999). This may be related to the serotonergic retinopetal 
axons, which fire most rapidly during waking hours, thus releasing more serotonin during 
the day among diurnal animals (Gastinger et al., 2006). Consequently, serotonin is also 
involved in photopic vision.
All classes of ganglion cells receive input from lACs and appear to be the 
primary target of most serotonin activity in the retina (Brunken & Daw, 1987, 1988a; 
Brunken et ah, 1993). Serotonergic agents impact the principal functions of ganglion 
cells, which are responsible for retinal output to higher areas of the visual system. 
Specifically, serotonin affects the spontaneous activity, light-evoked response, and 
receptive field surrounds of ganglion cells (Brunken & Daw, 1986, 1987, 1988a, 1988b; 
Brunken et al., 1993; Brunken & Jin, 1993; Sandell et al., 1989). The direction of effect 
is dependent on which serotonin receptors are activated. Pharmacological studies indicate
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that 5-HT2 receptors are linked to enhanced ganglion cell activity, whereas 5-HTia 
receptors are associated with reduced ganglion cell activity (Brunken et al., 1993;
Mangell & Brunken, 1992; Osborne & Barnett, 1990). Although the application of 
serotonergic agents does not appear to have direct impact on photoreceptors, horizontal 
cells, or bipolar cells, part of their influence on ganglion cell activity is mediated through 
these preliminary processes. For instance, while serotonin does not alter the responding 
of horizontal cells, it does modulate their ability to affect ganglion cells’ surround fields 
(Mangel & Brunken, 1992). Also, the application of serotonin does not lead to any 
immediate effects on bipolar cells, but is associated with a slower, long-lasting 
potentiation of their response to photoreceptor input, suggesting that serotonin may be 
involved in the adaptational processes of bipolar cells (Skrandies & Wassle, 1988). 
Additionally, serotonin affects the release o f other retinal neurotransmitters, including 
modulation o f GABA and inhibition o f dopamine (Neal, Cunningham, & Matthews,
2001; Perez-Leon et ah, 2004; Gastinger et al., 2006).
Both serotonin and dopamine have been the focus of monoamine theories of 
depression and pharmacological intervention. Although a simple deficiency hypothesis 
has been excluded, alterations in brain levels o f serotonin and dopamine exert significant 
modulatory effects on other processes and downstream systems, and they remain the 
initial locus o f currently available antidepressant medications. Their important role in 
basic visual functions provides a link between depressive disorders and possible vision 
disturbance. That is, dysregulation o f serotonergic and dopaminergic systems in central 
brain regions may also manifest in disruption o f these systems in the retina and other
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early stages of visual processing. Similarly, GABA and glutamate, the primary retinal 
neurotransmitters, have recently been implicated in the pathophysiology of depressive 
disorders.
Chromatic visual channels. The possible involvement of chromatic processes in 
visual anomalies o f depressive disorders also draws attention to distinct pathways of 
colour vision communication in the early stages of the visual system. Wavelength 
specific signals from the S-, M-, and L-cone photoreceptors are recoded into “red-green” 
and “blue-yellow” colour opponent channels in subsequent retinal neurons; the “red- 
green” channel contrasts signals from L- and M-cones and the “blue-yellow” channel 
contrasts S-cone signals with L- and M-cone signals combined. The two chromatic 
channels are thought to have evolved at different times and for different purposes and 
their substrates remain anatomically distinct. The majority of cone photoreceptors in the 
human retina are of the L- and M-cone types, which are densely packed in the fovea and 
decline in number with increasing eccentricity. S-cones comprise fewer than 10% of all 
cones (Dartnall, Bowmaker, & Moller, 1983). They are sparsely distributed across the 
retina, being most prevalent just outside the fovea, then declining gradually with 
increasing eccentricity. Inside the fovea, S-cones are scarce and appear to be entirely 
absent at the fovea centralis. It was initially believed that both colour-opponent channels 
were mediated by the parvocellular stream. However, it is now understood that not only 
are the “red-green” and “blue-yellow” channels associated with distinct cell 
morphologies and physiologies, but they also occupy separate retino-cortical projecting
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streams (Dacey, 1999; Goodchild & Martin, 1998; Hendry & Reid, 2000; Martin, White, 
Goodchild, Wilder, & Septon, 1997).
The retinal connections related to S-cones are discrete and largely independent 
from L- and M-cone connections. Among L- and M-cones, small gap junctions couple 
immediate neighbours, but S-cones are excluded from this interreceptor pathway (Ahnelt 
& Kolb, 1994; Hornstein, Verweij, & Schnapf, 2004; Li & DeVries, 2004). O f the two 
types of lateral processes in the outer plexiform layer, the wide-field horizontal cell, 
which has thick dendrites and couples strongly to its neighbours, avoids S-cone contact, 
while the narrow-field horizontal cell, with thin dendrites and weak gap junctions, 
connects especially strongly to S-cones (Dacey, Lee, Stafford, Pokorny, & Smith, 1996; 
Mills & Massey, 1994; Piechl & Gonzalez-Soriano, 1994; Sandmann, Boycott, & Peichl, 
1996; Vaney, 1990). There is also a distinct population of bipolar cells which connect 
exclusively to S-cones (Herr, Klug, Sterling, & Schein, 2003; Kolb, Goede, Roberts, 
McDermott, & Gouras, 1997; Kouyama & Mashak, 1992, 1997; Mariani, 1984). These 
supply a family o f ganglion cell types that carry “blue-yellow” opponent signals to 
higher areas of the visual system. The most prominent is the small-field hi stratified 
ganglion cell type, which signals blue-ON, yellow-OFF colour opponency with one set of 
dendritic connections contacting S-cone bipolar cells and another set contacting bipolar 
cells conveying L- and M-cone information (Calkins, et al., 1998; Dacey, 1993; Dacey & 
Lee, 1994; Dacey et al., 1996; Ghosh, Martin, & Grunert, 1997). S-cone bipolar cells 
also connect to a large-field bistratified ganglion cell, which signals a blue-ON type of 
response (Dacey, Peterson, Robinson, & Gamlin, 2003), as well as to a sparse
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monostratified ganglion cell type that is thought to carry an S-OFF signal by sign 
inverting the bipolar cell signal (Dacey & Packer, 2003; Klug, Herr, Ngo, Sterling, & 
Schein, 2003). These S-cone related ganglion cells project in parallel to the LGN. Both 
the midget ganglion cells of the parvocellular system and the parasol ganglion cells of the 
magnocellular system collect information derived from L- and M-cones, but avoid input 
from S-cone related processes (Sun, Smithson, Zaidi, & Lee, 2006a, 2006b).
Beyond the retina, the “blue-yellow” channel appears to remain distinct. While 
projections from some types of the S-cone family of ganglion cells are not yet clear, the 
small bistratified ganglion cells are known to project to koniocellular zones o f the lateral 
geniculate nucleus (Hendry & Reid, 2000; Martin et ah, 1997), and not to the main 
parvocellular layers, as was orginally presumed. Information from the koniocellular areas 
of the LGN projects directly to the colour-processing blobs of layers II and III o f the 
primary visual cortex (Hendry & Yoshioka, 1994), whereas information from LGN 
parvocellular layers first projects to layer IV-Cp of the primary visual cortex, before 
connecting to the blobs in layers II and III. Thus, the koniocellular stream is now 
considered to represent a distinct stream for “blue-yellow” chromatic processes driven by 
S-cone mediated mechanisms o f the retina (Hendry & Reid, 2000). Psychophysical tests 
can be used to separately assess the performance of “red-green” and “blue-yellow” 
opponency channels, thus distinguishing possible involvement o f the parvocellular and 
koniocellular visual streams.
DEPRESSION, ANTIDEPRESSANTS, AND VISION 57
Proposed Model of Retinal Mechanisms and Visual Anomalies in Depression
Communication in the retina, as in the rest of the brain, involves an intricate 
network o f diverse and specialized interconnections. Despite our enormously improved 
understanding of retinal physiology within the last 50 years, a complete and detailed 
understanding o f the full complexity o f retinal communications has yet to be achieved. 
Consequently, while pathway localization is possible, it is difficult to state with certainty 
which specific mechanisms or substrates are responsible for given vision abnormalities. 
This is particularly challenging in the area o f depressive disorders, where vision research 
has only recently been initiated and early findings require much clarification. Further, the 
elusiveness o f the biological underpinnings of mood disorders also makes interpretation 
difficult. Nevertheless, it is possible to construct a working hypothesis about specific 
retinal mechanisms that can account for many of the visual anomalies that have so far 
been observed in depressive disorders: abnormal retinal light sensitivity; potential 
enhancement o f contrast sensitivity at high spatial frequencies, with low spatial and high 
temporal frequencies relatively unaffected; and S-cone selectivity in phototherapeutic 
and, possibly, pharmacological treatments.
The serotonergic system has received the most attention in biological theories o f 
depression and is the target of the most commonly prescribed antidepressants. 
Dysfunction in the serotonin system could affect the early stages o f visual processing. 
Serotonin is integral to the production of melatonin, which is a major inhibitor of 
dopamine synthesis in the retina (Brunken et al., 1993; Dubocovich et al., 1985; Tosini & 
Dirden, 2000). Low levels o f serotonin impede melatonin production, contributing to an
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excess of retinal dopamine. Because dopamine is a primary neurotransmitter and 
neuromodulator in the retina involved in basic visual functions o f light adaptation and 
contrast sensitivity, its dysregulation would have an extensive impact on early-stage 
visual processes.
Retinal dopamine is stimulated by light. Thus, an increase o f dopamine levels in 
the retina normally signals an increase in light levels, and initiates relevant mechanisms 
o f adaptation, including adjustments of retinal light sensitivity (luvone, 1978; Godley, 
Flaherty, & Wurtman, 1985). Abnormally elevated dopamine would instigate retinal 
adaptation processes not concordant with actual light conditions. This may account for 
the findings of atypical retinal sensitivity to ambient light among individuals with SAD 
and non-seasonal depression (e.g. Oren et al., 1991; Seggie et al., 1989; Terman & 
Terman, 1999). Light levels are also associated with contrast sensitivity, fundamental to 
higher-end pattern or form perception. Under normal conditions, increases of 
surrounding light trigger a shift in the peak o f contrast sensitivity functions toward higher 
spatial frequencies (Ehinger, 1983; Shapley & Enroth-Cugell, 1984). This resembles the 
high spatial frequency enhancement in luminance contrast sensitivity that was observed 
in Wesner and Tan (2006). Essentially, the contrast sensitivity functions of depressed 
individuals may be similar to what is observed in healthy individuals under increased 
light conditions. However, in the case of depression, it may be deficits of serotonin, 
rather than light changes, that cause the elevated dopamine levels associated with 
contrast sensitivity shifts (Wesner & Tan, 2006).
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By uncoupling the gap junction connections o f horizontal cells, dopamine 
modulates the size o f the surround portions of receptive fields (Djamgoz et ah, 1997). An 
excess of retinal dopamine would intensify this uncoupling, effectively reducing 
receptive field size. Smaller receptive fields are better suited to the processing of finer 
details or higher spatial frequencies o f the visual image. Thus, elevated levels of 
dopamine would enhance retinal sensitivity to higher spatial frequencies. This effect 
would be particularly pronounced among narrow-field horizontal cells, which have 
relatively weaker connections to their neighbours than wide-field horizontal cells (Mills 
& Massey, 1994; Peichl & Gonzalez-Soriano, 1994; Peichl, Sandmann, & Boycott, 1998; 
Sandmann, et ah, 1996). Since narrow-field cells are involved in the processing o f higher 
spatial frequencies, dopamine dysregulation can be expected to disrupt the parvocellular 
and koniocellular streams more than the magnocellular stream, which is primarily 
associated with wide-field cells. Additionally, narrow-field horizontal cells make strong 
connections to S-cones, while these are explicitly avoided by wide-field horizontal cells 
(Dacey et ah, 1996; Sandmann et ah, 1996; Sterling & Demb, 2004). Effects specific to 
narrow-field horizontal cells may therefore selectively impact S-cone mediated 
processes, while L- and M-cone processes may remain intact through their 
interconnections with wide-field horizontal cells.
In sum, this hypothesis suggests that a reduced availability of serotonin among 
individuals with depression results in an excess o f dopamine in the retina, leading to 
enhanced luminance contrast sensitivity for higher spatial frequencies. The increased 
vulnerability to dopaminergic de-coupling between narrow-field horizontal cells would
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also selectively impact S-cone connections. Thus, the koniocellular stream is expected to 
be most susceptible to the neurotransmitter dysregulation associated with depression. The 
parvocellular stream is also expected to be impacted, but to a lesser degree, due to more 
redundancy and interconnections, while the magnocellular stream is expected to remain 
unaffected. Antidepressant medications are anticipated to reverse these visual 
abnormalities.
This working hypothesis does not refer to a number of other important links 
between the biology of depression and basic visual functions. For example, serotonergic 
dysregulation in depression may also have a direct impact upon retinal processes, outside 
o f any interaction with dopamine. Conversely, disturbances in retinal dopamine may not 
be mediated by serotonin, but may instead be related to the proposed dopaminergic 
dysfunction in depression. Other neurotransmitters which play an important role in visual 
processes, such as GABA and glutamate, have also been implicated in depressive 
disorders and may contribute to visual disturbances.
The Present Study
The proposed model is based upon observations o f visual anomalies which need 
to be confirmed and clarified. Since psychophysical investigation of visual processes has 
only recently begun to be applied in the area o f depressive disorders, further research is 
required to establish the nature and pathway involvement of potential vision 
abnormalities. Awareness o f the effects of antidepressant medication on vision is crucial 
to avoid confounds and misinterpretation of causality. Investigation of antidepressant 
treatment additionally contributes to an increased understanding of the relationship
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between visual perception and neurobiological substrates of depression. Further, given 
the rising prevalence and increased range of uses for antidepressant pharmacology, 
knowledge o f the visual effects of antidepressant medications is important in its own 
right, regardless o f diagnosis. Current information concerning antidepressant treatment 
and vision is largely limited to self-reported side-effects studies assessing non-specific 
visual complaints, such as blurring or dullness.
The present study was intended to collect detailed and objective information 
about the impact o f depression and antidepressant medication on fundamental processes 
o f visual perception. Specifically, spatiotemporal luminance contrast sensitivity and 
chromatic processes were explored with a set o f non-invasive psychophysical tests 
designed to assess the involvement of the magno-, parvo-, and koniocellular streams. 
Analyses included a comparison of medicated and unmedicated individuals, with and 
without symptoms of depression. Measures o f anxiety were also included due to high 




Participants were recruited from among the university population and the larger 
community. At the university, announcements were made in psychology classes and 
advertisements were posted on bulletin boards across campus, at the library, and at the 
student health centre. In the community, radio and newspaper advertisements were used, 
as well as postings at clinics and other health care facilities. Advertisements indicated
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that the study was about the effects of antidepressant medication on visual functioning. It 
was noted that participants would have the opportunity to enter their name in a draw for 
$100. Additionally, students enrolled in certain psychology classes were eligible for three 
bonus points toward their course mark. There were no other direct incentives for 
participation.
Fifty-one individuals completed the study. However, five were removed from 
analysis due to various exclusion criteria, including confounding medical conditions and 
pharmacological prescriptions, eye disease (i.e., macular degeneration), concurrent light 
therapy, and age. Additionally, since only two participants were prescribed bupropion, 
which involves a dopaminergic effect, their data was excluded and the study focused on 
antidepressant medications involving a primary effect on the serotonergic system. A final 
total o f 44 participants were included in analyses. O f these, 29 were university students 
and 15 were recruited from the larger community. Participants ranged from 18 to 41 
years of age, with a mean o f 23.86 {SD  = 6.88). Seventy-five percent were women. All 
had normal or corrected-to-normal visual acuity and no evidence of colour vision 
deficits.
The SSRI group included a total of 13 participants (Table 1), who were taking 
either citalopram (n = 3), fluoxetine (n = 2), paroxetine (« = 3), or sertraline (« = 5).
These had been taken for between 1 and 120 months, with a median duration of 42 
months (M = 45.46, SD =  36.23). Dose regiments were within standard recommended 
protocols (Physicians’ Desk Reference, 2007). All participants indicated either 
depression or anxiety as the reason for their SSRI prescription. In some cases, symptoms
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of both depression and anxiety were endorsed and participants were required to choose 
one as the primary reason, which was found to be consistent with responses to mood and 
symptom questionnaires.
Measures
Screening measures. The Freiburg Visual Acuity Test (Bach, 1996) was used to 
screen for possible visual acuity problems. All participants included in analysis 
demonstrated normal or corrected-to-normal visual acuity. Colour vision deficits were 
assessed using Ishihara pseudoisochromatic plates (1993; 24-plate edition), and no 
problems with colour vision were found among participants.
The Digit Symbol subtest o f the the Wechsler Adult Intelligence Scale -  Third 
Edition (WAIS-III; Wechsler, 1997) was included as a measure o f general attention 
capability, since the psychophysical vision tests are sometimes described as repetitive 
and monotonous, and may present a problem for individuals with limited attention 
abilities. Raw scores on the Digit Symbol subtest were not significantly correlated with 
the dependent variables in any experimental condition {p > .05), nor did they alter the 
pattern of ANCOVA results when entered as a covariate. Thus, Digit Symbol scores 
were not included in primary analyses.
Current mood symptoms. Participants were asked to complete a set of 
standardized self-report questionnaires pertaining to current symptoms o f depression and 
anxiety. These included the Depression Anxiety Stress Scales (S.H. Lovibond & P.F. 
Lovibond, 1995), the Diagnostic Inventory for Depression (Zimmerman, Sheeran, &
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Young, 2004), and the State-Trait Anxiety Inventory (Spielberger, Gorsuch, & Lushene, 
1983).
The Depression Anxiety Stress Scales (DASS) were designed to distinguish 
between respondents’ experiences of depression, anxiety, and stress over the previous 
week. These three dimensions have been confirmed by exploratory and confirmatory 
factor analysis o f the DASS (Brown, Chorpita, Korotitsch, & Barlow, 1997). Within the 
three scales, test-retest reliability and internal consistency indices are high, with the latter 
demonstrating alpha coefficients of 0.91 for Depression, 0.84 for Anxiety, and 0.90 for 
Stress (P.F. Lovibond & S.FI. Lovibond, 1995). The standard DASS form includes 42 
items, with content from the different scales interspersed throughout the questionnaire. 
Response options are presented in a 4-point Likert scale format. Scores are totaled to 
provide a dimensional score for each scale. Additionally, the authors provide category 
cut-off scores for classifications o f normal, mild, moderate, severe, and extremely severe. 
The DASS Depression and Anxiety scales were used to create dichotomous variables o f 
depressed and anxious mood for data analysis, with participants reporting at least mild 
symptoms being categorized as having depressed or anxious mood.
The Diagnostic Inventory for Depression (DID) evaluates the presence o f an 
episode of depression according to criteria of the D iagnostic and Statistical M anual o f  
M ental D isorders  (4̂ '’ ed., text rev.; DSM-IV-TR; American Psychiatric Association, 
2000). It includes 38 items that are rated with reference to the preceding week. For each 
item, four response options are provided representing a range o f severity for the 
particular symptom being assessed. A scoring guide is provided to evaluate the items
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related to each DSM-IV symptom and to determine if DSM-IV diagnostic criteria are 
met for an episode of depression. Internal consistency o f the DID is high (alpha = .91), as 
is test-retest reliability (Zimmerman et ah, 2004). It has also demonstrated good 
convergent and discriminant validity when compared to other related measures 
(Zimmerman, Chelminski, McGlinchey, & Young, 2006; Zimmerman, McGlinchey, 
Young, & Chelminski, 2007; Zimmerman et ah, 2004). The DID was used to create a 
dichotomous variable o f clinical depression for data analysis.
The State-Trait Anxiety Inventory (STAI) differentiates between the temporary 
experience of ‘state’ anxiety and a more general and long-standing quality of ‘trait’ 
anxiety. It includes 20 items for each scale, which are presented separately. State anxiety 
items refer respondents to how they feel at that moment, while trait anxiety items refer to 
how they generally feel. Response options are presented in a 4-point Likert scale format, 
resulting in total scores for state and trait anxiety. Scores on the STAI-Trait scale were 
used as a covariate in primary data analysis. In some cases, it was necessary to instead 
include trait anxiety as a between-subjects variable. This was accomplished by dividing 
the sample in half according to STAI-Trait scores, creating a low trait anxiety group and 
a high trait anxiety group.
Antidepressant medication questionnaires. In order to determine the reason for 
antidepressant medications, participants were asked to complete the following 
questionnaires with reference to the 6-month time period prior to beginning treatment; 
symptom questionnaires based on DSM-IV-TR criteria for Mood Disorders, Anxiety 
Disorders, and Eating Disorders; DASS and STAI-Trait with instructions adapted to the
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relevant time period; and a checklist o f possible reasons for taking antidepressant 
medications.
Psychophysical Stimuli and Apparatus
S-cone sensitivity. Short-wavelength automated perimetry (SWAP) was 
conducted to assess retinal sensitivity to short-wavelength light across the visual field. 
This procedure isolates short-wavelength sensitive mechanisms by using a high 
luminance “yellow” background to saturate M- and L-cones and suppress rod activity, 
while leaving S-cones relatively unaffected. The SWAP program used for this study was 
run on an OPTO AP200 Automated Perimeter (Opto-Global; Adelaide, South Australia). 
The background was set to a luminance o f 100 cd/m^ and included dominant 
wavelengths higher than 530 nm. Against this background, “blue” target stimuli were 
presented to preferentially stimulate S-cones. The target stimuli consisted of Goldmann 
size V points o f narrow-hand light with a peak transmission of 440 nm. Each target was 
presented for 200 ms to maximize the temporal summation of S-cone channels (Wild, 
2001).
Participants were seated in front of the bowl background, with their heads 
situated on a chin rest to facilitate constant fixation. SWAP testing was conducted 
monocularly, so an eye patch was used to cover the untested eye. Following 7 minutes of 
dark adaptation, participants were adapted to the bright “yellow” light o f the bowl 
background for 3 minutes prior to presentation o f target stimuli. For testing, participants 
were instructed to press a joystick button whenever they saw a blue circle flash on the 
background. It was emphasized that a constant focus on the central fixation dot be
DEPRESSION, ANTIDEPRESSANTS, AND VISION 67
maintained, as loss of fixation would lengthen test duration. This instruction was 
especially important, since the digital infrared eye-tracking option proved inconsistent 
and overly sensitive to slight deviations in pupil image. Thus, loss of fixation was 
sometimes recorded when participants were, in fact, focusing on the central dot, as 
observed in their pupil image on the experimenter monitor. To examine the possible 
impact of lost fixation on SWAP results, Pearson correlations were computed between 
SWAP measurements and the percentage o f stimulus presentations associated with a 
reported loss of fixation. No significant correlations were found for any visual field 
locations, with correlations ranging from r =  .04 to .20 and significance ranging from p  =  
.206 to .776. Thus, although the fixation losses recorded by the SWAP program were 
inflated to some degree, they did not appear to influence the results of SWAP 
measurement.
Standard perimetry methods are designed to assess for retinal anomalies at 
multiple locations across the full visual field. In the current study, 162 target locations 
were tested, with the “blue” stimulus circle presented in each of these locations 3-5 
times, depending on participant response. Stimulus presentations began in central areas 
of the visual field, then moved peripherally. Within these general areas, each presentation 
of target stimuli was in a random location. S-cone sensitivity at each target location was 
expressed in decibels (dB).
The level of detail provided by the 162 target locations was not considered 
necessary for the purposes of the current study. Instead, mean S-cone sensitivity values 
were computed by averaging the decibel values for target locations across various sub-
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divisions o f the visual field, based upon the known spatial heterogeneity o f S-cone 
distributions and functional symmetries across the retina (e.g., Ahnelt, Schubert, Kubber- 
Heiss, S chi viz, & Anger, 2006; Bierne, Zlatkova, & Anderson, 2005; Curcio & Allen, 
1990; Sample, Martinez, & Yamagishi, 1997). The first set of analyses divided the retina 
into three zones according to eccentricity, with the central zone referring to 1-6° o f visual 
angle, the paracentral zone referring to 10-22°, and the peripheral zone referring to 30- 
50°. The second set of analyses divided retinal area into five hemiretinal locations 
involving a central section (1-6°) and four outer quadrants (10-50°) corresponding to the 
superior nasal, inferior nasal, inferior temporal, and superior temporal sections of the 
retina. The final analyses combined sub-divisions from the previous two analyses, 
resulting in a detailed division o f the retinal area into 11 sections, including three 
concentric rings of the central retina, representing 1°, 3°, and 6° of visual angle, and eight 
sections in the remainder of the retina, referring to the paracentral (10-22°) and 
peripheral (30-50°) areas of the superior nasal, inferior nasal, inferior temporal, and 
superior temporal quadrants.
Luminance contrast sensitivity. Luminance contrast thresholds were measured 
using achromatic vertically-oriented Gabors, created by convolving sinusoidal gratings 
with a Gaussian luminance profile (see Figure I). Specifically, each sinusoidal luminance 
grating was presented in a circular window overlayed with a two-dimensional Gaussian 
envelope with space constant values (0 \y) o f 1.3, 1.0, or 0.8, according to the peak spatial 
frequency. These vertical luminance patterns were presented against a space-averaged 
“gray” background. Contrast was defined according to the Michelson formula [(Lmax-
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Emin) / (Lmax + Lmin)], wherc Lmax and Lmin refer to peak and trough luminances, 
respectively. At 0% contrast, there was no difference in luminance across the grating, and 
the stimulus appeared as a uniform field. The minimum amount of contrast needed to 
detect a grating represented contrast threshold, the inverse o f which defined luminance 
contrast sensitivity.
Luminance gratings were created using a Vision Research Graphics''"''^ program 
and presented on a high-resolution Nanao 9080i RGB monitor driven by a 32-bit 
microprocessor (Texas Instruments 34020 GSP) configured for monochromatic 
presentations. The monitor was positioned 75 cm from the participant’s entrance pupil, 
subtending a height and width of 13° and 16° o f visual angle, respectively. The size of 
the circular stimulus window was 7.5° o f visual angle for gratings under 1.0 cpd (cycles 
per degree), 5.0° for gratings between I.O and 2.0 cpd, and 3.0° for gratings of 4.0 cpd 
and higher spatial frequencies. A centrally positioned cross-hair was used to facilitate 
center fixation. The homogenous “gray” background of the monitor screen was set at a 
space-averaged luminance of 13.6 cd/m^.
Testing was conducted binocularly and in a darkened room. Participants were 
dark adapted for 7 minutes, followed by 3 minutes of light adapt to the monitor 
background screen, after which contrast sensitivity trials began. Stimulus trials involved 
a two-alternative forced choice (2AFC) procedure in which participants were asked to 
report whether a grating was presented to the left or right of the cross-hair. They used a 
corresponding two-button keypad to indicate the left or right position. Each trial was 
signaled by a tone, followed by a 975 ms presentation of the stimulus grating.
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Subsequent trials were not presented until a response had been entered; consequently, 
participants were required to guess when they were unsure or unable to see a grating.
The luminance contrast o f the gratings was modulated using two interwoven 
staircases o f relative log contrast proportions, beginning at either 0.75 or 0.01, and 
adjusted according to participant response. Three successive correct responses resulted in 
a decrease o f contrast by 0.10 log units. A single error response resulted in an increase of 
contrast by 0.10 log units. Additionally, in order to avoid artificially low contrast 
thresholds, four successive error responses reset the luminance contrast to initial levels. 
When the contrast proportions of the two interleaved staircases converged, a reversal was 
considered to have occurred. Participants practiced through four reversals before 
completing the six trial reversals needed to compute their contrast threshold. The 
geometric means of the six trial reversals were used to determine a Michelson contrast 
threshold at 75% detection. The inverse of this contrast threshold equals the luminance 
contrast sensitivity for each participant at the presented spatial frequency.
In order to plot a complete contrast sensitivity function, luminance contrast 
thresholds were determined for ten randomly presented static (i.e., 0 Hz) Gabors with 
center spatial frequencies o f 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd. 
Additionally, a subset of Gabors with center spatial frequencies of 0.5, 1.5, and 4.0 cpd 
were randomly presented with temporal modulation; their peaks and troughs were 180° 
counterphase flickered at 4 Hz. Altogether, participants viewed 13 luminance gratings, 
presented as a set in random order.
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Chromatic contrast sensitivity. In these trials, a near-isoluminant, 
heterochromatic sinusoidal pattern was modulated between two pairs o f opponent 
chromaticities processed by either L-M weighted (“red-green”) or S-(L+M) weighted 
(“blue-yellow”) opponency streams. In other words, periodic gratings with alternating 
peak “red” and trough “green” bands were presented to probe parvocellular functioning 
and periodic gratings of alternating peak “blue” and trough “yellow” bands were used to 
assess koniocellular functioning (see Figure 1). These Gabors were vertically oriented 
with a space-averaged constant value (Oxy) of 1.0. Maximum chromatic contrast, defining 
a relative contrast proportion of 1.0, involved using intial x,y pairs that were near 
complimentary and equiluminant in CIE (1931) space (Figure 2). Relative chromatic 
contrast was then reduced by adjusting the chromaticities of each “red-green” or “blue- 
yellow” peak-to-trough compliment toward the intermediate chromaticity of the 
background (i.e., a yellowish background for red-to-green modulation and a grayish 
background for blue-to-yellow modulation). Thus, at 0% contrast, the stimulus appeared 
as a uniform field indistinguishable from the background. Chromatic contrast sensitivity, 
as the inverse of threshold (i.e., the minimum level of chromatic contrast needed to detect 
the stimulus grating), was calculated in the same manner as the achromatic luminance 
contrast sensitivities described above, using two interleaved staircases in a 2AFC task. 
Participants were asked to indicate whether a stimulus grating had been presented to the 
left or right o f the centrally positioned “white” cross-hair.
Whereas luminance contrast gratings were achromatic to ensure that chromaticity 
did not contribute to a participant’s response, chromatic contrast gratings were designed
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to be near-isoluminant in order to minimize the influence of luminance stream operations 
in the determination of threshold. An instrument-based approach to isoluminance was 
used rather than a perceptually-based method involving the determination o f unique 
isoluminance values for each participant (e.g., heterochromatic flicker photometry). 
Although there is inter-individual variability in the M- and L-cone ratios o f the retinal 
mosaic, the impact of these variations is reduced post-receptorally and does not translate 
into substantial individual differences in colour perception (e.g., “red-green” or “blue- 
yellow” hue cancellation; Cicerone, 1990; Cicerone & Merger, 1989). Due to the 
logistical challenge o f measuring each participant’s unique isoluminance points 
accompanied with chromatic stimulus recalibration prior to experimental presentations, it 
was decided that an instrument-based approach would sufficiently approximate 
isoluminance for our purposes. Thus, normative population values o f isoluminance were 
taken from previous literature and adjusted according to spectroradiometric luminance 
measurement. Specifically, the chromaticities used to create the near-isoluminant peaks 
and troughs were derived from a hue scaling study by DeValois et al. (1997), which was 
based upon MacLeod & Boynton’s (1979) isoluminant colour space. Plots o f contrast 
sensitivity functions (see Results) for chromatic conditions conformed to the low-pass 
characteristics expected of chromatic stimuli, rather than the bandpass properties of 
luminance stimuli, suggesting that the influence of luminance was indeed minimized for 
measures of chromatic contrast sensitivity.
For the grating assessing parvocellular processing, at relative contrast of 1.0, the 
initial “red” was set to CIE (1931) coordinates of x = .3828 and y = .2846, and the initial
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“green” to x = .2639 and y = .3772. Spectroradiometric measurements also confirmed 
near-isoluminance of the stimuli, with a luminance of 35.3 cd/m^ and 35.1 cd/m^ for 
“red” and “green”, respectively. For the grating probing the koniocellular stream, the 
initial “blue” was set to x = .2739 and y = .2263, and the initial “yellow” to x = .4280 and 
y = .4976. Spectroradiometric measurements indicated 35.6 cd/m^ for the “blue” peak 
and 35.4 cd/m^ for the “yellow” trough. Luminance for the background screen was 
measured at 36.8 cd/m^for the “red-green” condition and 33.91 cd/m^for the “blue- 
yellow” condition.
Chromatic Cabors were presented on a gamma corrected ViewSonic C225 21- 
inch CRT monitor with a resolution of 1024x768 pixels at 150 Hz. The display was 
driven by a NVIDIA CeForce 6600 LE graphics card on a Dell Dimension DXP051 PC 
with a 3.2 CHz processor. Participants were situated on a chin rest at a distance of 75 cm 
from the monitor screen. Testing was conducted binocularly and in a darkened room. 
Participants were dark adapted for 7 minutes, followed by 3 minutes o f light adaptation 
to the background screen. Cabors were presented at three spatial frequencies (0.5, 1.5, 
and 4.0 cpd) and two temporal frequencies (0 and 4 Hz). The circular windows of the 
Cabors subtended 7.5°, 5.0°, and 3.0° o f visual angle for the 0.5, 1.5, and 4.0 cpd spatial 
frequency stimuli, respectively. Each grating was presented for 975 ms.
“Red-green” and “blue-yellow” Cabors were presented in separate trial blocks, 
with the block order counter-balanced across participants. Within the two blocks, the 
different spatial and temporal frequency stimuli were presented randomly. Similar to the 
luminance contrast test design, chromatic contrast was modulated using two interwoven
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staircases of relative log contrast proportions, adjusted according to participant response. 
Three successive correct responses resulted in a decrease of contrast, while a single error 
response resulted in an increase of contrast. Additionally, four successive error responses 
reset contrast to initial levels. Participants practiced through four reversals before 
completing the six trial reversals that were required to compute their contrast threshold. 
Specifically, the geometric means of the six trial reversals were used to determine 
chromatic contrast thresholds.
Procedure
Participants were introduced to the nature and procedures of the study and 
provided written informed consent (Appendix A). Screening measures for visual acuity, 
colour vision, and attention capability were conducted. Participants were then asked to 
complete a questionnaire regarding demographic information, eye conditions, medical 
conditions, mental health, and pharmacology (Appendix B). For participants who were 
taking antidepressant medications, an additional questionnaire was included referring to 
prescription details and reasons for antidepressant medication (Appendix C). Current 
mood measures were completed by all participants, followed by a series of 
psychophysicial vision tests. These began with the luminance contrast sensitivity test, 
followed by SWAP, and concluded with the heterochromatic, near-isoluminant “red- 
green” and “blue-yellow” contrast sensitivity measurements. Participation took 
approximately 2.5 hours to complete the experiment.
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Design
Dependent variables Included S-cone sensitivity, luminance contrast sensitivity, 
chromatic R-G contrast sensitivity, and chromatic B-Y contrast sensitivity. These were 
examined separately. Independent variables involved between- and within-subjects 
variables. The original between-subject variables were SSRI medication status (SSRIs, 
no SSRIs), DASS depressed mood (depressed mood, no depressed mood), and DID 
clinically-defined depression (clinical depression, no clinical depression).
The DASS Anxiety scale score was intended to be used as a covariate, but 
demonstrated significant interactions with independent variables in some analyses, 
violating assumptions of homogeneity of regression for covariates. It was therefore 
converted to a dichotomous between-subjects variable, referred to as DASS anxious 
mood (anxious mood, no anxious mood), and included as an independent variable in all 
analyses, for the sake of consistency. Similarly, the STAI-Trait Anxiety scale score was 
included as a covariate, but demonstrated significant interactions with independent 
variables in analysis of S-cone sensitivity. Thus, it was converted into a dichotomous 
variable of trait anxiety (high trait anxiety, low trait anxiety) and entered as a between- 
subjects variable in S-cone sensitivity analysis. This was only done for S-cone sensitivity 
analysis, since violations of homogeneity of regression assumption were limited to this 
dependent variable. Trait anxiety remained a covariate in analysis of luminance and 
chromatic contrast sensitivity. Age was used as a covariate in all analyses because of 
progressive age-related declines in visual functioning (e.g., Eiorentini, Porciatti,
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Morrone, & Burr, 1996; Haegerstrom-Portnoy, Hewlett, & Barr, 1989; Hardy, Delahunt, 
Okajima, & Werner, 2005).
Within-subjects independent variables for contrast sensitivity measures included 
spatial frequency, with ten levels for analyses restricted to static luminance conditions 
(0 .5 ,1 .0 ,1 .5 ,2 .0 ,2 .5 ,4 .0 ,6 .0 , 8.0, lO.O, and 12.0 cpd) and with three levels for the 
remaining contrast sensitivity analyses (0 .5 ,1.5, and 4.0 cpd), as well as temporal 
frequency (0 and 4 Hz). Within-subject variables for S-cone sensitivity (SWAP) 
measurement included three sets of retinal location divisions: retinal eccentricity (3 
levels), hemiretina sections (5 levels), and specific retinal locations ( I I  levels).
Data Analysis
Between-subjects variables. Two primary sets of between-subjects variables 
were used to examine different aspects and interactions of medication and symptomology 
on visual functioning. Specifically, they were constructed to disentangle the effects o f 
potentially transient and less severe mood states compared to clinically relevant and 
chronic conditions. The first set included SSRI medication status (SSRI, no SSRI),
DASS depressed mood (depressed mood, no depressed mood), and DASS anxious mood 
(anxious mood, no anxious mood) as three dichotomous between-subjects variables, with 
age entered as a covariate. The second set included SSRI medication status (SSRI, no 
SSRI) and DID clinically-defined depression (clinical depression, no clinical depression) 
as two dichotomous between-subjects variables, with age and trait anxiety scores (STAI- 
Trait scale) used as covariates. However, it was sometimes necessary to instead include 
trait anxiety scores as a between-subjects variable rather than a covariate. Thus, a
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dichotomous trait anxiety (high trait anxiety, low trait anxiety) variable was created by 
dividing the sample in half according to STAI-Trait scores. Cell sizes for these primary 
sets of between-subjects variables are presented in Tables 2, 3, and 4. Demographic and 
clinical characteristics associated with the between-subjects variables are presented in 
Table 5 and average values on the DASS, STAI, and DID are presented in Table 6.
For plotting and further analysis with contrast sensitivity measures, the second set 
o f between-subjects variables were combined into a single four-level 
medication/depression variable consisting of participants who were not taking SSRI 
medication and did not meet DID clinical criteria for depression (HEALTHY), 
participants who were taking SSRI medication but did not demonstrate current clinical 
depression (MEDONLY), participants who met clinical criteria for depression and were 
not taking SSRI medication (DEPONEY), and participants who were both clinically 
depressed and taking SSRI medication (DEPMED). This medication/depression variable 
was entered into analyses of contrast sensitivity as a single between-subjects variable, 
along with age and trait anxiety scores as covariates.
S-cone sensitivity. Mixed-model ANCOVAs were conducted on S-cone 
sensitivity, with the three retinal eccentricity zones (central, paracentral, peripheral) 
entered as a single within-subjects variable in one analysis, the five hemiretinal sections 
(central, superior nasal, inferior nasal, inferior temporal, superior temporal) entered as a 
single within-subjects variable in another analysis, and the eleven specific retinal 
locations (central 1°, central 3°, central 6°, paracentral superior nasal, peripheral superior 
nasal, paracentral inferior nasal, peripheral inferior nasal, paracentral inferior temporal.
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peripheral inferior temporal, paracentral superior temporal, peripheral superior temporal) 
entered as a single within-subjects variable in a final analysis. The two primary sets of 
between-subjects variables, described above, were included in separate ANCOVAs for 
each of the three retinal divisions. Age was entered as a covariate in all ANCOVAs. Trait 
anxiety scores from the STAI-Trait scale were initially entered as a covariate, along with 
age, for ANCOVAs that included SSRI medication status and DID clinically-defined 
depression as between-subjects variables. However, due to significant interactions 
between trait anxiety scores and retinal area locations violating the ANCOVA 
assumption of homogeneity of regression for covariates, ANCOVAs were re-run with 
trait anxiety (low trait anxiety, high trait anxiety) instead entered as a dichotomous 
between-subjects variable, alongside SSRI medication status and DID clinically-defined 
depression.
A summary of the ANCOVAs conducted on average S-cone sensitivity is 
presented in Table 7. This includes two mixed-model ANCOVAs for the three retinal 
eccentricities; (a) SSRI Medication Status (SSRI, no SSRI) x DASS Depressed Mood 
(depressed mood, no depressed mood) x DASS Anxious Mood (anxious mood, no 
anxious mood) x Eccentricity (central, paracentral, peripheral), with age as a covariate; 
and (b) SSRI Medication Status (SSRI, no SSRI) x DID Clinically-Defined Depression 
(clinical depression, no clinical depression) x Trait Anxiety (high trait anxiety, low trait 
anxiety) x Eccentricity (central, paracentral, peripheral), with age as a covariate. Two 
mixed-model ANCOVAs were also used to examine average S-cone sensitivity for the 
five hemiretinal locations: a) SSRI Medication Status (SSRI, no SSRI) x DASS
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Depressed Mood (depressed mood, no depressed mood) x DASS Anxious Mood 
(anxious mood, no anxious mood) x Hemiretinal Location (central, superior nasal, 
inferior nasal, inferior temporal, superior temporal), with age as a covariate; and (b) SSRI 
Medication Status (SSRI, no SSRI) x DID Clinically-Defined Depression (clinical 
depression, no clinical depression) x Trait Anxiety (high trait anxiety, low trait anxiety) x 
Hemiretinal Location (central, superior nasal, inferior nasal, inferior temporal, superior 
temporal), with age as a covariate. Finally, two mixed-model ANCOVAs were conducted 
on S-cone sensitivity for the eleven specific retinal locations: (a) SSRI Medication 
Status (SSRI, no SSRI) x DASS Depressed Mood (depressed mood, no depressed mood) 
X DASS Anxious Mood (anxious mood, no anxious mood) x Retinal Location (11 levels, 
described above), with age as a covariate; and (b) SSRI Medication Status (SSRI, no 
SSRI) X DID Clinically-Defined Depression (clinical depression, no clinical depression)
X Trait Anxiety (high trait anxiety, low trait anxiety) x Retinal Location (11 levels, 
described above), with age as a covariate. Bar graphs representing age-adjusted S-cone 
sensitivity means were created for variables demonstrating significant effects.
Homogeneity of variance was assessed with the F(max) test, which demonstrated 
no violations. Although Mauchly’s IT indicated sufficient sphericity for several of the 
analyses, Huynh-Feldt corrections were used throughout, due to sample size. Type-lII 
sum of squares was applied to balance unequal cell sizes for most ANCOVAs. However, 
Type-IV sum of squares was used for the mixed-model ANCOVAs involving SSRI 
medication status, DID clinically-defined depression, and trait anxiety as between- 
subjects variables, due to an empty cell. Specifically, no participants who were taking
DEPRESSION, ANTIDEPRESSA NTS, AND VISION 80
SSRI medications and experiencing clinical depression were classified as having low 
trait anxiety. Post-hoc simple effects analysis was used to examine significant 
interactions. Significance levels were set to ^  < .05.
Contrast sensitivity (CS). Luminance CS functions were examined across the 
ten spatial frequencies (0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd) presented 
in the statie condition (0 Hz). Luminance CS was also assessed at the three spatial 
frequencies (0.5, 1.5, and 4.0 cpd) presented in both the static (no temporal modulation - 
0 Hz) and dynamic (counterphase flickered at 4 Hz) conditions. Similarly, “red-green” 
(R-G) chromatic CS and “blue-yellow” (B-Y) chromatic CS were examined at three 
spatial frequencies (0.5, 1.5, and 4.0 cpd) for both the static (0 Hz) and dynamic 
conditions (4 Hz).
The first method of analysis involved the use o f traditional CS plots, whereby 
unadjusted mean sensitivity values were plotted as a function of spatial frequency on 
logarithm-scaled axes. Curves were fit according to a double exponential template 
(Movshon & Kiorpes, 1988), with error bars expressing the standard error o f the means 
(SEM). In order to highlight patterns, group differences of 0.10 log units or more were 
noted and are reported in the Results section. Although a cut-off of 0.10 log units is 
somewhat arbitrary, it nevertheless reflects a difference that is well beyond 
suprathreshold levels o f discrimination, as traditionally defined by a relative contrast 
difference larger than 2% (i.e., Weber fraction at 0.02).
The second method o f analysis used mixed-model ANCOVAs to assess CS 
differences, with spatial and temporal frequency entered as within-subjects variables.
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Age was included as a covariate in all ANCOVA analyses. For those ANCOVAs that 
included SSRI medication status and DID clinically-defined depression as between- 
subjects variables, trait anxiety scores from the STAI-Trait scale were also entered as a 
covariate, along with age.
A summary of the ANCOVAs conducted on CS is presented in Table 7. 
Specifically, analyses for the ten static luminance Gabors involved three mixed-model 
ANCOVAs: (a) SSRI Medication Status (SSRI, no SSRI) x DASS Depressed Mood 
(depressed mood, no depressed mood) x DASS Anxious Mood (anxious mood, no 
anxious mood) x Spatial Frequency (0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 
cpd), with age as a covariate; (b) SSRI Medication Status (SSRI, no SSRI) x DID 
Clinically-Defined Depression (clinical depression, no clinical depression) x Spatial 
Frequency (0.5, I.O, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd), with age and trait 
anxiety scores as covariates; and (c) Medication/Depression (HEALTHY, MEDONLY, 
DEPONLY, and DEPMED) x Spatial Frequency (0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0,
10.0, and 12.0 cpd), with age and trait anxiety scores as covariates. Analyses for the 
luminance Gabors that were presented in both static and dynamic conditions also 
involved three mixed-model ANCOVAs: (a) SSRI Medication Status (SSRI, no SSRI) x 
DASS Depressed Mood (depressed mood, no depressed mood) x DASS Anxious Mood 
(anxious mood, no anxious mood) x Spatial Frequency (0.5, 1.5, and 4.0 cpd) x Temporal 
Frequency (0 and 4 Hz), with age as a covariate; (b) SSRI Medication Status (SSRI, no 
SSRI) X DID Clinically-Defined Depression (clinical depression, no clinical depression)
X Spatial Frequency (0.5, 1.5, and 4.0 cpd) x Temporal Frequency (0 and 4 Hz), with age
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and trait anxiety scores as covariates; and (c) Medication/Depression (HEALTHY, 
MEDONLY, DEPONLY, and DEPMED) x Spatial Frequency (0.5, 1.5, and 4.0 cpd) x 
Temporal Frequency (0 and 4 Hz), with age and trait anxiety scores as covariates. A 
similar set o f three mixed-model ANCOVAs was conducted for R-G chromatic CS and 
B-Y chromatic CS separately.
Homogeneity o f variance for the ANCOVAs was assessed with the F(max) test, 
which demonstrated no violations. Although Mauchly’s ITindicated sphericity for 
several of the analyses, Huynh-Feldt corrections were nevertheless used throughout, due 
to sample size. Type-Ill sum of squares was applied to balance unequal cell sizes. Post- 
hoc simple effects analysis examined significant interactions and significant main effects 
for non-dichotomous variables. Significance levels were set t o p  <  .05.
O f note, significant effects involving only spatial and/or temporal frequency 
variables are omitted from the Results section for brevity and because the effects 
conformed to expected patterns of spatiotemporal contrast sensitivity which are unrelated 
to the questions posed in the current study. For example, significant main effects of 
spatial frequency on luminance contrast sensitivity across the range of 0.5 to 12.0 cpd 
were expected, and found, for all groups of participants, due to the bandpass properties of 
typical luminance contrast sensitivity functions. O f course, significant interactions of 
spatial and/or temporal frequency with any of the between-subjects variables are reported 
in the Results section, as are significant main effects for the between-subjects variables.
SSRI dosage. Effective doses vary notably across SSRI medications and there is 
no common equivalency scale with which to compare the dosing potency of different
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medications. In order to explore the effects o f dosage on visual functioning, a relative 
dosage scale was created for the current study based upon standard dose protocols 
indicated for depression (Physicians’ Desk Reference, 2007). Specifically, the standard 
range of dosage is between 20 mg and 60 mg for citalopram, between 20 mg and 80 mg 
for fluoxetine, between 20 mg and 60 mg for paroxetine, and between 50 mg and 200 mg 
for sertraline. The prescription of doses outside o f these ranges is not uncommon in 
clinical practice. Nevertheless, these ranges were used to construct a relative scale to 
compare SSRI doses in the current study. This scale ranged from 1 to 10, with the lowest 
standard dose for each medication equaling 1 and the highest standard dose for each 
medication equaling 10. Intermediate doses were divided with equal spacing according to 
each medication’s standard dose range. This resulted in six scale scores being used to 
represent the different dose prescriptions evident in the current study (Table 8). It should 
be noted that this is only a rough approximation with which to compare relative doses 
across medications, and does not reflect actual psychopharmacological equivalency. 
Further, the number of participants taking SSRIs in the current study involved a 
relatively small sample size to be examined on its own {n = 13). Thus, analyses related to 
SSRI dosage were considered exploratory and results tentative.
The relationship between relative SSRI dose and contrast sensitivity for the 
luminance, R-G, and B-Y conditions was examined with Spearman rank correlations. 
Similarly, Spearman rank correlations were used to assess the relationship between 
relative SSRI dose and average S-cone sensitivity for each of the retinal location 
divisions. Significance was set at/> < .05.
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Month of testing. Although the present study was not designed to examine 
seasonal effects, correlations between month of testing and visual functioning were 
conducted to assess whether test month may have contributed to primary findings. 
Specifically, Spearman rank correlations were computed between month o f testing and 
each aspect o f visual functioning examined in primary analysis, including average S-cone 
sensitivity at the various retinal area divisions, luminance CS, R-G chromatie CS, and B- 
Y chromatic CS. Chi-square tests were used to assess whether there were differences in 
month of testing between the groups of each between-subjects variable, including SSRI 
medication status (SSRI, no SSRI), DASS depressed mood (depressed mood, no 
depressed mood), DASS anxious mood (anxious mood, no anxious mood), and DID 
clinical depression episode (clinical depression, no clinical depression). Significant 
differences in month of testing were observed for DASS depressed mood and DID 
clinically-defined depression (see Results). Thus, Spearman rank correlations between 
test month and visual functioning were also conducted within groups of depressed and 
non-depressed participants, with the sample split by DASS depressed mood (depressed 
mood, no depressed mood) in one analysis and by DID clinically-defined depression 
(clinical depression, no clinical depression) in another analysis.
Results 
Data Screening
Prior to analysis, data were screened for normality and outliers within groups. 
Examination of Mahalonobis distances revealed no multivariate outliers; however, a 
number of univariate outliers were noted. O f the 1100 contrast sensitivity values
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recorded across the 25 spatial, temporal, and chromatic conditions, 20 (1.8%) cases were 
identified as extreme values based upon interquartile range distances, z-scores, and 
detrended normal probability plots. Dummy eoding analysis confirmed that these outliers 
were not associated with medication status, mood variables, specific individuals, or 
experimental conditions o f spatial and temporal frequency. The extreme values 
contributed to significant non-normality within their respective group by experimental 
condition. Logarithmic and inverse transformations were attempted but discarded, since 
they did not produce notable improvement in distributions. In order to lessen the 
influence o f these extreme scores, their original values were winsored at 0.5 o f an 
interquartile range beyond the next highest or lowest value within their group and 
experimental condition. Thus, they retained their rank order and some distance from the 
remainder o f values, but the severity of their separation was reduced. The same screening 
and adjustment procedure was undertaken with S-cone sensitivity, resulting in 
modification for 15 (3.1%) extreme cases from among the total 484 observations. 
Following these adjustments, the distributions of contrast sensitivity and S-cone 
sensitivity values within groups and conditions were within acceptable limits of 
normality.
S-cone Sensitivity
Retinal location: Eccentricity. Mixed model ANCOVAs were conducted on S- 
cone sensitivity with retinal eccentricity (central, paracentral, peripheral) as the within- 
subjects variable and age as a covariate. The first ANCOVA entered SSRI medication 
status (SSRI, no SSRI), DASS depressed mood (depressed mood, no depressed mood).
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and DASS anxious mood (anxious mood, no anxious mood) as between-subjects 
variables. No significant main effects or interactions involving the between-subjects 
variables were observed. The second ANCOVA entered SSRI medication status (SSRI, 
no SSRI) and DID clinically-defined depression (clinical depression, no clinical 
depression) as between-subjects variables, and included trait anxiety scores as a 
covariate, along with age. However, trait anxiety scores demonstrated a significant 
interaction with retinal eccentricity, F(2,I52) = 5.56, p  =  .010, partial t]^ = .13, violating 
the assumption o f homogeneity o f regression for covariates. Thus, the ANCOVA was re­
run with trait anxiety (high trait anxiety, low trait anxiety) instead entered as a 
dichotomous between-subjects variable. No significant main effects were observed for 
SSRI medication status, DID clinically-defined depression, or trait anxiety. However, 
significant two-way interactions were apparent for DID Clinically-Defined Depression x 
Eccentricity, F(2,152) = 7.74, p  =  .001, partial r|^ = .18, and for Trait Anxiety x 
Eccentricity, F(2,152) = 10.06,p < .001, partial r|^ = .22.
For the two-way interaction involving DID clinically-defined depression, simple 
effects analysis found significant differences in the peripheral portion of the retina 
(Figure 3, top panel), F(l,36) = 4 .3 4 ,p  = .044, partial = .11, with participants who 
reported clinical depression {Madj = 21.42, SE = 1.58) demonstrating higher S-cone 
sensitivity than those who did not describe clinical depression {Madj =  17.82, SE =  0.84), 
but no significant differences in either the central or paracentral portions of the retina.
For the two-way interaction involving trait anxiety, significant differences were also 
limited to the peripheral portion of the retina (Figure 3, bottom panel), F(l,36) = 6.01,p
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= .019, partial r |‘ = .14, with lower S-cone sensitivity observed among people reporting 
high trait anxiety {Madj = 17.58, SE  = 0.80) compared to low trait anxiety {Madj = 21.73, 
SE = 1.59). The three-way interaction between DID Clinically-Defined Depression x 
Trait Anxiety x Eccentricity was also significant, F(2,125) = 11.22, p < .001, partial r)“ = 
.24, with post-hoc analysis revealing results consistent with the two-way interactions. 
That is, differences in S-cone sensitivity were limited to peripheral portions o f the retina, 
with higher sensitivity associated with low trait anxiety and the presence of clinical 
depression. SSRI medication status was not involved in significant interaction effects.
Retinal location: Hemiretina sections. Mixed model ANCOVAs were 
conducted on S-cone sensitivity, with hemiretinal location (central, superior nasal, 
inferior nasal, superior temporal, and inferior temporal) entered as the within-subjects 
variable and age as a covariate. The first ANCOVA entered SSRI medication status 
(SSRI, no SSRI), DASS depressed mood (depressed mood, no depressed mood) and 
DASS anxious mood (anxious mood, no anxious mood) as between-subjects variables. 
These were not associated with significant main effects or interactions. The second 
ANCOVA entered SSRI medication status (SSRI, no SSRI) and DID clinically-defined 
depression (clinical depression, no elinical depression) as between-subjects variables and 
included trait anxiety score as a covariate, along with age. However, a significant 
interaction between trait anxiety score and hemiretinal location was observed, F(4,152) = 
3.18, ju = .015, partial r ^ =  .08, which violated the assumption o f homogeneity of 
regression for covariates. Thus, the ANCOVA was re-run with trait anxiety (high trait 
anxiety, low trait anxiety) as a dichotomous between-subjects variable instead of a
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covariate. No significant main effects were observed for SSRI medication status, DID 
clinically-defined depression, or trait anxiety. Significant two-way interactions were 
demonstrated for DID Clinically-Defined Depression x Trait Anxiety, F (l,36) = 4.28,p  
= .046, partial ri^= .11; for DID Clinically-Defined Depression x Hemiretinal Location, 
F(4,144) = 2.80, p  = .028, partial =  .07; and for Trait Anxiety x Hemiretinal Location, 
F(4,144) = 2.47,/? = .047, partial r]^= .06.
Post-hoc simple effects analysis o f the DID Clinically-Defined Depression x 
Hemiretinal Location interaction demonstrated higher S-cone sensitivity among people 
experiencing clinical depression compared to those who were not (Figure 4, top panel) in 
the superior temporal quadrant, F(I,36) = 5.11,F = .030, partial r f =  .12 (Clinical 
depression: Madj = 25.09, S E =  1.18; No clinical depression: Madj =  22.17, SE  = 0.63), 
and in the inferior temporal quadrant, F(l,26) = 6 .0 5 ,p  =  .019, partial .14 (Clinical 
depression: Madj = 24.33, S E =  1.60; No clinical depression: Madj = 20.01, SE  = 0.86). For 
the Trait Anxiety x Hemiretinal Location interaction, simple effects analysis showed 
lower S-cone sensitivity among people with high anxiety compared to those with low 
anxiety (Figure 4, bottom panel) for the superior temporal quadrant, F(l,36) = 5.38,/? = 
.026, partial .13 (High trait anxiety: Madj = 22.16, SE =  0.60; Low trait anxiety: Madj 
= 25.10, SE  = 1.19) and for the inferior temporal quadrant, F(I,36) = 5.23,/? = .028, 
partial r |^  =  .13 (High trait anxiety: Madj =  20.17, SE =  0.81; Low trait anxiety: Madj =
24.11, 5'F= 1.62). The three-way interaction between DID Clinically-Defined 
Depression x Trait Anxiety x Hemiretinal Location was also significant, F(4,144) = 2.86, 
p  = .026, partial = .07, and consistent with the patterns observed in the two-way
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interactions. Specifically, differences in S-cone sensitivity were observed in the inferior 
and superior temporal quadrants, with higher S-cone sensitivity associated with low 
anxiety and the presence o f an episode of elinical depression. SSRI medication status was 
not involved in any significant interactions.
Retinal location: Eleven levels. In order to explore the effects o f retinal location 
in further detail, the retinal area was sub-divided into 11 sectors: the central T , 3°, and 
6°, and the paracentral and peripheral sections o f the superior nasal, inferior nasal, 
inferior temporal, and superior temporal quadrants. Mixed-model ANCOVAs were 
conducted on S-cone sensitivity with retinal location (11 levels) as the within-subjects 
variable and age included as a covariate. The first ANCOVA included SSRI medication 
status (SSRI, no SSRI), DASS depressed mood (depressed mood, no depressed mood), 
and DASS anxious mood (anxious mood, no anxious mood) as the between-subjects 
variables. These variables demonstrated no significant main effects and were not 
involved in significant interactions. The second mixed-model ANCOVA included SSRI 
medieation status (SSRI, no SSRI) and DID clinically-defined depression (clinical 
depression, no clinical depression) as the between-subjects variables. Trait anxiety scores 
were initially entered as a covariate, along with age. However, a significant interaction 
was observed between trait anxiety and retinal location, F(7, 276) = 4.183,/? < .001, 
partial = .10, violating the ANCOVA assumption of homogeneity o f regression for 
covariates. Thus, the ANCOVA was re-run with trait anxiety (high trait anxiety, low trait 
anxiety) entered as a dichotomous between-subjects variable. Main effects were not 
significant for SSRI medication status, DID clinically-defined depression, or trait
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anxiety. Significant interactions were observed for DID Clinically-Defined Depression x 
Retinal Location, F(8, 286)= 3.69,p  <. 001, partial r f  =  .09, for Trait Anxiety x Retinal 
Location, F(8,286) = 4.237, p  < .001, partial t]‘ = .11, and for DID Clinically-Defined 
Depression x Trait Anxiety, F(8, 286) = 5.19,p  < .001, partial r f  = A3. SSRI medication 
status was not involved in any significant interactions.
Post-hoc simple effects analysis of the DID Clinical Depression x Retinal 
Location interaction revealed higher S-cone sensitivity among people meeting clinical 
criteria for depression compared to those who did not (Figure 5), in the peripheral section 
o f the inferior temporal quadrant, F(l,36) = 9.23, p  = .004, partial r]  ̂=  .20 (Clinical 
depression: Madj = 21.85, SE =  2.22; No clinical depression: Madj =  14.50, S E =  1.18) and 
in the peripheral section of the superior temporal quadrant, F(l,36) = 6.66,p  = .014, 
partial r\  ̂~ . \ 6 (Clinical depression: Madj =  21.54, S E =  1.61; No clinical depression:
Madj = 17.02, SE  = 0.86). This pattern approached significanee in the paracentral section 
o f the superior nasal quadrant, F (l,36) = 3.98, p  = .054, partial = .10 (Clinical 
depression: Madj =  30.83, SF = 1.06; No clinical depression: Madj = 28.53, SE  = 0.56).
Post-hoc simple effects analysis of the Trait Anxiety x Retinal Location 
interaction demonstrated lower S-cone sensitivity among people in the high trait anxiety 
group compared to the low trait anxiety group (Figure 6) for the peripheral section of the 
inferior temporal quadrant, F (l,36) = 7.90,p  = .008, partial = .18 (High trait anxiety: 
Madj =  14.78, S E =  1.12; Low trait anxiety: Madj =  21.46, SE = 2.23), the peripheral 
section o f the superior temporal quadrant, F (l,36) = 6.54, p  = .015, partial t]^ = .15 (High 
trait anxiety: Madj = 17.07, SE  = 0.81 ; Low trait anxiety: Madj = 21.47, SE =  1.62), as well
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as the paracentral section of the superior nasal quadrant, F(l,36) = 9.20, p = .004, partial 
~  .20 (High trait anxiety; Madj = 28.04, SE ~ 0.53; Low trait anxiety: Madj = 31.48, SE  
=  1.06). The pattern of results for the interaction between DID Clinically-Defined 
Depression x Trait Anxiety x Retinal Location was consistent with the two-way 
interactions, showing that significant simple effects were limited to the peripheral 
sections o f the superior and inferior temporal quadrants, as well as the paracentral 
superior nasal quadrant, and that higher S-cone sensitivity was associated with low trait 
anxiety and the presence of an episode o f clinical depression.
Luminance Contrast Sensitivity Functions
SSRI medication, DID depressed mood, and DID anxious mood. Mean log 
luminance CS was plotted as a function of the ten spatial frequencies used for static 
Gabor presentations. The resulting luminance CS functions revealed typical bandpass 
properties, which were plotted separately for SSRI medication status (Figure 7), DASS 
depressed mood (Figure 8), and DASS anxious mood (Figure 9). Differences in mean 
luminance CS for each group and each spatial frequency are summarized in Table 9. 
Contrast sensitivity functions for participants taking SSRIs were generally similar to 
those not taking SSRIs, with exceptions apparent for high spatial frequencies. 
Specifically, lower average luminance CS was observed among participants taking SSRIs 
at 10.0 cpd (0.12 log units) and 12.0 cpd (0.19 log units). Mean luminance CS tended to 
be lower among participants reporting depressed mood compared to those who did not, 
especially in the low-to-mid range of spatial frequency, with differences most notable at
2.0 cpd (0.11 log units) and 2.5 cpd (0.12 log units), as well as 10.0 cpd (0.10 log units).
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The low-to-mid range of spatial frequency also demonstrated differences in luminance 
CS among participants reporting anxious mood, who yielded higher mean CS values than 
those without anxious mood at 2.0 cpd (0.12 log units) and 2.5 cpd (0.12 log units). No 
other differences exceeded 0.10 log units.
A mixed-model ANCOVA was conducted on luminance CS, with spatial 
frequency (0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd) entered as the within- 
subjects variable and age as the covariate. SSRI medication status (SSRI, no SSRI),
DASS depressed mood (depressed mood, no depressed mood), and DASS anxious mood 
(anxious mood, no anxious mood) were included as between-subjects variables. O f these, 
only DASS depressed mood was associated with a significant main effect, F(l,35) = 
5.15,/? = .029, partial r|^ = .13, with lower overall luminance CS evident among 
participants who reported depressed mood {Madj = 353.11, SE =  19.84) than among those 
who did not {Madj = 437.67, SE = 19.84). Interaction effects involving the between- 
subjects variables were not found to be significant.
SSRI medication status and DID clinically-defined depression. Mean log 
luminance CS was plotted as a function o f the ten spatial frequencies used for static 
Gabor presentations. Luminance CS functions demonstrated typical bandpass properties. 
Separate plots were created for SSRI medication status (Figure 7, discussed above) and 
DID clinically-defined depression (Figure 10). As previously described, luminance CS 
functions differed only at the highest spatial frequencies for the SSRI medication status 
variable, with lower luminance CS at 10.0 cpd (0.12 log units) and, especially, 12.0 cpd 
(0.19 log units) among participants taking SSRI medications compared to those who
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were not (see Table 9). For DID clinically-defined depression, lower luminance CS was 
most notable at 1.0 cpd (0.10 log units) and 2.5 cpd (0.13 log units) among participants 
describing clinical depression compared to those who did not. No other differences 
exceeded 0.10 log units.
A mixed-model ANCOVA was conducted on static luminance CS with spatial 
frequency (0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd) entered as the within- 
subjects variable. SSRI medication status (SSRI, no SSRI) and DID clinically-defined 
depression (clinical depression, no clinical depression) were entered as between-subjects 
variables, controlling for trait anxiety score and age as covariates. DID clinically-defined 
depression demonstrated a significant main effect, F(I,38) = 5.08,/? = .030, partial r\  ̂=  
.12, with lower luminance CS among participants who met clinical criteria for a 
depressive episode (AQ, = 326.15, SE = 44.02) compared to those who did not (Madj -  
437.39, SE -  17.78). No other significant main effects or interactions were found for the 
between-subject variables.
C om bined m edication/depression  variable. To examine the effects of SSRI 
medication and clinical depression in relation to one another, they were combined to 
create a medication/depression between-subjects variable, consisting o f four mutually 
exclusive groups (FIEALTHY, MEDONLY, DEPONLY, and DEPMED). Mean static 
luminance CS values were plotted as a function of spatial frequency for each of the 
medication/depression groups (Figure 11). The luminance CS function of the 
MEDONLY group was highly similar to that o f the HEALTHY group, with the 
exception of a 0.20 log unit difference at 12.0 cpd in favour of healthy control
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participants (see Table 9). The CS function for the DEPONLY group showed somewhat 
lower sensitivity than the HEALTHY group for the low-to-mid range o f spatial 
frequency, with the largest difference observed at 1.0 cpd (O.11 log units). At higher 
spatial frequencies, the luminance CS values o f the DEPONLY group were somewhat 
elevated compared to the HEALTHY group, with the largest difference observed at 6.0 
cpd (O.11 log units). Comparison o f these two clinical groups showed that the 
MEDONLY group was higher than the DEPONLY group at 1.0 cpd (0.19 log units), 
whereas the DEPONLY group was higher than the MEDONLY group at 12.0 cpd (0.25 
log units). The CS function for individuals who were both depressed and taking SSRIs 
(DEPMED) was consistently lower than that of the HEALTHY group. Differences 
exceeded 0.10 log units for eight of the ten spatial frequencies, with the largest 
differences observed at 2.5 cpd (0.27 log units) and 10.0 cpd (0.21 log units). The CS 
function of the DEPMED group was also lower than those o f the other clinical groups, 
with differences higher than 0.10 log units for seven of the ten spatial frequencies in each 
case. The largest luminance CS differences between the DEPMED and DEPONLY 
groups were evident at 2.5 cpd (0.21 log units), 6.0 cpd (0.28 log units), and 10.0 cpd 
(0.24 log units). The largest CS differences between the DEPMED and the MEDONLY 
groups were also observed at 2.5 cpd (0.30 log units) and 6.0 cpd (0.23 log units).
The medication/depression variable was also entered as a between-subjects 
variable in a mixed-model ANCOVA of luminance CS, with spatial frequency (0.5, 1.0,
1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, and 12.0 cpd) as the within-subjects variable, and age and 
trait anxiety scores included as covariates. The main effect of the medication/depression
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variable was not significant, F(3,38) = 2.18,/? = .106, partial ri“ = .15. It was also not 
involved in significant interaction effects.
Static and Dynamic Luminance Contrast Sensitivity 
SSRI medication status, DASS depressed mood, and DASS anxious mood.
Mean log luminance CS values were plotted for the three spatial frequencies (0.5, 1.5, 
and 4.0 cpd) presented in both the static (0 Hz) and dynamic (4 Hz) conditions. Separate 
plots were created for SSRI medication status (Figure 12), DASS depressed mood 
(Figure 13), and DASS anxious mood (Figure 14) variables. There was little difference in 
plot values between participants who were taking SSRIs and those who were not. 
Luminance CS differences were also minimal between participants reporting anxious 
mood and those who did not. Some separation was noted for DASS depressed mood at
1.5 cpd in the dynamic condition (see Table 10), with lower mean luminance CS among 
participants describing depressed mood compared to those who did not (0.10 log units). 
There were no other instances where groups differed by 0.10 log units or greater.
A mixed-model ANCOVA was conducted on luminance CS with spatial 
frequency (0.5, 1.5, and 4.0 cpd) and temporal frequency (0 and 4 Hz) included as 
within-subjects variables, and age entered as a covariate. SSRI medication status (SSRI, 
no SSRI), DASS depressed mood (depressed mood, no depressed mood), and DASS 
anxious mood (anxious mood, no anxious mood) were entered as the between-subjects 
variables. O f these, DASS depressed mood was the only variable to demonstrate a 
significant main effect, F(l,35) = 5 .0 I,F  = .032, partial = .13. Comparison of adjusted 
marginal means indicated that luminance CS was lower for participants who reported
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depressed mood {Madj = 481.81, SF = 40.21) than for those who did not {Madj =  587.32, 
SF = 25.10). Interaction effects involving any o f the between-subjects variables were not 
significant.
SSRI medication status and DID clinically-defined depression. Mean log 
luminance CS values were plotted for each o f the three spatial frequencies (0.5, 1.5, and
4.0 cpd) presented in both the static (0 Hz) and dynamic (4 Hz) conditions. Separate plots 
were created for the SSRI medication status variable (Figure 12, discussed above) and 
the DID elinically-defmed depression variable (Figure 15). As previously described, the 
plots for participants taking SSRIs were highly similar to those for participants not taking 
SSRIs in both the static and dynamic conditions. For DID clinically-defined depression, 
lower luminance CS values were most notable in the dynamic condition at 0.5 cpd (O.11 
log units) and 1.5 cpd (0.13 log units) for participants describing clinical depression 
compared to those who did not (see Table 10). Otherwise, no differences equal to or 
greater than 0.10 log units were observed.
A mixed-model ANCOVA was conducted on luminance CS with spatial (0.5, 1.5, 
and 4.0 cpd) and temporal (0 and 4 Hz) frequency entered as within-subjects variables. 
SSRI medication status (SSRI, no SSRI) and DID clinically-defined depression (clinical 
depression, no clinical depression) were entered as the between-subjects variables, 
controlling for trait anxiety score as a covariate, along with age. The main effect of SSRI 
medication status approached significance, F(l,38) = 3.82,/? = .058, partial r\ =  .09, 
suggesting a trend toward lower luminance CS among people taking antidepressant 
medications {Madj = 453.43, SE = 45. 40) compared to those who were not {Madj =
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548.76, SE =  22.58). DID clinically-defined depression demonstrated a significant main 
effect, F(l,38) = 9.81,/? = .003, partial r f  = .21), with lower luminance CS found among 
people reporting clinical criteria for a depressive episode {Majj = 411.85, SE =  50.85) 
compared to those who did not {Madj = 590.34, SE = 20.54). Further, there was a three- 
way interaction between DID Clinically-Defined Depression x Spatial Frequency x 
Temporal Frequency, F(2,76) = 5.27,/? = .007, partial = .12. Post-hoc analysis of 
simple effects found lower luminance CS among people reporting clinical depression 
than among those who did not at 1.5 cpd in the static condition, F (l,38) = 4.23,/? = .047, 
partial = .10 (Clinical depression: Madj = 455.93, SE =  116.68; No clinical depression: 
Madj = 724.96, SE = 47.13), and at 0.5 cpd in the dynamic condition, F (l,38) = 11.37,/? = 
.002, partial r\  ̂= .23 (Clinical depression: Madj = 430.80, SE =  110.90; No clinical 
depression: Madj =  849.90, SE = 44.80). SSRI medication status was not involved in any 
significant interaction effects.
C om bined m edication/depression  variable. The SSRI medication status and DID 
clinically-defined depression variables were combined to create a four level 
medication/depression variable (HEALTHY, MEDONLY, DEPONLY, DEPMED).
Mean log luminance CS values were plotted for this variable at each of the three spatial 
frequencies (0.5, 1.5, and 4.0 cpd) presented in both the static (0 Hz; Figure 16, top 
panel) and dynamic (4 Hz; Figure 16, bottom panel) conditions. In the static condition, 
mean luminance CS values were similar between the HEALTHY, MEDONLY, and 
DEPONLY groups, with no differences of 0.10 log units or greater (see Table 10). By 
contrast, the CS plot for the DEPMED group was notably lower than the other three
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groups at all three spatial frequencies, with differences o f 0.13 to 0.16 log units 
compared to the HEALTHY group, 0.14 to 0.16 log units compared to the MEDONLY 
group, and 0.11 to 0.18 log units compared to the DEPONLY group. In the dynamic 
condition, there was similarly little difference in the plots for the HEALTHY and 
MEDONLY groups. The DEPONLY group exhibited lower luminance CS than the 
HEALTHY group at 1.5 cpd (0.14 log units). The DEPONLY group was also somewhat 
lower than the MEDONLY group at 0.5 cpd (0.12 log units) and 4.0 cpd (0.10 log units). 
Participants who were both depressed and taking SSRIs (DEPMED) had lower mean 
luminance CS than participants in the HEALTHY group at 0.5 cpd (0.15 log units) and
1.5 cpd (0.18 log units). They were also lower than the MEDONLY group at 0.5 cpd 
(0.20 log units). No other group differences greater than 0.10 log units were apparent in 
the dynamie condition.
The medication/depression variable (HEALTHY, MEDONLY, DEPONLY, 
DEPMED) was entered as the between-subjects variable in a mixed-model ANCOVA of 
luminance CS, with spatial (0.5, 1.5, and 4.0 cpd) and temporal (0 Hz and 4 Hz) 
frequency entered as within-subjects variables, and age and trait anxiety scores included 
as covariates. A significant main effect was observed for the medication/depression 
variable, F(3,38) = 3.55,p  = .023, partial = .22. Simple effects analysis found overall 
luminance CS to be significantly higher for the HEALTHY group {Madj -  246.85, SE =  
14.75) than both the DEPMED {p = .005; Madj = 345.76, SE = 71.47) and DEPONLY {p 
= .046; Madj = 477.95, SE = 48.98) groups. The MEDONLY group {p = .004; Madj =
561.11, 5F  = 38.50) also showed significantly higher luminance CS than the DEPMED
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group. No interaction effects involving the medication/depression variable were found to 
be significant.
“Red-Green” Chromatic Contrast Sensitivity 
SSRI medication status, DASS depressed mood, and DASS anxious mood.
Mean chromatic CS values for the “red-green” (R-G) Gabors were plotted as a function 
of the three spatial frequencies (0.5, 1.5, and 4.0 cpd) presented in both the static (0 Hz) 
and dynamic (4 Hz) conditions. Plots depicted low-pass properties, which are commonly 
found with isoluminant heterochromatic stimuli. Separate plots were created for SSRI 
medication status (Figure 17), DASS depressed mood (Figure 18), and DASS anxious 
mood (Figure 19) variables. Measurements o f R-G chromatic CS were lower among 
participants taking SSRI medications compared to those who were not at 4.0 cpd in the 
static (0.11 log units) and dynamic (0.15 log units) conditions (see Table 11), whereas 
differences were minimal at other spatial frequencies. Mean R-G chromatic CS was 
similar between participants reporting depressed mood and those who did not, and also 
between participants describing anxious mood compared to those who did not, with no 
differences o f 0.10 log units or more.
A mixed-model ANCOVA was conducted on R-G chromatic CS values, with 
spatial frequency (0.5, 1.5, and 4.0 cpd) and temporal frequency (0 and 4 Hz) as the 
within-subjects variables and age as a covariate. SSRI medication status (SSRI, no 
SSRI), DASS depressed mood (depressed mood, no depressed mood), and DASS 
anxious mood (anxious mood, no anxious mood) were entered as between-subjects 
variables. Although significance was not observed for the main effects of between-
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subjects variables, the main effect of medication approached significance, F(I,35) = 
4.03,/) = .052, partial r)  ̂= . 10, with a trend toward lower R-G CS among participants 
taking SSRI medication {Madj =161.77, SE  = 18.65) compared to those who were not 
{Madj = 215.33, SE = 16.44). Interactions involving the between-subjects variables were 
not significant.
SSRI medication status and DID clinically-defined depression. Mean R-G 
chromatic CS values were plotted for the three spatial frequencies (0.5, 1.5, and 4.0 cpd) 
presented in both the static (0 Hz) and dynamic (4 Hz) conditions. Again, plots revealed 
a low-pass property typical o f isoluminant heterochromatic stimuli. Separate plots were 
created for the SSRI medication status variable (Figure 17, described above) and the DID 
clinically-defined depression variable (Figure 20). As discussed previously, mean R-G 
chromatic CS was lower among participants taking SSRI medications compared to those 
who were not at 4.0 cpd in the static (O.11 log units) and dynamic (0.15 log units) 
conditions. Lower R-G chromatic CS was also observed among participants meeting 
clinical criteria for depression compared to those who did not at 1.5 cpd in the static 
condition (0.10 log units; see Table 11). Differences of O.IO log units or greater were not 
observed at any other spatial or temporal frequency for these between-subjects variables.
A mixed-model ANCOVA was conducted on R-G chromatic CS, with spatial 
(0.5, 1.5, and 4.0 cpd) and temporal (0 and 4 Hz) frequency as the within-subjects 
variables. SSRI medication status (SSRI, no SSRI) and DID clinically-defined 
depression (clinical depression, no clinical depression) were entered as between-subjects 
variables, and trait anxiety scores were included as a covariate, along with age. A
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significant effect was observed for trait anxiety scores, F(I,38) = 5.40,/) = .026, partial 
T]' = .12; beta-coefficients indicated a positive relationship between trait anxiety and R-G 
CS, indicating that higher trait anxiety was associated with higher R-G chromatic CS 
values. SSRI medication status exhibited a significant main effect, F(l,38) = 12.64,/) = 
.001, partial r\  ̂=  .25, involving lower R-G chromatic CS values among participants 
taking SSRI medication {Madj =  122.49, SE =  21.43) than among those who were not 
(Madj -  204.27, SE =  10.66). Interactions involving SSRI medication status were not 
significant.
DID clinically-defined depression also demonstrated a significant main effect, 
F(I,38) = 12.33,/) = .001, partial r\  ̂= .25), as well as a significant DID Clinically- 
Defined Depression x Spatial Frequency interaction, F(2,76) = 3.84,/) = .026, partial r\^
= .09, and a significant DID Clinically-Defined Depression x Spatial Frequency x 
Temporal Frequency interaction, F(2,76) = 3.26,/) = .044, partial r]  ̂= .08. Post-hoc 
analysis of simple effects for the three-way interaction showed that R-G chromatic CS 
was significantly lower among people reporting clinical criteria for a depressive episode 
compared to those who did not at: 0.5 cpd -  0 Hz, F(l,38) = 7.14,/) = .011, partial r|^ = 
.16 (Clinical depression: Madj = 122.38, SE = 54.11; No clinical depression: Madj = 
284.51, SE = 21.86); at 1.5 cpd -  0 Hz, F(I,38) = 8.61,/) = .006, partial = .19 (Clinical 
depression: Madj = 102.27, SE = 57.33; No clinical depression: Madj = 290.86, SE = 
23.16); and at 0.5 cpd - 4  Hz, F(l,38) = 10.82,/) = .002, partial = .22 (Clinical 
depression: Madj = 124.49, SE = 32.11; No clinical depression: Madj = 242.89, SE = 
12.97).
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C om bined m edication/depression  variable. The SSRI medication status and DID 
clinical depression variables were combined into a four-level medication/depression 
variable (HEALTHY, MEDONLY, DEPONLY, DEPMED). Mean R-G chromatic CS 
values were plotted for this variable at each of the three spatial frequencies (0.5, 1.5, and
4.0 cpd) presented in both the static (0 Hz; Figure 21, top panel) and dynamic (4 Hz; 
Figure 21, bottom panel) conditions. In the static condition, the mean R-G chromatic CS 
values o f the HEALTHY group were similar to those of the DEPONLY group at all 
spatial frequencies (see Table 11) and were somewhat lower than those o f the 
MEDONLY group at 1.5 cpd (0.12 log units). Between these latter two groups, 
MEDONLY had higher mean R-G chromatic CS values at 1.5 cpd (O.11 log units), 
whereas DEPONLY had higher mean CS values at 4.0 cpd (0.17 log units). Individuals 
who were both depressed and taking SSRI medications (DEPMED) showed notable 
reductions in mean R-G CS values compared to participants in the HEALTHY group at 
all spatial frequencies, with differences ranging from 0.10 to 0.22 log units. The R-G 
chromatic CS values were also lower for the DEPMED group than the DEPONLY group 
at all spatial frequencies in the static condition, with differences between 0.18 and 0.24 
log units. Similarly, R-G CS values were lower for the DEPMED group than the 
MEDONLY group at 0.5 cpd (0.23 log units) and 1.5 cpd (0.35 log units). No other 
group differences exceeded O.IO log units in the static condition. For plots o f the 
dynamic condition, group differences were only apparent at 4.0 cpd. Specifically, 
individuals in the HEALTHY group had higher mean R-G chromatic CS values than 
those in the MEDONLY group (0.19 log units) and DEPMED group (0.13 log units).
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The DEPMED group also showed lower R-G CS means than the DEPONLY group (0 .11 
log units). Group differences in R-G CS did not exceed O.IO log units in the dynamic 
condition at either 0.5 cpd or 1.5 cpd.
The combined medication/depression variable (HEALTHY, MEDONLY, 
DEPONLY, DEPMED) was entered as the between-subjects variable in a mixed-model 
ANCOVA of R-G chromatic CS, with spatial (0.5, 1.5, and 4.0 cpd) and temporal (0 and 
4 Hz) frequency entered as the within-subjects variables, and age and trait anxiety scores 
included as covariates. Trait anxiety scores exhibited a significant effect, F(I,38) = 5.40, 
p  =  .026, partial = .12, with beta-coefficients indicating a positive relationship 
between trait anxiety and R-G chromatic CS. The medication/depression variable 
demonstrated a significant main effect, F(I,38) = 5.60,/) = .003, partial t]^= .31, but no 
significant interactions. Post-hoc simple effects analysis found R-G chromatic CS to be 
significantly higher for the HEALTHY group {Madj =  246.85, SE = 14.75) than all other 
groups and significantly lower for the DEPMED group {Madj = 70.60, SE  = 33.73) than 
all other groups (MEDONLY: Madj = 174.38, S E =  18.17; DEPONLY: Madj ~  161.69, SE  
= 23.12).
“Blue-Yellow” Chromatic Contrast Sensitivity 
SSRI medication status, DASS depressed mood, and DASS anxious mood.
Mean chromatic CS values for the “blue-yellow” (B-Y) Gabors were plotted as a 
function o f the three spatial frequencies (0.5, 1.5, and 4.0 cpd) presented in both the static 
(0 Hz) and dynamic (4 Hz) conditions. Plots demonstrated low-pass properties which are 
commonly found with isoluminant heterochromatic stimuli. Separate plots were created
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for SSRI medication status (Figure 22), DASS depressed mood (Figure 23), and DASS 
anxious mood (Figure 24). Plots related to SSRI medication status revealed differences at
4.0 cpd in the static condition, with lower mean B-Y chromatic CS observed among 
participants taking SSRIs compared to those who were not (0.13 log units; see Table 12). 
For the DASS depressed mood variable, B-Y chromatic CS was lower among 
participants describing depressed mood compared to those who did not at 0.5 cpd (0.15 
log units) and 1.5 cpd (0.14 log units) in the static condition . For the DASS anxious 
mood variable, differences were also apparent at 4.0 cpd in the static condition, but with 
higher mean B-Y chromatic CS among individuals reporting anxious mood compared to 
those who did not (0.10 log units). No other differences of 0.10 log units or more were 
observed at any of the spatial or temporal frequencies.
A mixed-model ANCOVA was conducted on B-Y chromatic CS, with spatial 
frequency (0.5, 1.5, and 4.0 cpd) and temporal frequency (0 and 4 Hz) as within-subjects 
variables and age as a covariate. SSRI medication status (SSRI, no SSRI), DASS 
depressed mood (depressed mood, no depressed mood), and DASS anxious mood 
(anxious mood, no anxious mood) were entered as the between-subjects variables.
Results indicated significant two-way interactions for DASS Depressed Mood x 
Temporal Frequency, F(I,35) = 4.92,/? = .033, partial = .12, and for DASS Depressed 
Mood X Spatial Frequency, F(2,70) = 3.47, jr> = .037, partial = .09. For the interaction 
involving temporal frequency, post-hoc analysis of simple effects found lower B-Y 
chromatic CS at 0 Hz, F (l,35) = 4.92,/) = .034, partial = .12, among people reporting 
depressed mood {M^dj = 92.85, SE = 15.48) compared to those who did not {Madj =
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133.09, SE = 9.66), but no significant differences at 4 Hz, F(l,35) = 0.51,/? = .478, 
partial r\  ̂= 0.14. For the interaction involving spatial frequency, significantly lower B-Y 
chromatic CS was found at 1.5 cpd, F (l,35) = 4.16,/? = .049, partial =.l 1 among 
people who reported depressed mood {Madj ~ 117.98, S E =  18.61) compared to those who 
did not {Madj = 162.49, SE  = 11.62), with no significant differences found at 0.5 or 4.0 
cpd. SSRI medication status and DASS anxious mood were not involved in any 
significant effects.
SSRI medication status and DID clinically-defined depression. Mean B-Y 
chromatic CS values were plotted for the three spatial frequencies (0.5, 1.5, and 4.0 cpd) 
presented in the static (0 Hz) and dynamic (4 Hz) conditions. A low-pass property typical 
o f isoluminant heterochromatic stimuli was observed. Separate plots were created for the 
SSRI medication status variable (Figure 22, described above) and the DID clinically- 
defined depression variable (Figure 25). As previously discussed, mean B-Y chromatic 
CS values were lower among participants taking SSRIs than those not taking SSRIs at
4.0 cpd in the static condition (0.13 log units), but were comparable at other spatial and 
temporal frequencies. For the DID clinically-defined depression variable, lower B-Y 
chromatic CS was observed among participants reporting clinical depression compared to 
those who did not, with the most substantial reductions noted at 0.5 cpd (0.20 log units) 
and 1.5 cpd (0.13 log units) in the static condition (see Table 12). No other group 
differences equal to or greater than O.IO log units were observed.
A mixed-model ANCOVA was conducted on B-Y chromatic CS with spatial 
frequency (0.5, 1.5, and 4.0 cpd) and temporal frequency (0 and 4 Hz) as within-subjects
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variables. SSRI medication status (SSRI, no SSRI) and DID clinically-defined depressin 
(clinical depression, no clinical depression) were entered as the between-subjects 
variables, with trait anxiety scores included as a covariate along with age. A significant 
main effect was observed for DID clinically-defined depression, F(I,38) = 4.15,/? = .049, 
partial r|^ = .10. Specifically, lower B-Y chromatic CS was observed among participants 
reporting clinical criteria for a depressive episode {Madj = 87.37, S E =  15.15) compared 
to those who did not {Madj = 121.97, SE = 6.12). No other significant effects were 
demonstrated for the between-subject variables.
C om bined m edication/depression  variable. The SSRI medication status and DID 
clinically-defined depression variables were combined into a four-level 
medication/depression variable (HEALTHY, MEDONLY, DEPONLY, DEPMED).
Mean B-Y chromatic CS values were plotted for this variable at each of the three spatial 
frequencies (0.5, 1.5, and 4.0 cpd) presented in both the static (0 Hz; Figure 26, top 
panel) and dynamic (4 Hz; Figure 26, bottom panel) conditions. Several group 
differences were apparent in the static condition (see Table 12). Mean B-Y chromatic CS 
values were higher for the HEALTHY group than the DEPONLY group at 0.5 cpd (0.14 
log units), and were also higher for the HEALTHY group than the MEDONLY group at
4.0 cpd (0.15 log units). When these two clinical groups were compared, the MEDONLY 
group had a higher mean B-Y CS value than the DEPONLY group at 0.5 cpd (0.20 log 
units) and 1.5 cpd (0.14 log units), whereas the reverse was true at 4.0 cpd (0.17 log 
units). The lowest mean B-Y chromatic CS values were consistently observed for 
individuals who were both medicated and clinically depressed (DEPMED). Specifically,
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lower B-Y CS was observed among the DEPMED group than the HEALTHY group at 
0.5 cpd (0.28 log units) and 1.5 cpd (0.21 log units). Mean B-Y chromatic CS was lower 
for the DEPMED group than the DEPONLY group at all three spatial frequencies, with 
differences between O.IO and 0.17 log units. Lower B-Y CS was also found for the 
DEPMED group compared to the MEDONLY group at 0.5 cpd (0.35 log units) and 1.5 
cpd (0.31 log units).
In the dynamic condition, the mean B-Y chromatic CS values for DEPONLY and 
MEDONLY were not substantially different than those for the HEALTHY group. 
Similarly, differences between the DEPONLY and MEDONLY groups were minimal. 
However, at all spatial frequencies in the dynamic condition, B-Y chromatic CS was 
lower among individuals who were both medicated and depressed (DEPMED) than all 
other groups (see Table 12). Differences ranged from 0.16 to 0.17 log units when 
compared to participants in the HEALTHY group; 0.17 to 0.22 log units compared to the 
MEDONLY group; and 0.12 to 0.19 log units compared to individuals in the DEPONLY 
group.
The combined medication/depression variable was entered as the between- 
subjects variable in a mixed-model ANCOVA of B-Y chromatic CS, with spatial (0.5,
1.5, and 4.0 cpd) and temporal (0 and 4 Hz) frequency entered as within-subjects 
variables, and age and trait anxiety scores included as covariates. Significance was not 
observed for the main effect of medication/depression, F(l,38) = 2.21,/? = .103, partial 
T|̂  = .15, nor its interactions.
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SSRI Dosage
Spearman’s rank correlations were computed between relative SSRI dose (see 
Table 8) and luminance CS for each of the spatial frequencies of the ten static luminance 
Gabors. A significant correlation was observed at 12.0 cpd (rs = -.68,/? = .010), 
indicating that higher relative doses o f SSRI medication were associated with lower 
luminance CS at this spatial frequency. The next highest correlation was apparent at I.O 
cpd (rs = -.51,/? = .073), but was not significant. Correlations for the remaining spatial 
frequencies were not significant and ranged from Ks =  -.27 to .12, with significance 
ranging from /? = .373 to .890. The relationship between relative SSRI dose and 
luminance CS was also explored in the subset o f spatial frequencies presented in both the 
static and dynamic conditions. Correlations were not significant, ranging from rs = -.28 to 
.40, and from /? = .182 to .712.
Correlations were computed between relative SSRI dose and R-G chromatic CS 
for the three spatial frequencies in both the static and dynamic conditions. A significant 
correlation was observed in the static condition at 4.0 cpd (r  ̂= -.58,/? = .037).
Remaining correlations ranged from = -.41 to .06, with significance ranging from /? = 
.159 to .934. Correlations between relative SSRI dose and B-Y chromatic CS were not 
significant at any of the three spatial frequencies in either the static or dynamic 
conditions, ranging from rs = -.30 to .38,/? = .207 to .890.
The effect o f SSRI dose was also explored in relation to S-cone sensitivity. 
Spearman’s rank correlations were not significant for any o f the retinal locations, ranging 
from rs = -.46 to .30, with significance ranging from /? = .115 to .861.
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Month of Testing
Participants were tested between February and June. There no significant 
differences in month of testing between participants taking SSRI medications and those 
who were not, y j { A , N =  44) = 6.08,/? = .193, nor between participants describing 
anxious mood on the DASS compared to those who did not, y ^{ A , N=  44) = 3.33,/? = 
.505. Significant differences in month o f testing were observed between participants 
reporting DASS depressed mood compared to those who did not, y ^{ A , N=  44) = 10.78,
/? = .029. Specifically, participants describing depressed mood tended to be tested later in 
the year than those who did not (Table 13). Similarly, significant differences in month o f 
testing were evident between participants describing an episode of clinical depression on 
the DID compared to those who did not, %̂ (4, N =  44) = 17.91,/? = .001. Again, 
participants reporting clinical depression tended to be tested later in the year than those 
who did not (Table 13).
The relationship between month of testing and visual functioning was examined 
with Spearman’s rank correlations. No significant correlations were observed for any of 
the spatial or temporal frequencies used to assess luminance CS. Specifically, 
correlations ranged from =  -.20 to .19 and significance ranged from /? = .202 to .944. 
Similarly, no significant correlations were observed at any o f the spatial or temporal 
frequencies used to assess B-Y chromatic CS, with correlations ranging from = -.25 to 
.04 and significance ranging from/? = .097 to .881. Significant correlations were also not 
observed for dynamic R-G Gabors; however, for static R-G Gabors, a significant 
correlation between month of testing and R-G chromatic CS was observed at 4.0 cpd {r^
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= .30, p  =  .048) and correlations approached significance at 0.5 cpd (rs = .29, p  = .057) 
and 1.5 cpd (r  ̂= .29,p  = .055). These were in the positive direction, indicating that later 
months were associated with higher R-G chromatic CS. Correlations between month of 
testing and S-cone sensitivity were also computed. None were significant at any of the 
retinal location divisions, with correlations ranging from rs = -.27 to .25 and significance 
ranging from p = .070 to .963.
Because depression was associated with significant differences in month of 
testing, the relationship between test month and CS was assessed within groups of 
depressed and non-depressed participants. Correlations were higher and more often 
significant when the DID clinically-defined depression variable was used to split the 
sample, rather than the DASS depressed mood variable. Thus, detailed results are 
presented for the sample divided according to DID clinical depression status. For 
luminance CS, significant correlations were observed among people describing clinical 
depression at 2.5 cpd -  0 Hz ( r ,  = .84, p  =  .001), 10.0 cpd -  0 Hz (rs = .75, p  =  .007), 0.5 
cpd -  4 Hz (rs =  .68, p  = .022), and 1.5 cpd -  4 Hz (r^ =  .70, p  =  .016). These correlations 
were positive, indicating that later months of testing were associated with higher 
luminance CS. Remaining correlations for the clinically depressed group ranged from rs 
= -.21 to .58 and significance ranged from p = .060 to .676. Among participants who did 
not report clinical depression, correlations between test month and luminance CS were 
not significant, ranging from rs = -.28 to .32 andp = .073 to .930.
For R-G chromatic CS, significant correlations were observed among participants 
reporting clinical depression at 0.5 cpd (rs =  .80, p  = .003), 1.5 cpd (rs =  .72, p  =  .013),
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and 4.0 cpd (rs = .91,p < .001) in the static condition. Again, these correlations were 
positive, indicating that later test months were associated with higher R-G CS in the 
static conditions. For the dynamic R-G conditions, correlations were not significant 
among clinically depressed individuals, ranging from rs  = -.10 to .21 and from p  =  .529 to 
.781. Among people not reporting clinical depression, correlations between month of 
testing and R-G chromatic CS were not significant at any temporal or spatial frequency, 
with correlations ranging from = -.29 to .06 and significance ranging from p  = .102 to 
.763.
For B-Y chromatic CS, a significant positive correlation was observed among 
individuals reporting clinical depression at 1.5 cpd -  4 Hz (rs = .69, p = .019), indicating 
that later test months were associated with higher B-Y chromatic CS. Remaining 
correlations among clinically depressed individuals ranged from r  ̂= -.05 to .45 andp  =
. 169 to .890. A significant negative correlation was observed at 1.5 cpd -  4 Hz among 
people not describing clinical depression (r  ̂= -.36, p  = .042), indicating that later test 
months were associated with lower B-Y chromatic CS. The remaining correlations 
among individuals without clinical depression ranged from = -.25 to .09 and p  = .153 
to .694.
For S-cone sensitivity in different retinal locations, the clinically depressed group 
demonstrated significant correlations in the peripheral sections o f the superior nasal 
quadrant (rs = .6 I ,p  = .048) and inferior temporal quadrant (rs = .82,p  = .002), again 
indicating that later test months were associated with higher S-cone sensitivity. The 
remaining correlations among the clinically depressed group ranged from rs = -.23 to .54,
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with significance ranging from p  = .089 to .989. Among participants who did not report 
clinical depression, correlations were not significant at any of the retinal locations, 
ranging from rs = -.27 to .13 and from p  = .148 to .902.
Discussion
Psychophysical techniques have proved to be an informative and noninvasive 
method of exploring visual functioning in neurodegenerative diseases (e.g., Alzheimer’s 
disease, multiple sclerosis, Parkinson’s disease) and psychiatric disorders (e.g., 
schizophrenia). Initial psychophysical investigation with depressive disorders has 
documented anomalies in vision that are limited to specific visual streams, rather than 
global dysfunction, indicating the utility o f more detailed investigations of the visual 
system in depression. Additionally, the appearance o f at least mild visual disturbances on 
the side-effects profiles of most antidepressant medications also indicates the need for 
research into the specific effects of these medications on visual functioning.
The present study was designed to examine and disentangle the impact of 
depression and antidepressant pharmacotherapy on visual functioning. In order to isolate 
the functions of the magno-, parvo-, and koniocellular streams of the visual system, 
minimum thresholds of luminance, “red-green”, and “blue-yellow” contrast sensitivity 
were determined across a range o f spatial frequencies in both static and dynamic 
conditions. An additional focus on S-cone sensitivity was incorporated through short- 
wavelength automated perimetry (SWAP) in order to further explore the hypothesis of 
koniocellular stream vulnerability. The available sample compared individuals who were 
taking SSRI antidepressant medications with those who were not. Participants were
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assessed with respect to the presence of depressed mood, as well as whether they met 
clinical criteria for a depressive episode. In addition, due to the high comorbidity of 
depression and anxiety, and the prescription o f anti depressant medications to treat 
anxiety disorders, measures o f anxious mood and trait anxiety were also employed. 
Summary of Results
SSRI medications. Measures of S-cone sensitivity did not demonstrate 
significant results associated with SSRI medications, when potential effects o f depression 
and anxiety were accounted for. The luminance CS function for individuals taking SSRI 
medications was similar to control participants at all but the highest spatial frequencies. 
That is, at 10.0 cpd and especially 12.0 cpd, SSRI medications tended toward lower 
achromatic luminance CS. For chromatic CS, significant sensitivity shifts were observed 
for R-G but not B-Y Gabors. Specifically, SSRI medications were associated with lower 
R-G chromatic CS when compared to participants not taking SSRI medications, 
regardless o f mood status.
Higher relative SSRI dosages were associated with lower luminance CS at 12.0 
cpd -  0 Hz and with lower R-G CS at 4.0 cpd -  0 Hz. This suggests a possible dose- 
response relationship between SSRI medications and parvocellular functioning.
However, due to the lack of a standardized dose equivalency for SSRI medications, this 
finding is tentative and remains to be confirmed, either with larger numbers of 
participants taking the same medication to allow for within-group dose comparisons or 
with a direct biological measure of serotonin concentrations.
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Depression. Significant elevations in S-cone sensitivity were observed in the 
SWAP measurements of participants reporting clinical depression on the DID, when 
accounting for potential effects of SSRI medications and trait anxiety. These elevations 
were demonstrated in peripheral portions o f the temporal hemiretina, with a non­
significant trend found in the paracentral section of the superior nasal quadrant. No 
significant results related to S-cone sensitivity were observed with the DASS depressed 
mood variable.
Both DASS depressed mood and DID clinically-defined depression were 
associated with a significant overall reduction in luminance CS, when accounting for 
potential effects o f SSRI medications and anxiety. Sensitivity losses were most apparent 
at low-to-mid spatial frequencies, especially 2.0 and 2.5 cpd. For higher spatial 
frequencies, beginning with 6.0 cpd, luminance CS functions were similar among 
participants describing symptoms of depression and those who did not. The dynamic 4.0 
Hz counterphase flicker conditions assessing luminance CS also revealed lower 
luminance CS among depressed participants at certain spatial frequencies.
Depression was found to contribute to significantly reduced sensitivity in R-G 
chromatic CS, but only when the DID clinically-defined depression variable was used 
and only at specific spatial and temporal frequency combinations (i.e., 0.5 and 1.5 cpd in 
the static condition and 0.5 cpd in the dynamic condition). For B-Y Gabors, a global 
decrease in B-Y chromatic CS was demonstrated for DID clinical depression, and DASS 
depressed mood also led to reductions which were most pronounced at certain spatial 
(1.5 cpd) and temporal (0 Hz) frequencies. Thus, the unique contribution of depression
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was more consistent across a broader range o f spatiotemporal frequencies for the B-Y 
Gabors than the R-G Gabors, although in both cases the effect was significantly lower 
chromatic contrast sensitivities.
Anxiety. S-cone sensitivity was significantly reduced among individuals with 
high trait anxiety, when accounting for effects of SSRI medications and DID clinically- 
defined depression. This effect was observed in peripheral portions o f the temporal 
hemiretina and the paracentral section of the superior nasal quadrant. O f note, these 
retinal locations were the same as those affected by clinical depression, albeit with an 
opposite direction of effect.
Luminance CS was not associated with significant findings related to anxiety. 
However, plots demonstrated notable elevations in static luminance CS limited to 
specific low-to-mid spatial frequencies (i.e., 2.0 and 2.5 cpd) among individuals 
reporting anxious mood on the DASS. No trends were apparent for dynamic luminance 
gratings.
Trait anxiety demonstrated a significant effect on R-G chromatic CS when 
included as a covariate in analysis with SSRI and clinical depression variables. The 
direction of effect was positive, indicating that increased trait anxiety was associated 
with increased R-G CS. Significant effects o f anxiety were not observed for B-Y CS. 
However, plot values showed a tendency toward increased B-Y CS at 4.0 -  0 Hz among 
participants describing anxious mood on the DASS.
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Retinal Enhancements and Contrast Sensitivity Deficits for Depression
The current study hypothesized that depression would be associated with 
enhancements in visual functioning related to neurotransmitter changes in the retina, and 
that the koniocellular stream would be most impacted by these enhancements, as 
suggested by previous findings that short-wavelength light is most effective in 
influencing neurometric and psychometric dysphoric symptoms (Glickman et ah, 2005; 
Ly et ah, 2001). The finding of higher S-cone sensitivity in depression for certain retinal 
locations supports the hypothesis o f enhancements at the retinal level. That is, in 
peripheral temporal portions o f the retina, S-cones were more sensitive among people 
reporting clinical depression than among those who did not.
The increase in S-cone sensitivity among participants with clinical depression did 
not translate into enhanced B-Y chromatic CS. Rather, depression was associated with 
reduced B-Y CS, which suggests the possibility of over-compensatory activity in post- 
receptoral or post-retinal mechanisms. Alternatively, depression may differentially 
impact the distinct S-on and S-off cell pathways of the koniocellular stream, both of 
which are involved in the processing o f B-Y CS, whereas SWAP assessment relies more 
prominently on the S-on pathways. At the same time, increased S-cone sensitivity in the 
current study was restricted to peripheral (30-50°) portions of the retina, whereas CS 
stimuli were presented just off center, at 2.5° eccentricity, and SWAP assessment was 
conducted monocularly, whereas CS measurement was conducted binocularly. Thus, the 
observed enhancements in S-cone sensitivity for depression may be independent o f the 
reductions that were noted for B-Y CS.
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Contrast sensitivity deficits for depression in the current study were not limited to 
B-Y CS, but also appeared for R-G CS and luminance CS. Although the effects were 
widespread across the various conditions, the potential of a global reduction is countered 
by some spatial frequency specificity in static luminance CS, as well as more 
spatiotemporally extensive reductions in B-Y than R-G CS. Thus, selectivity of deficit 
was apparent. Early stages o f visual functioning were implicated in prior research 
documenting enhanced luminance CS among individuals with depression (Wesner &
Tan, 2006). With the lowest signal to noise ratios o f the visual system, the retina sets 
ceiling levels for higher-order visual performance, and enhancements suggest 
mechanisms involved in the initiation of the signal. However, CS reductions can occur at 
any stage of the visual system. Thus, the source of CS deficits among depressed 
individuals in the current study cannot be isolated to a particular hierarchical stage. 
Functional anomaly, including possible over-compensation, may occur at the retinal 
level, where chromatic opponency and luminance contrast arise, or at later stages which 
integrate these fundamental components of visual information.
Mood versus Disorder Symptoms
Effects on visual functioning were more consistent and significant for the clinical 
depression variable than the depressed mood variable. Indeed, for S-cone sensitivity and 
R-G CS, contributions of depressed mood were unremarkable, whereas significant 
differences were demonstrated for clinical depression. More pronounced results tended to 
also be observed for trait anxiety compared to anxious mood. This pattern suggests that.
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although alterations o f mood did have some impact in certain test conditions, visual 
functioning is most affected by more severe or chronic affective disturbances. 
Combination of SSRI Medications and Depression
A common finding throughout analyses was that the combined effect of SSRI 
medication and clinical depression resulted in larger CS reductions than either on its 
own. For instance, although SSRI medication did not exert a notable unique influence on 
luminance CS throughout most of the CS function, it did appear to exacerbate the 
reductions associated with clinical depression in the low-to-mid range and counteract 
potential elevation or normalization at the highest spatial frequencies. Similarly, the 
unique contribution o f clinical depression led to significant reductions in B-Y CS, 
whereas no significant effects were found for SSRI medication; yet, plots demonstrated 
that the combination o f SSRI medication and clinical depression resulted in the lowest 
levels o f B-Y CS. For R-G CS, reductions associated with SSRI medication were more 
consistent and pronounced than those of depression, but again, the lowest R-G CS was 
observed among participants who were both clinically depressed and taking SSRI 
medications.
These findings challenge the hypothesis that anomalies in visual functioning 
associated with depression would be corrected for by pharmacotherapy. Specifically, if 
disruption o f visual functioning in depression were related to monoamine deficits in the 
retina, then antidepressant medications, which exert their primary influence on 
monoamines, were expected to rectify the visual disturbance. However, an opposite 
pattern was observed in the current study. When significant unique effects were observed
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for both SSRI medication and depression, as was the case with R-G CS, they 
demonstrated the same direction o f effect, acting to reduce CS. Further, when significant 
findings were not observed for SSRI medication, as was the case for most conditions in 
the assessment o f luminance and B-Y CS, it nevertheless exacerbated the deficits 
demonstrated for depression. Thus, although participants who reported depression 
demonstrated reduced CS, those who were also taking SSRI medications showed the 
most extreme reductions, while participants who were taking SSRI medications but were 
no longer depressed often demonstrated CS levels that were comparable to those of 
healthy control participants. This pattern points away from a simple imbalance in retinal 
monoamines as causing visual disturbances in depression, and instead suggests a more 
complex interplay between the downstream neurotransmitter or neuromodulatory actions 
o f SSRI medication, other neurochemical correlates of depression, and anomalies of 
visual functioning. GABA and glutamate, which are primary neurotransmitters in the 
retina and throughout later stages o f the visual system, may be involved in the visual 
effects noted in the current study, since they have been implicated in both anxiety and 
depressive disorders (Brambilla et al., 2003; Choudry et al., 2005; Kelmendi et al., 2006; 
Paul & Skolnick, 2003; Young et al., 2002), and are known to be affected by SSRI 
medications (Kelmendi et al., 2006; Sanacora et al., 2002; Slattery & Cry an, 2006).
When SSRI medications did demonstrate unique contributions to CS, the effects 
o f depression were not as consistent. Specifically, at the highest spatial frequencies o f the 
static luminance condition, SSRI medications were associated with reduced luminance 
CS, whereas luminance CS for depression was comparable to normal levels. Also, SSRI
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medications showed significant main effects for R-G CS, whereas depression was only 
linked to lower CS at certain spatial and temporal frequencies, and even then, only if it 
was the variable o f clinical depression and not depressed mood. By contrast, SSRI 
medications failed to demonstrate unique effects in conditions where the most consistent 
and prominent results were apparent for depression, in the low-to-mid range of 
luminance CS and for B-Y CS. This suggests that although an interaction between SSRI 
medication and depression is indicated by the observation of their combined effects 
leading to more extreme results than either alone, their strongest unique contributions to 
visual functioning appear to be produced in separate visual streams or perceptual 
channels.
Opposite Effects of Depression and Anxiety
The effects of anxiety and depression were in opposite directions for both CS and 
S-cone sensitivity. Anxiety was associated with CS enhancements, which were apparent 
at the low-to-mid spatial frequencies of static luminance CS conditions and for R-G CS, 
as well as a tendency toward some elevation at certain spatiotemporal frequencies for B- 
Y CS. By comparison, the results o f depression indicated reduced CS in these conditions. 
The reverse pattern was evident for S-cone sensitivity, for which depression was 
associated with significant elevations in S-cone sensitivity in the peripheral sections o f 
the temporal hemiretina, while anxiety was associated with significant reductions in these 
areas, as well as the paracentral portion o f the superior nasal quadrant.
These results suggest that anxiety and depression are largely impacting the same 
mechanisms of visual functioning, but with opposite effects. This is consistent with the
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diverging symptom dimensions of anxiety and depressive disorders, despite frequent co­
occurrence and similar treatments. Specifically, symptoms o f anxiety relate to 
physiological and cognitive over-activity, including arousal and hypervigilance, whereas 
symptoms of depression more often reflect diminished energy and concentration, and 
dulled responsivity in terms o f motivation, pleasure, and interest (American Psychiatric 
Association, 2000). Yet, there is high co-morbidity between anxiety and depressive 
disorders, and many of the same pharmacotherapies are used for their treatment.
For both depression and anxiety, the shifts in S-cone sensitivity observed in the 
current study were largely limited to peripheral portions of the temporal hemiretina. The 
retinal location specificity of these results parallels the various asymmetries o f retinal 
function and physiology which have been documented. For instance, visual acuity for 
achromatic and short-wavelength-isolating stimuli has been found to be significantly 
higher in the nasal than the temporal retina beginning around 25° eccentricity (S.J. 
Anderson, Mullen, & Hess, 1991; R.S. Anderson, Wilkinson, & Thibos, 1992; Bierne et 
al., 2005; Rovamo, Virsu, Laurinen, & Hyvarinen, 1982). This has been linked with an 
increase in corresponding retinal ganglion cell densities along the nasal horizontal 
meridian compared to the temporal horizontal meridian (Curcio & Allen, 1990). At 25° 
eccentricity, a similar increase in ganglion cell densities has been observed in superior 
portions of the retina compared to inferior portions (Curcio & Allen, 1990). Differential 
acuity and contrast thresholds for S-on pathways compared to S-off pathways has also 
been observed in peripheral locations, but not more central locations (Zlatkova, Vassilev, 
& Anderson, 2008). A previous SWAP study found enhanced peripheral sensitivity in the
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temporal quadrant compared to the nasal quadrant in healthy participants (Sample et al., 
1997). Examination o f S-cone distributions has indicated a slight increase in S-cone 
density in superior portions of human retina (Ahnelt et al., 2006). A nasal-temporal 
asymmetry has not been reported for humans (Curcio et al., 1991), although studies with 
other primates have noted such asymmetry (DeMonasterio, McCrane, Newlander, & 
Schein, 1985; Martin & Grunet, 1999). Asymmetries in retinal physiology and function 
could make certain retinal locations more susceptible to the effects of depression and 
anxiety.
Peripheral vision narrowing, involving decreased detection of peripheral stimuli, 
has been reported among athletes in high stress sports situations (e.g., Andersen & 
Williams, 1999; Rogers & Landers, 2005; Williams & Andersen, 1997; Williams,
Tony mon, & Andersen, 1991). This has been attributed to a stress response affecting 
visual attention. Similarly, human centrifuge studies and examination of aviation pilots in 
high acceleration have documented a specific pattern of visual effects (Lambert, 1945; 
Whinnery & Shender, 1993; Wieling et al., 2009; Wood, Lambert, Baldes, & Code,
1946; Yilmaz, Cetinguc, & Akin, 1999), beginning with peripheral “graying” (i.e., loss 
of colour vision in periphery), followed by complete loss of vision or “blacking out” that 
begins in the periphery and moves inward, but is not accompanied by a loss of 
consciousness. This is caused by changes in blood pressure resulting in retinal 
hypoperfusion but not cerebral hypoperfusion, due to intraocular pressure additionally 
contributing to the former. Because retinal vasculature becomes less dense as it radiates 
outward from the optic nerve, initial reductions in blood pressure first impact peripheral
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portions of the retina. This suggests the possibility of milder blood pressure changes 
affecting peripheral vision sensitivity among individuals with anxiety or stress. That is, 
activation of the sympathetic system due to the physiological arousal associated with 
anxiety may attenuate retinal perfusion, leading to subtle reductions in peripheral vision 
sensitivity, as was observed in the current study; however, it is unclear how retinal 
vasculature may impact peripherally-specific enhancements in S-cone sensitivity among 
individuals who instead experience depression.
Visual Streams Impacted by SSRI Medications, Depression, and Anxiety
Unique effects of SSRI medications were limited to reduced luminance CS at the 
highest static spatial frequency and reduced R-G chromatic CS, which corresponds to 
primary deficits in the parvocellular stream. SSRI medications may also impact other 
streams indirectly through their exacerbation of the CS reductions associated with 
depression. Results of chromatic vision tests indicate definite involvement of the 
koniocellular stream in depression, with respect to significant findings for S-cone 
sensitivity and B-Y chromatic CS. Anxiety also impacted S-cone sensitivity, implicating 
the koniocellular stream, although results for B-Y CS were less pronounced. For R-G CS, 
which reflects parvocellular functioning, a significant overall effect was demonstrated by 
trait anxiety and clinical depression showed selective spatiotemporal effects.
Interpretation of luminance CS results for depression and anxiety is less 
straightforward with respect to visual stream localization. The lack of notable group 
differences at the lowest luminance spatial frequencies for static stimuli points away 
from the magnocellular stream. However, the finding of significant effects for depression
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in certain dynamic luminance CS conditions suggests possible magnocellular 
involvement, although both the parvocellular and koniocellular streams are known to 
contribute to motion processing, albeit to a much lesser degree than the magnocellular 
stream (e.g., Michna, Yoshizawa, & Mullen, 2006; Morand et al., 2000; Nassi & 
Callaway, 2006; Riecansky, Thiele, Distler, & Hoffman, 2005; Ruppertsberg, Wuerger,
& Bertamini, 2003, 2007; Takeuchi, DeValois, & Hardy, 2003). The temporal frequency 
o f 4 Hz was chosen for this study to allow for temporal modulation in chromatic Gabors, 
which are not perceived well at higher temporal frequencies; however, 4 Hz may not be 
high enough to exclude possible parvocellular or koniocellular processing of motion for 
luminance stimuli.
For static luminance CS, the most notable effects of depression and anxiety were 
observed at spatial frequencies intermediate to exclusive magnocellular and parvocellular 
functioning. The lowest and highest spatial frequencies of static luminance CS are known 
to be processed separately by the magnocellular and parvocellular streams, respectively. 
Intermediate spatial frequencies are thought to be processed by an overlap of channels 
associated with both magnocellular and parvocellular functions. However, the current 
study used threshold levels to isolate only the most sensitive channels, and the literature 
is not clear about whether the magnocellular or parvocellular stream is most sensitive at 
the affected spatial frequencies. Thus, results could either reflect the low end of 
parvocellular functioning or the high end o f magnocellular functioning. Further, the most 
sensitive channel at these intermediate spatial frequencies may differ between clinical
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and control groups and, consequently, threshold measurements could refer to different 
channels for different groups of participants.
An alternative explanation has been suggested that intermediate spatial 
frequencies may be optimally processed by an independent visual stream (e.g., Maddock, 
Casson, Lott, Carter, & Johnson, 1993), separate from the magnocellular and 
parvocellular streams. The koniocellular stream may be a candidate. Although the bulk of 
knowledge that has accumulated over the last decade about the koniocellular stream has 
focused on its S-cone connections and B-Y chromatic opponency, it has in fact been 
shown to comprise a diverse collection o f cells and LGN layers, many o f which have not 
been studied sufficiently to infer functionality (Casagrande, 1994; Dacey & Packer,
2003; Hashemi-Nezhad, Blessing, Dreher, & Martin, 2008; Hendry & Reid, 2000; Roy et 
al., 2009; White, Goodchild, Wilder, Sefton, & Martin, 1998; Xu et al., 2001). The 
assumption that koniocellular functions are limited to processes that involve S-cones is 
not warranted, given that at least some cells in the koniocellular stream do not appear to 
process S-cone input (Casagrande & Xu, 2003; Casagrande, Yazar, Jones, & Ding, 2007; 
Forte, Hashemi-Nezhad, Dobie, Dreher, & Martin, 2005; Szmajda, Grunert, & Martin, 
2008). Further, even among koniocellular cells that do process S-cone information, 
connections with L- and M-cones are required for B-Y opponency, and there is recent 
evidence to suggest that achromatic luminance signals are also processed by these cells 
(Forte et al., 2005; Horwitz, Chichilnisky, Albright, 2005; Ripamonti, Woo, Crowther, & 
Stockman, 2009; Roy, et al., 2009; Tailby, Solomon, & Lennie, 2008; White et al.,
2001). The spatial frequency parameters of luminance processing in the koniocellular
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system has not yet been clearly specified, but there is suggestion that they may respond 
to spatial frequencies intermediate to those optimally processed by the magnocellular and 
parvocellular streams (Forte et al., 2005; Roy et al., 2009; White et al., 2001). If this 
holds true, then the luminance and chromatic results o f the current study would most 
consistently point to the koniocellular stream as the site o f primary effects o f depression 
on visual functioning, with additional involvement o f the parvocellular stream and less 
support for magnocelluar involvement. The effects o f anxiety would similarly include 
both koniocellular and parvocellular streams.
Comparison with Previous Research
The finding that depression was associated with reduced luminance CS in the 
low-to-mid ranges of spatial frequency corresponds to the luminance CS research 
conducted by Szabo et al. (2004), which found that marginal CS deficits among 
individuals experiencing a depressive phase o f seasonal depression were corrected to 
normal levels by light therapy, with the most pronounced increases evident in the low 
and mid ranges of spatial frequency (i.e., 0.5, 1.2, 3.6, 4.8, and 5.7 cpd). Flowever, results 
of the current study appear to contradict the only previously published investigation of 
luminance CS which included a focus on non-seasonal depression. Specifically, Wesner 
and Tan (2006) found elevated luminance CS at static spatial frequencies above 2.5 cpd 
among participants with seasonal and non-seasonal depression compared to control 
participants, with significant increases beginning at 6.0 cpd.
Examination of the luminance CS functions in the current study and the study by 
Wesner and Tan (2006) indicates a similar broader curve evident among depressed
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participants compared to non-depressed individuals, with the two studies differing 
primarily in terms of baseline levels. In Wesner and Tan, the luminance CS function of 
depressed individuals begins with sensitivity levels similar to those o f control 
participants at low and mid spatial frequencies, but increases to elevated sensitivities at 
higher spatial frequencies, whereas in the current study, the luminance CS of depressed 
individuals is reduced at low-to-mid spatial frequencies, but increases to levels similar to 
control participants at higher spatial frequencies. Thus, the CS functions of depressed 
participants in the current study represent a general downward shift in baseline CS when 
compared to the findings o f Wesner and Tan.
One methodological difference between the studies relates to month of testing. A 
preliminary study by Gallant & Wesner (2004) found a notable reduction in luminance 
CS in the summer months than the winter months among non-seasonally depressed 
individuals. This would seem to account for the lower baseline levels of luminance CS in 
the current study, which had a larger proportion of depressed participants tested in the 
spring and summer months compared to the study by Wesner and Tan (2006). However, 
analysis of the correlations between test month and CS in the current study found an 
opposite trend. Specifically, when significant relationships were present, they indicated 
higher CS in the summer than in the winter, which does not explain the lower luminance 
CS levels demonstrated by depressed individuals in the current study and indicates that 
test month did not impact the pattern o f results.
Another methodological difference is the inclusion of anxiety measures in the 
current study, with plots demonstrating some elevation in luminance CS among
DEPRESSION, ANTIDEPRESSANTS, AND VISION 128
individuals with anxiety. This suggests the possibility that the higher CS among 
depressed participants in Wesner and Tan (2006) may reflect unmeasured comorbid 
anxiety. However, in the current investigation, elevations associated with anxiety were 
most notable at low-to-mid spatial frequencies (i.e., 2.0 and 2.5 cpd), whereas increases 
among depressed individuals in Wesner and Tan were limited to high spatial frequencies. 
Antidepressant medications were not controlled for in Wesner and Tan, despite a small 
proportion taking SSRIs (11.8% of non-seasonally depressed participants and 17.4% of 
seasonally depressed participants). This is not considered to account for the different 
results between studies, however, since the current investigation found that SSRIs 
contributed to reduced luminance CS at the highest spatial frequencies, whereas Wesner 
and Tan found elevations at these spatial frequencies. The mean age of participants 
reporting depressed mood {M =  27.5, SD = 7.2) and clinical depression (M = 29.3, SD =  
6.1) in the current study was somewhat higher than that for non-seasonally depressed 
participants (M = 22.41, SD =  8.94) in Wesner and Tan, but comparable to that for SAD 
participants (M = 29.33, SD = 12.20). Since contrast sensitivity generally declines with 
age, it is possible that the higher age in the current study may explain the lower baseline 
levels for luminance CS functions. However, there were no significant correlations 
between age and luminance CS in the current study, neither across the total sample nor 
among participants who reported clinical depression or depressed mood.
Other methodological differences between the current study and Wesner and Tan 
(2006) were minimal. The procedures and stimuli used for psychophysical measurement 
of luminance CS were nearly identical. Sample sizes for depressed mood participants («
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= 15) and clinical depression participants (n =  II) in the current study were slightly 
lower, than that of the non-seasonal depression group {n =  17) in Wesner and Tan, but 
nevertheless demonstrated sufficient power to detect significant results. Thus, the 
divergent findings for depression of elevated luminance CS at high spatial frequencies in 
the Wesner and Tan study, compared to reduced luminance CS at low-to-mid spatial 
frequencies in the current study, are not satisfactorily accounted for by methodological 
differences. Although an explanation for the different results remains unclear, the 
similarity o f findings is also noteworthy, since the luminance CS function in both studies 
depicted a similar shaped curve for depressed individuals that was broader than that 
observed among non-depressed individuals.
Dynamic luminance CS was impacted by depression in the current study, but 
differences were more apparent for the clinical depression variable than the depressed 
mood variable, and were also restricted to specific spatial frequencies. These limited 
findings parallel those found in Wesner and Tan (2006), in which dynamic luminance CS 
differences were only observed at one spatial frequency in the 2 Hz conditions, but not at 
higher temporal frequencies, and were only evident for seasonally depressed participants. 
Again though, differences in the current study indicate dynamic luminance CS 
reductions, whereas differences in Wesner and Tan were in the direction of elevation, 
Szabo et al. (2004) did not find any significantly different changes in dynamic luminance 
CS (8 Hz) between individuals with seasonal depression and healthy control participants.
Comparison with previous research for SSRIs and for anxiety is difficult due to 
the dearth o f psychophysical vision research in these areas. Although general visual side-
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effects, such as blurred or “abnormal” vision, are included in the side-effect profiles o f 
most SSRI medications, systematic research into the nature of these visual anomalies has 
not been reported. Psychophysical research has examined TCAs and dopamine-based 
antidepressants, with contrast sensitivity research for the latter finding increased 
luminance CS for medium and high spatial frequencies after a single dose (Domenici et 
al., 1985). With respect to anxiety, investigations o f the effects o f lorazepam, a 
benzodiazepine often prescribed to treat anxiety, have documented losses in CS 
following acute administration (Harris & Phillipson, 1995). A study of lorazepam among 
long-term users additionally measured anxiety (Giersch et al., 2006). Lorazepam was 
associated with reduced luminance CS in median spatial frequencies (I.O to 4.0 cpd). No 
correlation was found between luminance CS performance and anxiety; however, the 
authors noted that indirect correlations suggested a possible partial contribution of 
anxiety to the effect o f lower luminance CS. The current study observed a trend in 
luminance CS that was similarly limited to intermediate spatial frequencies, although the 
direction of the trend was toward higher luminance CS among individuals with anxiety.
Chromatic contrast sensitivity has not been investigated in previous research 
regarding depression, anxiety, or antidepressant medications. Short-wavelength light was 
found to be sufficient to induce an antidepressant effect among individuals with seasonal 
affective disorder (T.M. Lee et al., 1997; Glickman et al., 2005). Phototherapy with 
narrow-band “blue” light (440 nm) was also found to correct for anomalies in luminance 
CS among individuals with seasonal and non-seasonal depression, whereas phototherapy 
with narrow-band “yellow” light (580 nm) did not (Ly et al., 2001). This suggests that
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depression is associated with chromatically selective effects involving the processing of 
short-wavelength light. In the current study, both B-Y CS and R-G CS deficits were 
observed for depression, although effects for B-Y CS were more extensive, lending some 
support to a possible short-wavelength bias in visual functioning associated with 
depression. It is not known if the observed shifts in S-cone sensitivity are specific to S- 
cones, since L- and M-cone sensitivity was not assessed in the current study.
Limitations and Future Directions
The current study would have benefited from increased numbers of participants. 
This is particularly true since a third between-subjects variable was added to several 
analyses when anxiety covariâtes were transformed into independent variables due to 
violations of homogeneity of regression. Consequently, the number of cells in these 
analyses was doubled, reducing power and increasing the chance of Type II errors. Thus, 
there is a greater likelihood that instances of nonsignificance may be due to insufficient 
power, rather than actual lack of effect. Additionally, multiple analyses were conducted, 
which could inflate the occurrence of significance to some degree. The current study did 
not adjust significance values to account for multiple analyses, given the debate about the 
appropriateness of this practice. However, exact significant levels and effect sizes were 
reported.
Some indication of a possible dose-response effect of SSRI medication was 
observed in the current study. However, the composition and sample size of the 
antidepressant group did not allow for reliable analysis of dose effects. Larger numbers 
o f participants taking the same medication would permit within-group comparisons of
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dose effects, as well as interactions with other relevant parameters, such as duration of 
medication or disorder. Alternatively, biological measurement of neurotransmitter 
concentrations would enable more precise analysis. In addition, due to participant 
availability, the present study was limited to investigation o f SSRI medications, and it is 
recommended that antidepressants other than SSRIs be included in future research.
The significant findings related to anxiety, as well as the frequent co-morbidity 
between anxiety and depression, highlight the importance of continuing to include 
anxiety as a variable in future vision research with depressive disorders. There was also a 
tendency for measures of depression and anxiety to be associated with the most 
consistent results when they referred to more chronic or severe symptom experiences. 
Thus, future research may be better informed by a focus on diagnosed disorders o f 
depression and anxiety, rather than questionnaire assessments. As well, previous research 
with seasonal depression suggests that an explicit control for effects of season on mood 
and visual functioning would help clarify this potential confound.
Results of SWAP measurement in the current study indicate anomalies in S-cone 
sensitivity associated with depression and anxiety, implicating the earliest levels of 
retinal processing. Further research examining M- and L-cone sensitivity would be useful 
for comparison. Additionally, the finding of retinal location specificity with respect to S- 
cone sensitivity suggests that other psychophysical techniques also sample multiple 
retinal locations and eccentricities.
Contrast sensitivity measurement, using sine-wave gratings, was chosen for the 
current study because it represents one of the most thorough methods o f assessing and
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manipulating a range of fundamental properties o f visual perception. Although 
commonly used in psychophysical investigations, some researchers have suggested that 
contrast sensitivity gratings may be too complex to reliably isolate visual streams and 
localize hierarchical stages o f the visual system (e.g., Keri et al., 2004, 2005). Indeed, 
there is some ambiguity with respect to the interpretation of results in the current study 
related to intermediate spatial frequencies in static luminance CS conditions, although 
this is more a reflection o f the state o f recently acquired knowledge regarding visual 
system complexities, rather than limitations in psychophysical stimuli. Nevertheless, the 
use o f additional psychophysical methods may provide new perspectives to help clarify 
the nature of visual anomalies associated with depression, anxiety, and antidepressant 
medication.
Within the more extensively studied areas o f visual functioning in 
neurodegenerative disorders and schizophrenia, some researchers have suggested that 
Vernier tasks use more basic visual stimuli than contrast sensitivity methods (Keri et al., 
2004, 2005). Alternatively, CS gratings have been adapted to include varying pedestal 
conditions to better isolate visual stream functioning, based upon the work of Pokorny 
and Smith (1997) and Leonova, Pokorny, and Smith (2003). Various masking and noise 
procedures have additionally been used to better isolate hierarchical stages of visual 
processing (e.g.. Censor, Bonneh, Arielli, & Sagi, 2009; Georgeson & Meese, 2006; 
Smith, 2000). Presentation of Gabors at varying orientations would also distinguish 
hierarchical stages of the visual system, since orientation-specificity is largely a cortical 
function (Edden, Muthukumaraswamy, Freeman, & Singh, 2009). Additionally,
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psychophysical assessements can be supplemented by electrophysiological (e.g., 
electroretinography, visual evoked potentials) and neuroimaging measures (MRI, fMRI) 
to help localize visual stream involvement and hierarchical levels of the visual system 
(e.g., Braus, Weber-Fahr, Tost, Ruf, & Henn, 2002; Butler et al., 2001; Doniger, Foxe, 
Murray, Higgins, & Javitt, et al., 2002). These types of methods are recommended for 
future research to more confidently isolate vision abnormalities in depressive disorders, 
now that such anomalies have been identified.
Conclusions
Psychophysical investigation o f visual functioning has only recently been applied 
in the area of depressive disorders. The current research extends upon a handful of 
previous studies that have explored luminance contrast sensitivity in depressive 
disorders. Additionally, the current research is the first known study to systematically 
examine chromatic visual functioning in depressive disorders, and to investigate the 
effects of SSRIs in conjunction with depression and anxiety.
Results document various sub-clinical visual anomalies. Depression was 
associated with reductions in luminance contrast sensitivity that were most apparent at 
intermediate spatial frequencies; reductions in chromatic contrast sensitivity, especially 
B-Y conditions; and increased S-cone sensitivity in peripheral temporal portions of the 
retina. These findings indicate an impact that is most prominent in, but not limited to, the 
koniocellular stream. The effects o f anxiety were opposite to those o f depression, with a 
tendency toward elevated luminance contrast sensitivity at intermediate spatial 
frequencies, increased chromatic contrast sensitivity, and reduced S-cone sensitivity.
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SSRI medications led to deficits that were indicative of primary effects in the 
parvocellular stream, with decreased luminance CS at the highest spatial frequencies and 
reduced R-G CS. When unique contributions of SSRI medications were not observed, 
they nevertheless tended to exacerbate the contrast sensitivity reductions associated with 
depression.
As a new line o f inquiry, results o f the current study raise a number of questions 
for further research. For instance, although the hypothesis of early stage visual anomalies 
in depression is supported by elevated S-cone sensitivity, the apparently contradictory 
finding o f reduced B-Y chromatic sensitivity negates straightforward interpretation and 
points to interaction, feedback, or compensatory effects that are at least post-receptoral 
and may involve higher-order visual system functions as well. Additionally, the 
hypothesis that antidepressant medications would correct for visual anomalies associated 
with depression did not hold true for SSRI medications, opposing a simple model of 
retinal monoamine availability. Thus, more research is required to better localize the 
effects of depression, anxiety, and antidepressant medications within the visual system 
and to determine the mechanisms through which these effects are produced. Results of 
the current study are compelling, however, and confirm the importance o f future research 
in this area.
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Table 1
Participan ts Taking SSRI M edications: D ose, Duration, and Reason
Age Gender SSRI Daily Duration (mos.) Reason for Medication
18 f citalopram 20 mg 1 depression
31 f citalopram 40 mg 24 depression
36 m citalopram 20 mg 62 depression
31 f fluoxetine 40 mg 30 depression primary, and anxiety
35 f fluoxetine 20 mg 96 depression
24 f paroxetine 50 mg 54 depression
36 m paroxetine 50 mg 58 anxiety primary, and depression
41 f paroxetine 20 mg 72 anxiety primary, and depression
18 f sertraline 175 mg 42 depression
19 f sertraline 150 mg 18 depression primary, and anxiety
20 f sertraline 150 mg 3 anxiety primary, and depression
24 f sertraline 50 mg 11 anxiety
40 f sertraline 100 mg 120 depression
D E P R E SSIO N , A N T ID E P R E S SA N T S, A N D  V ISIO N  
T able 2
C ell sizes fo r  ANCOVAs involving the Between-Subject Variables o f  SSRI M edication  
Status, DASS D epressed  M ood, and DASS Anxious M ood
180
SSRI Medication Status
DASS Depressed Mood DASS Anxious Mood No SSRI SSRI
No Depressed Mood No Anxious Mood 12 3 (15)"
Anxious Mood 10 4 (14)
(22) (7) (29)
Depressed Mood No Anxious Mood 8 4 (12)
Anxious Mood 1 2 (3)
(9) (6) (15)
N ote. D ue to unbalanced cell s izes , A N C O V A s relied on T ype III sum  o f  squares. 
“Num bers in parantheses represent marginal frequency totals.
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T able 3
C ell sizes fo r  ANCOVAs involving the Between-Subject Variables o f  SSRI 
M edication Status and DID Clinically-D efined D epression
SSRI Medication Status
DID Clinically-Defined Depression No SSRI SSRI
No Clinical Depression 24 9 (33)'
Clinical Depression 7 4 (11)
(31) (13) (44)
N ote. D ue to unbalanced cell s izes , A N C O V A s relied on Type III sum  o f  squares. 
“Num bers in parantheses represent marginal frequency totals.
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Table 4
C ell sizes fo r  ANCOVAs involving the Between-Subject Variables o f  SSRI M edication Status,
D ID  Clinically-D efined D epression, and STAI Trait Anxiety
SSRI Medication Status
DID Clinically-Defined Depression STAI Trait Anxiety No SSRI SSRI
No Clinical Depression Low Trait Anxiety 19 2 (21)'
High Trait Anxiety 5 7 (12)
(24) (9) (33)
Clinical Depression Low Trait Anxiety 1 - (1)
High Trait Anxiety 6 4 (10)
(7) (4) (11)
N ote. Due to an empty cell, ANCOVAs relied on Type IV sum of squares. 
“Numbers in parantheses represent marginal frequency totals.
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Table 5








Between-Subjects Variables n Range Men Women M(%) «(% ) M(%) M(%)
SSRI Medication Status
SSRI 13 28.7 (8.6) 18-41 2 11 13 (100.0) 12(92.3) 7 (53.8) 3(23.1)
No SSRI 31 21.8(4.9) 18-33 9 22 0 (0.0) 7 (22.6) 5(16.1) 2 (6.5)
DASS Depressed Mood
Depressed Mood 15 27.5 (7.2) 18-40 4 11 6 (40.0) 11 (73.3) 3 (20.0) 2(13.3)
No Depressed Mood 29 22.0 (7.1) 18-41 7 22 7(24.1) 8 (27.6) 9(31.0) 3(10.3)
DASS Anxious Mood
Anxious Mood 17 21.0 (5.7) 18-40 4 13 6(35.3) 7(41.2) 7(41.2) 4 (23.5)
No Anxious Mood 27 25.7 (7.1) 18-41 7 20 7 (25.9) 12(44.4) 5 (18.5) 1 (3.7)
DID Clinically-Defined Dep.
Clinical Depression 11 29.3 (6.1) 18-40 2 9 4 (36.4) 9(81.8) 2(18.2) 2(18.2)
No Clinical Depression 33 22.1 (6.2) 18-41 9 24 9 (27.3) 10(30.3) 10(30.3) 3(9.1)
Total Sample 44 23.9 (6.9) 18-41 11 33 13(29.5) 19(43.2) 12(27.3) 5(11.4)
'Previous Depression Diagnosis. ^Previous Anxiety Diagnosis. Trevious Hospitalization for Mental Illness.
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Table 6









Between-Subjects Variables n M{SD) Range M(5D) Range M(SD) Range "(% )












































































Total Sample 44 8.70(9.52) 0-35 5.84(4.58) 0-18 41.77(12.86) 20-68 11 (25.0)
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Table 7
Summary o f  ANCOVAs included in Prim ary Analyses
B etw een-Subjects V ariables W ithin-Subjects V ariables C ovariates
D ependent V ariable: S-cone Sensitivity
1. SSRI Medication Status (2) x DASS Depressed Mood (2) x DASS Anxious Mood (2)
2. SSRI Medication Status (2) x DID Clinically-Defined Depression (2) x Trait Anxiety (2)




3. SSRI Medication Status (2) x DASS Depressed Mood (2) x DASS Anxious Mood (2)
4. SSRI Medication Status (2) x DID Clinically-Defined Depression (2) x Trait Anxiety (2)




5. SSRI Medication Status (2) x DASS Depressed Mood (2) x DASS Anxious Mood (2)
6. SSRI Medication Status (2) x DID Clinically-Defined Depression (2) x Trait Anxiety (2)




D ependent V ariable: Static Lum inance CS
1. SSRI Medication Status (2) x DASS Depressed Mood (2) x DASS Anxious Mood (2)
2. SSRI Medication Status (2) x DID Clinically-Defined Depression (2)
3. Medication/Depression (4)
Spatial Frequency (10) 
Spatial Frequency (10) 
Spatial Frequency (10)
Age
Age, Trait Anxiety Score 
Age, Trait Anxiety Score
D eoendent V ariables: S eoarate A N C O V A s fo r (a.) L um inance CS (static and dvnam icL  (bl R-G  C hrom atic CS; and (c) B-Y C hrom atic  CS
1. SSRI Medication Status (2) x DASS Depressed Mood (2) x DASS Anxious Mood (2)
2. SSRI Medication Status (2) x DID Clinically-Defined Depression (2)
3. Medication/Depression (4)
Temporal Freq. (2) x Spatial Freq. (3) 
Temporal Freq. (2) x Spatial Freq. (3) 
Temporal Freq. (2) x Spatial Freq. (3)
Age
Age, Trait Anxiety Score 
Age, Trait Anxiety Score
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Table 8
Relative SSRI D osage Scale and Actual SSRI D oses
Relative SSRI Dosage Scale Score





(n =  1)
fluoxetine
20 mg 
(n =  1)
40 mg 
(n =  1)
paroxetine
20 mg 





(n =  1)
100 mg 




(n =  1)
N ote. The relative SSRI dosage scale was based upon the following standard dose ranges for the 
SSRIs included in the present study: citalopram = 20 to 60 mg; fluoxetine = 20 to 80 mg; 
paroxetine = 20 to 60 mg; and sertraline = 50 to 200 mg. Scores for the relative dosage scale 
ranged from I to 10, with the lowest standard dose for each medication equaling I and the 
highest standard dose for each medication equaling 10. Intermediate doses were divided with 
equal spacing according to each medication’s standard dose range.
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Table 9
Log Unit Differences in Luminance Contrast Sensitivity Function Values between Variable Levels
Variable Levels Comparisons
Spatial Frequency (cpd) at 0 Hz
0.5 1.0 1.5 2.0 2.5 4.0 6.0 8.0 10.0 12.0
SSRI Medication Status
No SSRI - SSRI 0.06 -0.07 0.02 0.05 0.03 0.02 0.03 0.05 0.12* 0.19*
DASS Depressed Mood
No Depressed Mood - Depressed Mood 0.01 0.06 0.05 0.11* 0.12* 0.07 0.01 0.06 0.10* 0.00
DASS Anxious Mood
No Anxious Mood - Anxious Mood -0.02 -0.02 0.01 -0.12* -0.12* -0.02 -0.01 -0.02 0.00 0.02
DID Clinically-Defined Depression
No Clinical Depression - Clinical 0.04 0.10* 0.07 0.05 0.13* 0.06 -0.01 0.06 0.03 -0.04
Medication/Depression
HEALTHY - MEDONLY 0.02 -0.08 -0.01 0.06 -0.03 -0.01 -0.06 0.04 0.05 0.20*
HEALTHY - DEPONLY -0.02 0.11* 0.03 0.06 0.06 0.02 -0.11* 0.05 -0.03 -0.05
HEALTHY - DEPMED 0.16* 0.03 0.14* 0.08 0.27* 0.13* 0.17* 0.11* 0.21* 0.14*
M EDO NLY- DEPONLY -0.03 0.19* 0.04 0.01 0.08 0.03 -0.05 0.00 -0.07 -0.25*
MEDONLY - DEPMED 0.15* 0.12* 0.16* 0.02 0.30* 0.14* 0.23* 0.07 0.16* -0.07
DEPONLY - DEPMED 0.18* -0.07 0.12* 0.02 0.21* 0.11* 0.28* 0.06 0.24* 0.18*
Note. Differences equal to or greater than 0.10 log units are indicated with a bullet (*) and in boldtype. They reflect contrast
differences that are well beyond suprathreshold levels for discrimination, as generally defined by differences larger than 2% relative
contrast.
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Table 10
Log Unit Differences in Luminance Contrast Sensitivity (Static and Dynam ic) between Variable 
Levels
Spatial Frequency (cpd) 
at 0 Hz
Spatial Frequency (cpd) 
at 4 Hz
Variable Levels Comparisons 0.5 1.5 4.0 0.5 1.5 4.0
SSRI Medication Status
No SSRI - SSRI 0.06 0.02 0.02 -0.01 0.09 -0.07
DASS Depressed Mood
No Dep. Mood -  Dep. Mood 0.01 0.05 0.07 0.06 0.10* 0.05
DASS Anxious Mood
No Anxious Mood - Anxious Mood -0.02 0.01 -0.02 -0.05 0.00 -0.07
DID Clinically-Defined Depression 
No Clinical Dep. - Clinical Dep. 0.04 0.07 0.06 0.11* 0.13* 0.03
Medication/Depression
HEALTHY - MEDONLY 0.02 -0.01 -O.OI -0.05 0.09 -0.08
HEALTHY - DEPONLY -0.02 0.03 0.02 0.07 0.14* 0.02
HEALTHY - DEPMED 0.16* 0.14* 0.13* 0.15* 0.18* -0.02
M EDO NLY - DEPONLY -0.03 0.04 0.03 0.12* 0.05 0.10*
MEDONLY - DEPMED 0.15* 0.16* 0.14* 0.20* 0.09 0.06
DEPONLY - DEPMED 0.18* 0.12* 0.11* 0.08 0.04 -0.04
N ote. Differences equal to or greater than 0.10 log units are indicated with a bullet (*) and in 
boldtype. They reflect contrast differences that are well beyond suprathreshold levels for 
discrimination, as generally defined by differences larger than 2% relative contrast.
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Table 11
Log Unit Differences in “Red-Green" Chrom atic Contrast Sensitivity between Variable Levels
Variable Level Comparisons
Spatial Frequency (cpd) 
at 0 Hz
Spatial Frequency (cpd) 
at 4 Hz
0.5 1.5 4.0 0.5 1.5 4.0
SSRI Medication Status
No SSRI - SSRI 0.04 -0.04 0.11* -0.02 0.05 0.15*
DASS Depressed Mood
No Dep. Mood -  Dep. Mood 0.01 0.04 -0.05 -0.09 0.02 0.05
DASS Anxious Mood
No Anxious Mood - Anxious Mood 0.03 0.01 0.05 -0.03 -0.04 -0.03
DID Clinical Depression
N o Clinical Dep. - Clinical Dep. 0.07 0.10* -0.05 -0.03 0.01 0.05
Medication/Depression
HEALTHY - MEDONLY -0.02 -0.12* 0.08 -0.04 0.08 0.19*
HEALTHY - DEPONLY -0.01 -0.01 -0.09 -0.06 0.04 0.08
HEALTHY - DEPMED 0.21* 0.22* 0.10* -0.02 0.01 0.13*
M ED O N LY - DEPONLY O.OI 0.11* -0.17* -0.02 -0.05 -0.11*
MEDONLY - DEPMED 0.23* 0.35* 0.02 0.02 -0.07 -0.06
DEPONLY - DEPMED 0.22* 0.24* 0.18* 0.04 -0.02 0.05
Note.  Differences equal to or greater than O.IO log units are indicated with a bullet (*) and in
boldtype. They reflect contrast differences that are well beyond suprathreshold levels for
discrimination, as generally defined by differences larger than 2% relative contrast.
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Table 12
Log Unit D ifferences in “B lue-Yellow ” Chrom atic Contrast Sensitivity between Variable Levels
Spatial Frequency (cpd) 
at 0 Hz
Spatial Frequency (cpd) 
at 4 Hz
Variable Levels Comparisons 0.5 1.5 4.0 0.5 1.5 4.0
SSRI Medication Status
No SSRI - SSRI -0.02 -0.03 0.13* 0.03 0.04 0.01
DASS Depressed Mood
No Dep. Mood -  Dep. Mood 0.15* 0.14* -0.02 0.04 0.05 -0.02
DASS Anxious Mood
No Anxious Mood - Anxious Mood 0.01 -O.OI -0.10* -0.09 -0.04 0.00
DID Clinical Depression
No Clinical Dep. - Clinical Dep. 0.20* 0.13* -0.02 0.09 0.08 0.05
Medication/Depression
HEALTHY - MEDONLY -0.07 -0.09 0.15* 0.00 0.00 -0.06
HEALTHY - DEPONLY 0.14* 0.05 -0.02 0.05 0.03 -0.03
HEALTHY - DEPMED 0.28* 0.21* 0.08 0.17* 0.17* 0.16*
MEDONLY - DEPONLY 0.20* 0.14* -0.17* 0.05 0.03 0.03
MEDONLY - DEPMED 0.35* 0.31* -0.07 0.17* 0.17* 0.22*
DEPONLY - DEPMED 0.15* 0.17* 0.10* 0.12* 0.14* 0.19*
Note. Differences equal to or greater than O.IO log units are indicated with a bullet (*) and in
boldtype. They reflect contrast differences that are well beyond suprathreshold levels for
discrimination, as generally defined by differences larger than 2% relative contrast.
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Table 13
Num ber o f  Participants tested  each Month
Depression Variable
Month o f Testing
February March April May June Total
DASS Depressed Mood'
Depressed Mood 7 0 4 1 3 15
No Depressed Mood 21 3 0 1 4 29
DID Clinically-Defined Dep.'’
Clinical Depression 3 0 4 1 3 11
No Clinical Depression 25 3 0 I 4 33
Total 28 3 4 2 7 44
b 44)=  17.91, j9 = .001




F igure L  Examples of Gabor stimuli. Top and middle rows depict chromatic isoluminant “blue- 
yellow” and “red-green” Gabors, respectively. Bottom row depicts achromatic luminance 
Gabors. Panels A, B, and C illustrate Gabors with center spatial frequencies of 0.5, 1.5 and 4.0 
cpd, respectively.
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kid R/(j SCimuli
2. CIE (1931) Colour Space showing the “blue-yellow" (B-Y) and "red-green" (R-G) 
peak-to-trough chromatic Gabor modulations. B-Y endpoints were [(.2739, .2263), (.4280,
.4976) and R-G endpoints were [(.3828, .2846), (.2639, .3722)]. Backgroimd chromaticities were 
halfway between the two endpoints.
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F igure 3. S-cone sensitivity (dB) by retinal eccentricity for DID Clinically-Defined Depression 
(top panel) and Trait Anxiety (bottom panel). In the top panel, solid blue bars represent the 
Clinical Depression group and open bars represent the No Clinical Depression group. In the 
bottom panel, solid red bars represent the High Trait Anxiety group and open bars represent the 
Low Trait Anxiety group. For retinal eccentricity, Central refers to 1-6°, Paracentral refers to 10- 
22°, and Peripheral refers to 30-50° of visual angle. For this figure and subsequent figures 
referring to S-cone sensitivity, mean values are adjusted for Age as a covariate (Age = 23.86) 
and error bars represent ± I SEM. *p < .05.
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Figure 4. S-cone sensitivity (dB) by hemiretinal locations for DID Clinically-Defined 
Depression (top panel) and Trait Anxiety (bottom panel). In the top panel, solid blue bars 
represent the Clinical Depression group and open bars represent the No Clinical Depression 
group. In the bottom panel, solid red bars represent the High Trait Anxiety group and open bars 
represent the Low Trait Anxiety group. For hemiretinal locations. Central refers to 1-6° of visual 
angle, and the remaining quadrants of Superior Nasal, Inferior Nasal, Inferior Temporal, and 
Superior Temporal refer to the outer 10-50° of visual angle. < .05.
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Figure 5. S-cone sensitivity by eleven retinal locations for DID Clinically-Defined Depression. 
Solid blue bars represent the Clinical Depression group and open bars represent the No Clinical 
Depression group. For retinal location, Central refers to 1-6°, Paracentral refers to 10-22°, and 
Peripheral refers to 30-50° of visual angle. < .05.
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Figure 6. S-cone sensitivity by eleven retinal locations for Trait Anxiety (bottom panel). Solid 
red bars represent the High Trait Anxiety group and open bars represent the Low Trait Anxiety 
group. For retinal location. Central refers to 1-6°, Paracentral refers to 10-22°, and Peripheral 
refers to 30-50° o f visual angle. *p < .05.
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Figure 7. Spatiotemporal luminance contrast sensitivity functions for SSRI Medication Status 
(SSRI, No SSRI) variable. Luminance CS values for the SSRI group are indicated with purple 
squares. For clarity, the data are fit with a solid purple line based on a double exponential fitting 
function (Moshvon & Kiorpes, 1988). Luminance CS values for the No SSRI group are indicated 
with dark grey circles and a dashed line denoting curve fit. For this figure and all subsequent 
figures, values refer to unadjusted data and error bars represent ± 1 SEM. No apparent error bars 
indicates SEM less than the data symbol size.
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F igure 8. Spatiotemporal luminance contrast sensitivity functions for the DASS Depressed 
Mood (Depressed Mood, No Depressed Mood) variable. Luminance CS values for the Depressed 
Mood group are indicated with inverted blue triangles and a solid blue line denoting the double 
exponential curve fit (as described in Fig. 7). Luminance CS values for the No Depressed Mood 
group are indicated with dark grey circles and a dashed line denoting curve fit.
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Figure 9. Spatiotemporal luminance contrast sensitivity functions for the DASS Anxious Mood 
variable (Anxious Mood, No Anxious Mood). Luminance CS values for the Anxious Mood 
group are indicated with red diamonds and a solid red line denoting the double exponential curve 
fit (as described in Fig. 7). Luminance CS values for the No Anxious Mood group are indicated 
with dark grey circles and a dashed line denoting curve fit.
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Figure 10. Spatiotemporal luminance contrast sensitivity functions for the DID Clinically- 
Defined Depression (Clinical Depression, No Clinical Depression) variable. Luminance CS 
values for the Clinical Depression group are indicated with blue triangles and a solid blue line 
denoting the double exponential curve fit (as described in Fig. 7). Luminance CS values for the 
No Clinical Depression group are indicated with dark grey circles and a dashed line denoting 
curve fit.
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F igure 11. Spatiotemporal luminance contrast sensitivity functions for the Medication/ 
Depression variable. Luminance CS values are indicated by dark grey circles and a dashed line 
denoting the curve fit for the HEALTHY group; purple squares and a solid purple line for the 
MEDONLY group; blue triangles and a solid blue line for the DEPONLY group; and orange 
diamonds and a solid orange line for the DEPMED group.
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F igure 12. Spatiotemporal luminance contrast sensitivity in the static (0 Hz; top panel) and 
dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the SSRI Medication Status 
(SSRI, No SSRI) variable. Luminance CS values for the SSRI group are indicated with purple 
squares and a solid purple line denoting the curve fit. Luminance CS values for the No SSRI 
group are indicated with dark grey circles and a dashed line denoting curve fit.
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F igure 13. Spatiotemporal luminance contrast sensitivity in the static (0 Hz; top panel) and 
dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS Depressed Mood 
(Depressed Mood, No Depressed Mood) variable. Luminance CS values for the Depressed Mood 
group are indicated with inverted blue triangles and a solid blue line denoting the curve fit. 
Luminance CS values for the No Depressed Mood group are indicated with dark grey circles and 
a dashed line denoting curve fit.
DEPRESSION, ANTIDEPRESSANTS, AND VISION 205










—^ A n x io u s  Mood 




















Figure 14. Spatiotemporal luminance contrast sensitivity in the static (0 Hz; top panel) and 
dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS Anxious Mood 
(Anxious Mood, No Anxious Mood) variable. Luminance CS values for the Anxious Mood 
group are indicated with red diamonds and a solid red line denoting the curve fit. Luminance CS 
values for the No Anxious Mood group are indicated with dark grey circles and a dashed line 
denoting curve fit.
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F igure 15. Spatiotemporal luminance contrast sensitivity in the static (0 Hz; top panel) and 
dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DID Clinically-Defined 
Depression (Clinical Depression, No Clinical Depression) variable. Luminance CS values for the 
Clinical Depression group are indicated with blue triangles and a solid blue line denoting the 
curve fit. Luminance CS values for the No Clinical Depression group are indicated with dark 
grey circles and a dashed line denoting curve fit.
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Figure 16. Spatiotemporal luminance contrast sensitivity in the static (0 Hz; top panel) and 
dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the combined 
Medication/Depression variable. Luminance CS values are indicated by dark grey circles and a 
dashed line denoting curve fit for the HEALTHY group; purple squares and a solid purple line 
for the MEDONLY group; blue triangles and a blue line for the DEPONLY group; and orange 
diamonds and an orange line for the DEPMED group.
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Figure 17. Isoluminant “red-green” (R-G) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the SSRI 
Medication Status (SSRI, No SSRI) variable. R-G chromatic CS values for the SSRI group are 
indicated with purple squares and a solid purple line denoting the curve fit. R-G chromatic CS 
values for the No SSRI group are indicated with dark grey circles and a dashed line denoting 
curve fit.
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F igure 18. Isoluminant “red-green” (R-G) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS 
Depressed Mood (Depressed Mood, No Depressed Mood) variable. R-G chromatic CS values for 
the Depressed Mood group are indicated with inverted blue triangles and a blue line denoting 
curve fit. R-G chromatic CS values for the No Depressed group are indicated with dark grey 
circles and a dashed line denoting curve fit.
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F igure 19. Isoluminant “red-green” (R-G) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS 
Anxious Mood (Anxious Mood, No Anxious Mood) variable. R-G chromatic CS values for the 
Anxious Mood group are indicated with red diamonds and a solid red line denoting the curve fit. 
R-G chromatic CS values for the No Anxious Mood group are indicated with dark grey circles 
and a dashed line denoting curve fit.
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Figure 20. Isoluminant “red-green” (R-G) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DID 
Clinically-Defined Depression (Depressed Mood, No Depressed Mood) variable. R-G chromatic 
CS values for the Clinical Depression group are indicated with blue triangles and a blue line 
denoting curve fit. R-G CS values for the No Clinical Depression group are indicated with dark 
grey circles and a dashed line denoting curve fit.
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F igure 21. Isoluminant “red-green” (R-G) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the 
Medication/Depression variable. R-G chromatic CS values are indicated by dark grey circles and 
a dashed line denoting curve fit for the HEALTHY group; purple squares and a solid purple line 
for the MEDONLY group; blue triangles and a blue line for the DEPONLY group; and orange 
diamonds and a solid orange line for the DEPMED group.
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F igure 22. Isoluminant “blue-yellow” (B-Y) chromatic contrast sensitivity in the static (0 Hz; 
top panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the SSRI 
Medication Status (SSRI, No SSRI) variable. B-Y chromatic CS values for the SSRI group are 
indicated with purple squares and a solid purple line denoting the curve fit. B-Y chromatic CS 
values for the No SSRI group are indicated with dark grey circles and a dashed line denoting 
curve fit.
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F igure 23. Isoluminant “blue-yellow” (B-Y) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS 
Depressed Mood (Depressed Mood, No Depressed Mood) variable. B-Y chromatic CS values for 
the Depressed Mood group are indicated with inverted blue triangles and a blue line denoting the 
curve fit. B-Y chromatic CS values for the No Depressed group are indicated with dark grey 
circles and a dashed line denoting curve fit.
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Figure 24. Isoluminant “blue-yellow” (B-Y) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DASS 
Anxious Mood (Anxious Mood, No Anxious Mood) variable. B-Y chromatic CS values for the 
Anxious Mood group are indicated with red diamonds and a solid red line denoting the curve fit. 
B-Y chromatic CS values for the No Anxious Mood group are indicated with dark grey circles 
and a dashed line denoting curve fit.
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Figure 25. Isoluminant “blue-yellow” (B-Y) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the DID 
Clinically-Defined Depression (Depressed Mood, No Depressed Mood) variable. B-Y chromatic 
CS values for the Clinical Depression group are indicated with blue triangles and a blue line 
denoting curve fit. B-Y CS values for the No Clinical Depression group are indicated with dark 
grey circles and a dashed line denoting curve fit.
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F igure 26. Isoluminant “blue-yellow” (B-Y) chromatic contrast sensitivity in the static (0 Hz; top 
panel) and dynamic (4 Hz, counterphase flickered; bottom panel) conditions for the 
Medication/Depression variable. B-Y chromatic CS values are indicated by dark grey circles and 
a dashed line denoting curve fit for the HEALTHY group; purple squares and a solid purple line 
for the MEDONLY group; blue triangles and a blue line for the DEPONLY group; and orange 
diamonds and a solid orange line for the DEPMED group.
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Appendix A 
Cover Letter, Contact Information and Informed Consent
[Letterhead]
Dear Potential Participant,
We are conducting a study that examines the effect of certain medications on visual functioning. Specifically, 
we are interested in comparing the visual performance of people who are taking antidepressant medication 
with those who are not. You are invited to be a participant in this research.
If you choose to participate, you will be asked to complete a number of non-invasive, automated vision tests. 
These involve viewing a screen and indicating when you see a dot appear, which side of the screen a pattern is 
presented, or which direction a shape is facing. Additionally, participants will be asked to fill out a series of 
questionnaires regarding general medical information and measures of mood. The vision tests and 
questionnaires will be completed in one research session, lasting approximately 2 hours. There are no physical 
or psychological risks associated with participation in any part of this research.
If you choose to participate, your involvement and the information you provide will remain strictly 
confidential and only shared amongst the researchers. Your name will not be associated with your responses to 
the questionnaires or the vision tests. Instead, your data will be assigned a random identification number. All 
the data collected for this study will be securely stored at Lakehead University for a period of 7 years, after 
which it will be destroyed.
The information you provide will not be analyzed separately or individually, but will be combined with the 
data provided by all other research participants and analyzed in aggregate, as a group. This means that the 
results of this study will not include information on any individual participant. This also means that 
participants will not be given individual feedback on their test performance or questionnaire responses. 
Potential participants will be given information on how to contact a health care professional for any concerns 
they might have regarding their vision or their mental health.
Participation in this study is completely voluntary. If you agree to participate, you will be able to withdraw at 
any point during the research session without explanation. You will also not be obligated to answer every 
question on the questionnaires. However, because each of the questions was chosen for a specific research 
purpose, we do encourage participants to be as complete as possible. Incomplete questionnaires may affect the 
validity of the results and might not be able to be included for analysis.
Because you have taken the time to meet with the researcher to discuss this study, you will be given the 
opportunity to enter your name in a draw for $50, even if you do not participate in the research session. 
Additionally, if you are a Lakehead University student enrolled in an Introductory Psychology class you may 
choose to have your participation counted toward course bonus marks. These are the only direct benefits to 
yourself as a potential participant.
Please feel free to ask questions at any time. We have provided our contact information if you wish to contact 
us outside of the research session. We have also provided contact information for Lakehead University’s 
Research Ethics Board, if you have any concerns. Additionally, if you wish to receive a summary report of the 
results of this study, there is a space for you to provide your mailing information on the following pages.
Thank you for your interest in this research.
Sincerely,
Joy Harrison, M.A. Michael Wesner, Ph.D.
DEPRESSION, ANTIDEPRESSANTS, AND VISION 219
Research Contact Information
Project Title: “The Impact of Depression and Antidepressant Medication on the Visual Functioning of the
Magno-, Parvo-, and Koniocellular Pathways”
Joy Harrison, Researcher ...................................................................346-1272; jjharrison@shaw,ca
Dr. Michael Wesner, Supervising Researcher................................ 343-8457; mwesner@lakeheadu.ca
Mail can be directed to either researcher at the following address:
Psychology Department 
Lakehead University 
955 Oliver Road 
Thunder Bay, ON 
P7B 5E1
Lakehead University Research Ethics Board.................................. 343-8283
Counselling and Mental Health Resources
■ A number of mental health services in Thunder Bay are available free of charge to individuals with a 
physician referral. These services include individual counseling, support groups, or education workshops. 
After you are referred by a physician, you will meet with a mental health worker to determine what 
services and resources would best meet your needs.
* Additionally, you may contact the following not-for-profit agencies directly:
Thunder Bay Counselling Centre...........................................684-1880 (www.tbaycounselling.com)
Catholic Family Development Centre 345-7323 (www.catholicfamilycentre.ca)
■ Lakehead University students are eligible for free counselling services by contacting:
LU Health and Counselling Services...................................  343-8361
■ Counselling services may also be available to you if your employer participates in an Employee Assistance 
Program (LAP). Check your terms of employment for details. Importantly, your involvement with any 
services provided through an LAP is kept confidential from your employer.
■ Therapists in private practice can be found in the Yellow Pages under Psychologists and Psychological 
Associates; Psychotherapy; or Marriage, Family & Individual Counsellor. Fees are set by therapists 
independently.
■ The Thunder Bay Branch of the Canadian Mental Health Association provides a 24-hour crisis phoneline, 
as well as crisis responses services:
Thunder Bay Crisis Response Phoneline.............................. 346-8282 (toll free: 1-888-269-3100)
■ Emergency services are also available at the Thunder Bay Regional Health Sciences Centre.
Eye Care and Vision Resources
■ Optometrists can be contacted directly for an appointment. Check the Yellow Pages under Optometrists 
for contact information. There is usually a fee, although CHIP may cover costs for clients with certain 
conditions.
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Informed Consent to Participate
Title of Research: “The Impact of Depression and Antidepressant Pharmacotherapy on Visual 
Functioning o f the Magno-, Parvo, and Koniocellular Pathways”
Researchers: Joy Harrison and Dr. Michael Wesner (Supervising Researcher)
PARTICIPANT CONSENT:
I have read the preceding cover letter and am aware of the nature and procedures of research as described
therein. In particular, I am aware that:
• My participation is voluntary. I am able to withdraw at any time, without explanation. I am also not 
obligated to answer every item on the questionnaires.
■ My participation and the responses I provide will be kept confidential. My name or identifying 
information will not be included in the results of the study. My responses will be securely stored at 
Lakehead University for 7 years, and will then be destroyed.
■ I am free to ask questions or raise concerns at any time. I have been given contact information for the 
researchers and the Research Ethics Board of Lakehead University.
■ As a potential participant, I have the opportunity to enter my name in a draw for $50. If I am enrolled 
in an Introductory Psychology class, I may also have my participation counted toward bonus marks. 
Otherwise, there are no direct benefits to my participation in this study. There are also no physical or 
psychological risks associated with participation.
I agree to volunteer as a participant in this study, according to the terms outlined above and in the cover
letter.
Print name here Sign name here Date here
Do you wish to be entered into a random draw for $50? YES / NO 










Birth Month: Current Month:
Section A. Vision Information
1. Eye colour:________________
2. Do you currently wear glasses or contact lenses? YES / NO
















4. Have you ever had eye surgery? YES / NO
5. If yes, please provide the following details: 
Date Type of Eye Surgery_________ Reason for Eye Surgery
6. Have you ever had bright light therapy? YES / NO
7. If yes, when was the last time you had the light therapy? .
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Section B. Medical Information








Hyperthyroidism or Grave’s Disease
Other Thyroid conditions. Please specify:___________
Pituitary or other Endocrine disorders. Please specify:
2. Do you currently have any chronic medical condition not listed above? If so, please specify:
3. Do you have high blood pressure / hypertension? YES / NO
4. Do you get migraine headaches? YES / NO
5. If yes, do you ever see auras or have other visual disturbances when you get a migraine? YES / NO
6. When was the first day of your most recent period?_______________________
7. Do you take birth control pills? YES / NO
8. Are you receiving any type of hormonal therapy? YES / NO
9. If yes, please indicate the type of hormone medication or treatment you are receiving.
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Section C. Mental Health Information
1. Have you ever been diagnosed by a health care professional with any of the following conditions? 
YES NO
Depression
Seasonal Affective Disorder (SAD); Seasonal Depression
Bipolar Disorder
Premenstrual Dysphoric Disorder









Alcohol or Substance Abuse or Dependence
Other Psychiatric or Psychological Disorder.
Please specify;__________________________________________
2. If you answered “YES” to any of the above:
a. How old were you when you first experienced symptoms? ,
b. Were you ever hospitalized for any of the above conditions? YES / NO
c. Have you ever received treatment for any of the above conditions? YES / NO
3. If you answered “YES” to having being diagnosed with depression, how many separate episodes 
have you experienced in your lifetim e?______________________
4. Please indicate with a check mark if you know of any biological family member who has been
diagnosed with or treated for any of the following conditions.
Sibling Parent Grandparent, 
Aunt or Uncle
Depression
Bipolar Disorder, Manic Depression
Anxiety Disorder
Obsessive-Compulsive Disorder (OCD)
Eating Disorder, Bulimia, Anorexia
Schizophrenia
Schizoaffective Disorder
Alcohol or substance abuse/dependence
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Section D. Drug Information
1. Have you consumed alcohol in the last 24 hours? YES / NO
a. How much did you drink?_________________________
b. How many hours ago did you last drink?
2. Have you used marijuana in the last 24 hours? YES / NO 
a. How many hours ago did you last use marijuana? _
3. Have you used any other mood-altering drugs in the last 24 hours? YES / NO
4. Do you smoke cigarettes? YES / NO
a. If yes, how many cigarettes do you smoke per day on average? _ _ _ _ _
5. Please list any over-the-counter medications you have used in the last 24 hours, including cold 
medicine, pain relievers, allergy medications, and supplements.
Name of medication Amount used How many hours ago?
5. Please list any prescription medication you are currently taking.
Name of medication
How long have you How many hours
been taking this ago did you take
— — o your last dose?
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Appendix C 
Medication Questionnaire 
Section A. Prescription Information (To be filled out by the researcher.)




Size of single dose: 
Number of doses per 
day (protocol):
b. When was the medication started (month/year)? ,




Size of single dose: 
Number of doses per 
day (protocol):
b. When was the medication started (month/year)? .
3. Other Antidepressant Prescriptions in the Last Year
a. If the current medication was started less than one year ago, was the participant being treated with 
other antidepressant medications in the last year? YES / NO
b. If so, what were they and when were they started? ____________________________________________
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Section B. Reason for Antidepressant Medication
Medications that fall under the broad classification o f antidepressants are prescribed for a variety of 
reasons other than depression, such as anxiety, eating disorders, sleep difficulties, chronic pain, and 
quitting smoking, for example. This section is meant to determine the reasons for your prescription.
Part 1. What is the reason that you are currently taking antidepressant medication?
Part 2. The following questions ask about possible symptoms, conditions, or issues that may have led you 
to seek the medical treatment resulting in your prescription. When responding to these questions, please 
think back to the few months before you were initially prescribed antidepressant medication for the 
reason you are currently taking it. Specifically, think back to the last 6-month time period when you 
were not taking antidepressant medication.
Module A . During the last 6-month time period when you were not taking antidepressant medication:
YES NO
1. Did you often feel that you couldn’t control what or how much you ate?
2. Did you often eat, within any 2-hour period, what most people would regard 
as an unusually large amount of food?
3. Did either of these usually happen at least twice a week for 3 months?
*lf “No” to all of the above, skip to the next Module.
4. During those 3 months, did you usually do any of the following at least twice 
a week in order to avoid gaining weight?
a. make yourself vomit?
b. take more than twice the recommended dose of laxatives?
c. fasted, not eating anything at all for at least 24 hours?
d. exercised for more than an hour specifically to avoid gaining weight after 
binge eating?
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Module B . During the last 6-month time period when you were not taking antidepressant medication:
227
YES NO
1. Was there a period of at least 2 weeks when you had any of the following 
experiences nearly every day?
a. Little interest or pleasure in doing things you normally enjoyed?
b. Feeling down, depressed, or hopeless?
c. Trouble falling asleep, trouble staying asleep, or sleeping too much?
d. Feeling tired or having little energy?
e. Poor appetite or else over-eating?
f. Feeling bad about yourself or worthless, feeling like a failure, or 
feeling that you had let yourself or others down?
g. Trouble concentrating on things?
h. Thoughts that you would be better off dead or of hurting yourself in 
some way?
i. Moving or speaking so slowly that other people could have noticed? Or 
the opposite, being so fidgety or restless that you were moving around a 
lot more than usual?
* lf “NO” to all of the above, skip to the next Module.
2. If you experienced any of these symptoms, did it make it hard for you to do 
your work, take care of things at home, or get along with other people?
3. If you experienced any of these symptoms, was it because
a. you were physically ill or had a general medical condition?
b. you were taking medication?
c. you were drinking alcohol or using recreational drugs?
d. someone close to you had died?
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Module C . During the last 6-month time period when you were not taking antidepressant medication:
YES NO
1. Did you have a period of time lasting at least I week when you were feeling so 
good, high, excited, or hyper that other people thought you were not your normal 
self or you got into trouble?
2. Did you ever have a period of time lasting at least 1 week when you were so 
irritable that you found yourself shouting at people or starting fights or 
arguments?
If so, did you find yourself yelling at people you didn’t really know?
*lf “NO” to all of the above, skip to the next Module.
3. During the period o f at least 1 week, did you experience any of the following:
a. feeling more self-confident than usual?
b. feeling that you had special abilities or powers?
c. needing less sleep than usual in order to feel rested?
d. being much more talkative than usual?
e. having your thoughts racing through your head?
f . being so easily distracted that you had trouble concentrating or staying 
on track?
g. feeling physically restless?
h. focusing more time than usual on any specific goals?
3. If you experienced any of these symptoms, was it because
a. you were physically ill or had a general medical condition?
b. you were taking medication?
c. you were drinking alcohol or using recreational drugs?
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Module D . During the last 6-month time period when you were not taking antidepressant medication:
YES NO
1. Did you have any panic attacks when you suddenly felt frightened or anxious?
*If “NO”, skip to the next Module.
2. Did these attacks ever come on out o f the blue, in situations where you did not expect 
to be nervous or uncomfortable?
3. Did you have more than one of these attacks?
4. For at least one month following any of these attacks:
a. did you worry that there might have been something very wrong with you?
b. did you worry a lot about having another one?
c. did you do anything differently because of the attacks, like avoid certain places or 
situations, or not go out alone?
5. During these attacks:
a. did the symptoms come on quickly and take less than 10 minutes to get really bad?
b. did your heart race, pound, or skip?
c. were you short of breath?
d. did you sweat?
e. did you have chest pain or pressure?
f. did you tremble or shake?
g. did you have nausea or an upset stomach?
e. did you feel as if you were choking?
f. did you have hot flashes or chills?
g. did you feel dizzy, unsteady, or faint?
h. did you have tingling or numbness in parts of your body?
i. were you afraid you might die?
j. were you afraid you were going crazy or might lose control?
k. did things around you seem unreal or did you feel detached from things around 
you or detached from parts of your body?
6. Did you have these attacks because
a. you were physically ill or had a general medical condition?
b. you were taking medications?
c. you were drinking alcohol or using recreational drugs?
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Module E . During the last 6-month time period when you were not taking antidepressant medication:
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YES NO
1. Was there a period of at least 4  weeks that you felt nervous, anxious, on edge, 
or worried a lot, nearly every day?
*lf “NO”, skip to the next Module.
2. Did you experience any of the following symptoms nearly every day for at 
least 4  weeks?
a. feeling restless so that it was hard to sit still
b. getting tired very easily
c. muscle tension, aches, or soreness
d. trouble falling asleep or staying asleep
e. trouble concentrating on things
f. becoming easily annoyed or irritable
Module F. During the last 6-month time period when you were not taking anti depressant medication:
YES NO
1. Were you ever afraid o f going out o f the house alone, being alone, being in a 
crowd, standing in a line, or traveling on buses or trains?
2. Is there anything that you have been afraid to do or felt uncomfortable doing 
in front of other people, such as speaking, eating, or writing?
3. If yes to either #1 or #2, did these behaviours or feelings interfere with your 
work or your social activities and relationships?
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Module G . During the last 6-month time period when you were not taking antidepressant medication:
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YES NO
1. Was there ever anything that you had to do over and over again and could not 
resist doing, such as washing your hands again and again, counting up to a certain 
number, or checking something several times to make sure you had done it right?
a. Did you engage in these behaviours because you felt you had to prevent 
something terrible from happening or in order to not feel distressed?
b. Would you spend more than an hour a day engaged in these behaviours?
2. Were you bothered by thoughts that kept coming back to you even when you tried 
not to have them?
a. Were these reasonable worries about real-life problems?
b. Were these your own thoughts?
c. Were these thoughts inserted into your mind from elsewhere?
*lf “NO” to #1 or #2, skip to the next Module.
3. Do you feel that these thoughts and/or behaviours were reasonable or appropriate?
4. Did these thoughts and/or behaviours interfere with your work, social activities, or 
relationships?
5. Did you have these thoughts and/or behaviours because
a. you were drinking alcohol or using recreational drugs?
b. you were taking medication?
c. you were physically ill or had a general medical condition?
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Module H . During the last 6-month time period when you were not taking antidepressant medication:
232
YES NO
1. Were you bothered by a traumatic event that had occurred at some point in the 
past and that had involved you experiencing or witnessing actual or threatened 
injury or death to someone else or yourself?
*If “NO”, skip to the next section.
2. Did you experience any of the following for at least 4  weeks?
a. thinking about the prior traumatic event when you did not want to?
b. dreaming about the traumatic event?
c. acting or feeling the traumatic event were happening again?
d. getting very upset when something reminded you o f the event?
e. physical reactions when you were reminded of the event, including 
sweating, irregular breathing, or your heart racing or pounding?
3. Did any o f the following occur for at least 4  weeks?
a. did you make a special effort to avoid thinking or talking about the 
traumatic event?
b. did you stay away from things or people that reminded you of the 
traumatic event?
c. were you ever unable to remember some important part of what had 
happened during the traumatic event?
d. did you have much less interest in doing things that used to be important 
to you?
e. did you feel distant or cut off from others?
f . did you feel numb or as if you no longer had strong feelings about 
anything?
g. did you change the way you thought about or planned for your future?
4. Did you experience any of the following for at least 4 weeks?
a. difficulty falling or staying asleep?
b. unusual irritability or outbursts of anger?
c. trouble concentrating?
d. being watchful or on guard even when there was no reason to be?
e. being jumpy or easily startled?
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Part 3. Please indicate what you were prescribed antidepressant medication for.
Please check the boxes for all the categories that apply. I f  you check more than one box, 
please circle which category is the main or primary reason.
Depression; Major Depressive Disorder; Dysthymia 
Premenstrual Dysphoric Disorder; Premenstrual symptoms 
Bipolar Disorder; Cyclothymia; Manic Depression 
Panic Attacks; Panic Disorder with or without Agoraphobia 
Anxiety; Generalized Anxiety Disorder; Social Anxiety Disorder 
Obsessive Compulsive Disorder (OCD)
Eating Disorder; Bulimia
Attention Deficit-Hyperactivity Disorder (ADHD)
Chronic Pain; Neuropathic Pain; Fibromyalgia 
Sleeping Difficulties; Insomnia 
Smoking Cessation
Other (please sp ecify)._______________________________________
Section C. Medication and Vision
1. Did you notice any changes in your vision after you started taking your medication? YES / NO
2. If yes, please describe those changes. __________________________________________________________
3. If yes, please circle the number on the rating scales below that best describes your visual experience 












No change High contrast 
More detail, Sharp
